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#The$ purpose$ of$ this$ thesis$ was$ to$ investigate$ the$ application$ of$ vibrational$spectroscopy,$ Raman$ and$ Fourier$ Transform$ Infrared$ (FTIR),$ in$ the$ early$diagnosis$ of$ Leukaemia$ and$ Lymphoma.$ The$ first$ two$ chapters$ illustrate$ the$current$ literature$ surrounding$ haematological$ malignancies,$ along$ with$ their$current$ diagnostic$ methods$ and$ the$ deficiencies$ associated$ with$ them.$ Also$reviewed$ here$ is$ the$ literature$ relating$ to$ the$ theories,$ uses$ and$ potential$application$of$vibrational$spectroscopies$in$the$early$diagnosis$of$haematological$malignancies$and$explores$the$methods$for$data$analysis.$Chapter$3$contains$the$experimental$ methods$ used.$ This$ includes$ the$ preliminary$ work$ into$ the$techniques,$which$has$been$vital$ in$producing$protocols$ for$ the$ leukaemia$and$lymphoma$studies.$Chapters$4,$5$and$6$contain$the$results$and$a$discussion$of$the$work$carried$out$and$chapter$7$concludes$the$project$with$further$ideas$for$the$experiments$and$future$work$suggested.$$$
1.1.#Background##In$England,$there$were$nearly$270,000$newly$diagnosed$cases$of$cancer$in$2010$–$an$increase$of$1.52$%$from$2009$(Office$for$National$Statistics,$2012).$It$is$the$principal$cause$of$death$in$the$Western$World$and$is$responsible$for$over$seven$million$deaths$worldwide$each$year.$Overall,$cancer$is$diagnosed$in$one$in$three$people;$ killing$ one$ in$ four$ thus$ the$ earlier$ a$ diagnosis$ is$ made$ the$ earlier$treatment$can$commence,$ leading$ to$a$better$prognosis$ for$ the$patient$ (Cancer$Research$UK,$2012a).$$$Leukaemia$ and$ lymphoma$ combined$ account$ for$ approximately$ 20,000$incidences$ of$ cancer$ and$ 9,000$ deaths$ in$ the$ United$ Kingdom$ (UK)$ each$ year$(Cancer$Research$UK,$2012b$&$2011a).$Unfortunately$these$cancers$are$the$most$common$to$occur$in$children$and$although$their$incidence$has$not$increased$over$the$last$forty$years,$they$currently$account$for$6$%$of$all$childhood$deaths$(Office$for$ National$ Statistics,$ 2011a).$ Some$ of$ the$ current$methods$ used$ to$ diagnose$
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these$ cancers$ identify$ molecular$ variations$ at$ the$ cellular$ level$ using$morphological,$ immunological$and$molecular$ techniques.$However,$ they$can$be$inaccurate$ due$ to$ the$ complexity$ of$ the$ interpretation$ involved,$ which$means$either$ repetitive$ or$multiple$methods$ are$ required$ to$ be$ carried$ out$ by$ highly$trained$professionals.$$$Vibrational$ spectroscopies$are$analytical$methods$ that$have$useful$applications$in$the$clinical$field.$They$can$be$used$to$identify$the$biochemical$composition$of$cells$ and$ tissues,$ which$ is$ useful$ in$ identifying$ the$ changes$ that$ occur$ at$ the$molecular$ level$ within$ disease.$ The$ biochemical$ differences$ between$ ‘normal’$and$ a$ disease$ state$ can$ therefore$ be$ identified$ as$ molecular$ markers.$ These$markers$ are$ disease^specific,$ as$ the$ information$ obtained$ in$ spectroscopy$ is$unique$ and$ the$ spectra$ obtained$ are$ effectively$ a$ ‘biochemical$ fingerprint’.$ By$using$the$two$vibrational$spectroscopies$Raman$and$FTIR$in$combination,$highly$detailed$ information$ can$ be$ identified$ as$ they$ have$ specificities$ to$ particular$chemical$ bonds.$ These$ techniques$ are$ automated,$ reliable$ and$ effective$ at$probing$ the$ underlying$ biochemical$ changes$ that$ occur.$ When$ used$ in$collaboration$ with$ multivariate$ statistical$ analysis$ more$ specific$ and$ accurate$information$can$be$extracted$from$the$data$obtained$leading$to$more$precise$and$robust$data$models$that$represent$the$cancers$at$the$biochemical$level$(Kendall$







1.2.#Haematological#Malignancies#Leukaemias,$ lymphomas$ and$ myelomas$ are$ classified$ as$ haematological$malignancies$with$leukaemia$and$lymphoma$having$a$high$incidence$in$children$(Lightfoot$ &$ Roman,$ 2004,$ Mostaço^Guidolin$ et# al,$ 2011$ &$ Zelig$ et# al,$ 2011).$However,$overall$ they$affect$a$ larger$number$of$adults,$with$ the$most$common$forms$of$leukaemia$and$lymphoma$most$prevalent$in$people$over$the$age$of$fifty$(Cancer$ Research$ UK,$ 2011b,$ 2012b,$ 2013a$ &$ 2013b).$ The$ main$ difference$between$ leukaemias$ and$ lymphomas$ is$ the$ way$ in$ which$ they$ progress.$Leukaemias$proliferate$as$single$cells$in$the$blood$or$lymph,$whereas$lymphomas$do$ so$ as$ a$ solid$ tumour$ mass$ within$ lymphoid$ tissue$ such$ as$ bone$ marrow$(Mostaço^Guidolin$et#al,$2011,$&$Hoffbrand$et#al,$2010).$ It$has$been$questioned$which$stage$of$differentiation$gives$rise$to$leukaemia;$however,$it$appears$most$likely$that$the$type$of$leukaemia$developed$is$dependent$on$the$cell$lineage$and$stage$ of$ differentiation$ at$which$ the$ abnormality$ occurred$ (Celso$ et# al,$ 2009).$Myeloma,$which$is$not$the$focus$of$this$thesis,$is$cancer$of$the$plasma$cells$found$in$bone$marrow.$$$
Leukaemia#Leukaemia$ is$ a$disease$ that$has$been$well$ recognised$ throughout$history,$with$Bennett$first$describing$it$in$the$mid$nineteenth$century$(Bennett,$1845$&$Piller,$2001).$It$is$a$cancer$of$the$leucocytes,$found$in$the$lymph$nodes$and$spleen,$and$the$bone$marrow$(Babrah$et#al,$2009$&$Sheng$et#al,$2013).$ It$develops$through$the$ proliferation$ of$ immature$ leucocytes,$ which$ are$ vital$ in$ the$ fight$ against$infection.$Thus$if$the$leucocytes$are$abnormal$then$the$risk$of$infection$is$higher$which$ in$ turn$becomes$more$difficult$ to$ fight$ (Sahu$et# al,$ 2006).$A$build$up$of$leucocytes$ in$ parts$ of$ the$ lymphatic$ system$ and$ liver$ can$ cause$ abdominal$swelling.$ Too$many$ leucocytes$ also$ reduce$ the$ space$ for$ other$ types$ of$ blood$cells$such$as$erythrocytes$(red$blood$cells)$and$megakaryocytes$(plasma$cells).$A$lack$of$erythrocytes$gives$rise$to$anaemia$and$not$enough$megakaryocytes$leads$to$problems$with$excess$bleeding$(Zelig$et#al,$2011$&$Hoffbrand$et#al,$2010).$$$There$are$several$subtypes$of$ leukaemia,$which$differ$ in$ the$ type$of$ leucocytes$affected$and$the$time$it$takes$to$develop.$The$two$main$forms$of$ leukaemia$are$
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acute,$ which$ is$ aggressive$ proliferation$ and$ accumulation$ of$ immature$leucocytes$ that$ develops$ quickly$ at$ any$ age,$ and$ chronic$ which$ is$ a$ slow$proliferation$ of$ mature$ leucocytes$ that$ develops$ slowly$ in$ adults.$ These$ are$further$ subdivided$ into$ myeloid$ and$ lymphoblastic$ (also$ referred$ to$ as$lymphocytic)$ according$ to$ the$ cells$ that$ are$ affected$ (Jennings$ &$ Foon,$ 1997,$Piller,$2001$&$Hoffbrand$et#al,$2010).$The$most$common$type$of$leukaemia$in$the$Western$world$ is$ chronic$ lymphoblastic$ leukaemia$ (CLL),$which$ affects$B$ cells$(Shultz$et#al,$1996$&$Cancer$Research$UK,$2013a).$It$is$probably$the$most$studied$form$of$ leukaemia$due$ to$ the$ fact$ that$ it$ is$more$accessible$ to$ researchers$and$that$it$can$be$studied$over$time.$$$
Lymphoma#Lymphoma$is$a$cancer$of$ the$ lymphatic$system,$commonly$affecting$the$spleen,$bone$ marrow$ and$ peripheral$ lymph$ nodes$ (Ronson$ et# al,$ 2006).$ It$ develops$through$ the$proliferation$of$ lymphocytes,$which$accumulate$ in$ lymph$nodes$ to$form$a$tumour.$There$are$two$main$types,$Hodgkin$Lymphoma$(HL),$named$after$Thomas$Hodgkin,$and$non^Hodgkin$Lymphoma$(NHL),$with$NHL$being$the$most$prevalent$ (Ansell$&$Armitage,$2005,$Cancer$Research$UK$2011b$&$2013b).$The$major$difference$between$HL$and$NHL$can$be$ identified$under$a$microscope$as$the$cells$affected$in$HL$have$a$particular$binucleate$appearance,$these$are$known$as$Reed$Sternberg$cells$(Jennings$&$Foon,$1997).$These$cells$are$not$present$ in$NHL.$$$Both$forms$of$lymphoma$affect$cells$of$the$lymph$nodes,$which$are$found$all$over$the$body$and$are$ connected$via$ lymph$vessels.$Unfortunately$ this$network$can$often$lead$to$the$spread$of$lymphoma$not$just$to$other$lymph$nodes$but$also$to$the$ blood$ and$ organs$ (Isabelle$ et# al,$ 2008).$ These$ cancers$ often$ present$ with$enlarged$ lymph$ nodes,$ owing$ to$ the$ accumulation$ of$ leucocytes$ within$ the$lymphatic$ system.$The$nodes$ that$ they$affect$ can$help$ to$differentiate$between$HL$and$NHL.$HL$tends$to$affect$the$lymph$nodes$in$the$neck$first$whereas$NHL$more$commonly$affects$ lymph$nodes$ in$ the$ tonsils$or$ thymus.$However,$ this$ is$not$ always$ true$ and$ cannot$ be$ relied$ upon$ as$ a$ method$ of$ classification$(Hoffbrand$et#al,$2010).$$
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Figure#1.2.$The#Lymphatic#System;$the$vast$lymphatic$network$is$represented$in$green,$the$major$organs$involved$and$their$functions$are$highlighted$(Source:$Purves$et#al,$2004)$$$Haematopoietic$cells$turn$over$rapidly$in$the$body$so$as$to$maintain$homeostasis$(Debatin$ et# al,$ 2003).$ If$ these$ cells$ fail$ to$ respond$ to$ the$ external$ stimuli$responsible$ for$ their$ growth,$ an$ excess$ accumulation$ of$ immature,$ non^functional$ cells$ can$ arise.$ It$ is$ vital$ that$ these$ cells$ are$ removed$ and$ thus$apoptotic$pathways$are$necessary$to$destroy$them.$Haematological$malignancies$tend$to$result$when$there$are$problems$with$apoptosis$as$there$is$an$increased$number$ of$ immature$ cells$ which$ are$ unable$ to$ carry$ out$ normal$ cellular$functions.$ Failures$ in$ the$ apoptotic$ pathways$ can$ create$ genetically$ unstable$environments$ whereby$ genetic$ mutations$ can$ arise$ that$ support$ tumour$ cell$
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survival.$Proto^oncogenes,$which$regulate$growth$and$proliferation,$and$tumour^suppressor$genes,$which$control$apoptosis$of$malignant$cells,$can$be$activated$or$inactivated$ by$ a$ cell$ in$ order$ to$ maintain$ the$ required$ balance$ of$ genes$ for$normal$cell$growth$(Figure$1.3).$An$unbalance$of$these$genes$results$ in$tumour$cell$growth$(Hoffbrand$et#al,$2010).$$$
$
#
Figure# 1.3.# Genetic# Regulation# of# Proliferation# and# Apoptosis;$ normal$ cell$proliferation$ depends$ on$ balance$ between$ proto^oncogenes$ and$ tumour^suppressor$genes,$which$is$unstable$in$malignant$cells$(adapted$from$Hoffbrand$
et#al,$2010)$
!$
1.2.2.#Classification##The$ distinctions$ between$ each$ type$ of$ cancer$ are$ based$ on$ morphology,$ and$clinical$ presentation$ combined$ with$ molecular$ and$ immunophenotyping$methods$ (Ottensmeier,$2001).$Leukaemias$are$broadly$divided$ into$myeloid$or$lymphoblastic$ and$ these$ can$ either$ be$ acute$ or$ chronic$ according$ to$ how$aggressive$ they$ are.$ High$ grade,$ or$ acute,$ leukaemias$ are$ very$ aggressive$ and$
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$Generated$ from$ UK$ cancer$ registries$ statistics$ (Cancer$ Research$ UK,$ 2011b,$2013a$&$2013b)$
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Many$ of$ the$ leukaemias$ and$ lymphomas$ in$ Table$ 1.2$ can$ be$ subdivided$ or$classified$ into$ even$ smaller$ groups.$ Different$ countries$ use$ different$classification$systems.$$
#






• M7$–$Acute$Megakaryocytic$Leukaemia$(rare)$$The$WHO$system$is$slightly$different.$ It$ looks$at$the$type$of$myeloid$cell$ that$ is$abnormal$as$well$as$any$genetic$changes,$whether$more$than$one$type$of$blood$cell$ is$ abnormal,$ whether$ the$ AML$ developed$ following$ a$ blood$ disorder$ and$finally$whether$AML$developed$after$other$cancer$treatment.$$$Acute$Lymphoblastic$Leukaemia$(ALL)#used$to$be$classified$into$three$groups,$L1,$L2,$ L3,$ according$ to$ the$FAB$system.$This$ system$ identifies$ changes$ to$ cell$ size,$nuclear$size$and$shape,$number$of$nucleoli$and$amount$of$cytoplasm.$Now$it$ is$classified$as$follows$according$to$the$WHO$system.$#
• Pre$(precursor)$B$Cell$$^$most$common$(70$%$of$cases)$
• Mature$B$Cell$or$Burkitt$Type$$
• Pre$(Precursor)$T$Cell$–$more$common$in$men$and$young$adults$$Classification$of$ chronic$ leukaemias$ is$much$ simpler.$The$most$ common$ forms$are$chronic$myeloid$leukaemia$(CML)$and$chronic$lymphocytic$leukaemia$(CLL).$
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More$ rare$ forms$ include$ prolymphocytic$ leukaemia$ and$ hairy$ cell$ leukaemia.$(Lilleyman$et#al,$1986,$Jennings$&$Foon,$1997,$Woolf,$1998$&$Szczepański$et#al,$2003).$$$




• Lymphocyte$Depleted$(very$rare)$Nodular$ lymphocyte$predominant$ type$accounts$ for$20$%$of$ cases.$They$differ$from$ the$ classical$ type$ in$ that$ they$ have$ very$ few$ Reed^Sternberg$ cells$ but$instead$have$‘popcorn’$shaped$cells$(Cancer$Research$UK,$2013c).$$Non^Hodgkin$Lymphoma$(NHL)$is$classified$according$to$the$WHO$system.$There$are$ over$ sixty$ different$ subtypes$ and$ thus$ classification$ is$ difficult.$ However,$generally$ they$ are$ classified$ according$ to$whether$ they$ are$ high$ grade$ or$ low$grade,$B^cell$or$T^cell,$their$cellular$appearance$(large,$small,$grouped$or$diffuse),$what$ proteins$ or$markers$ are$ present$ on$ the$ cell$ surface$ and$ if$ there$ are$ any$genetic$abnormalities$(Cancer$Research$UK,$2013d).$$$
1.2.3.#Staging#Haematological$malignancies$can$also$be$staged$according$to$their$progression.$This$is$vital$in$providing$the$most$suitable$treatment$to$the$patient.$$$
Leukaemia#Staging#There$ is$ no$ standard$ staging$ system$ for$ the$ acute$ leukaemias.$ Patients$ are$broadly$staged$as:$
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• Untreated$–$newly$diagnosed$patients$with$an$abnormal$full$blood$count,$>5$ %$ of$ cells$ in$ bone$ marrow$ are$ blasts$ and$ signs$ and$ symptoms$ of$leukaemia.$
• Remission$–$these$patients$have$a$normal$full$blood$count,$<5$%$blasts$in$their$bone$marrow$and$no$signs$or$symptoms$of$leukaemia.$$There$ are$ three$ stages$ of$ CML:$ chronic,$ accelerated$ and$ blast$ phases$ (Cancer$Research$UK,$2013a):$
• Chronic#phase$–$leukaemia$is$most$stable$and$still$developing$slowly.$Ten$per$cent$of$the$blood$cells$in$bone$marrow$will$be$immature$blasts.$About$90$%$of$people$are$in$the$chronic$phase$when$they$are$diagnosed. 
• Accelerated#phase$–$symptoms$such$as$tiredness,$weight$loss$and$painful$stomach$due$to$an$enlarged$spleen$can$arise.$Between$10$and$30$%$of$the$blood$cells$will$be$immature$blasts.$ 
• Blast#phase$–$Rapid$and$aggressive$leukaemia,$also$called$acute$phase$or$blast$crisis.$Over$30$%$of$the$blood$cells$will$be$immature$blasts$and$the$disease$will$have$spread$to$other$organs.$ $There$are$two$systems$used$to$stage$CLL,$one$is$the$Rai$system$used$in$America$and$the$other$is$known$as$the$Binet$System,$which$is$used$in$the$UK$and$Europe.$The$ Binet$ System$ categorises$ the$ cancer$ into$ three$ stages,$ A,$ B$ and$ C$ (Cancer$Research$UK,$2013a):$
• Stage#A$ –$ fewer$ than$ three$ groups$ of$ enlarged$ lymph$nodes$ and$ a$ high$white$blood$cell$count.$Patient$is$unlikely$to$show$symptoms.$ 
• Stage#B$ –$more$ than$ three$ groups$of$ enlarged$ lymph$nodes$ are$present$and$there$is$a$high$white$blood$cell$count.$Patient$will$be$tired$and$poorly$or$show$no$symptoms.$ 





Lymphoma#Staging#The$system$used$to$stage$both$types$of$ lymphoma$in$ the$UK$and$Europe$ is$ the$Ann$Arbor$system,$which$divides$the$cancer$ in$to$four$stages,$1,$2,$3$and$4$and$within$ these$ four$ stages$ cancers$ can$ also$ be$ further$ divided$ into$ type$ A$ or$ B.$Type$A$refers$to$an$absence$of$symptoms$whereas$B$refers$to$a$patient$suffering$with$symptoms$(Ansell$&$Armitage,$2005,$Cancer$Research$UK,$2011b$&$2013b):$
• Stage#1$–$only$a$single$tumour$resides$and$has$not$spread.$One$group$of$lymph$ nodes$ is$ affected$ or$ lymphoma$ occurs$ in$ just$ one$ organ$ of$ the$body.$$
• Stage#2$–$two$or$more$groups$of$lymph$nodes$are$affected$or$an$organ$and$one$or$more$groups$of$lymph$nodes$but$these$are$on$the$same$side$of$the$diaphragm,$i.e.$the$tumour$has$not$spread$far.$$
• Stage#3$–$lymph$nodes$are$affected$on$both$sides$of$the$diaphragm.$$
• Stage# 4$ –$ lymphoma$ has$ spread$ outside$ the$ lymph$ nodes$ and$ reached$organs$such$as$the$liver,$bone$or$lungs.$$$$




and#2007#$ Leukaemia# Hodgkin#Lymphoma# NonSHodgkin#





5.9$$4.9$ 2.8$$2.6$ 1.4$$0.4$ 5.5$$14.2$ 3.3$$5.2$$Generated$ from$ UK$ cancer$ registries$ statistics$ (Cancer$ Research$ UK,$ 2011a,$2012b,$&$Office$for$National$Statistics,$2011b)$$$
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Comparing$ the$data$ in$Table$1.3$with$Figure$1.4$ it$ is$ clear$ to$ see$ that$ in$2007,$there$were$7.4$cases$of$leukaemia$per$100,000$people,$an$increase$of$28$%$from$1975.$The$mortality$rates$for$the$disease$reduced$by$17$%$which$although$is$an$improvement,$when$compared$to$the$five^year$survival$rate$of$40$%$of$cases,$it$is$still$ poor.$ Both$ the$ incidence$ and$mortality$ rates$ for$Hodgkin$ lymphoma$ have$improved$over$the$last$thirty$years,$alongside$the$five^year$survival$rate.$In$1975,$53.9$ %$ of$ sufferers$ survived$ for$ five$ years,$ better$ than$ the$ survival$ rate$ for$leukaemia$in$2005.$Today$over$80$%$of$Hodgkin$Lymphoma$patients$survive$for$more$ than$ five$ years.$ The$ incidence$ of$ non^Hodgkin$ Lymphoma$ has$ almost$tripled$ since$ 1975,$which$ is$ a$ significant$ growth$ in$ the$ disease.$ The$mortality$also$ increased$ by$ 58$ %,$ again$ a$ significant$ increase$ in$ the$ last$ thirty$ years.$Fortunately$the$five^year$chance$of$survival$has$improved$from$29$to$55.5$%$of$cases,$although$like$leukaemia$this$is$still$low$compared$to$other$cancers.$These$statistics$show$that$leukaemia$and$non^Hodgkin$lymphoma$still$have$a$fair$way$to$go$ to$be$on$par$with$ the$ survival$ rates$of$diseases$ such$as$ testicular$ cancer$(97.1$%)$and$breast$cancer$(84.2$%),$which$means$more$research$is$needed$into$the$ aetiology,$ potential$ molecular$ markers$ for$ diagnosis$ as$ well$ as$ improved$methods$ for$ diagnosis$ and$ treatment$ (Office$ for$ National$ Statistics,$ 2011b).$Trends$ similar$ to$ these$ can$be$ seen$across$ the$world,$mainly$ in$ the$developed$countries$ where$ diagnosis$ and$ treatment$ is$ available.$ In$ countries$ where$medical$help$ is$ less$ readily$ available$ the$ incidence$appears$ the$ same,$however$mortality$is$higher$and$the$one,$five,$and$ten^year$survival$rates$are$significantly$lower.$$$
1.2.5.#Aetiology$The$ aetiology$ of$ these$ cancers$ remains$ unknown$ as$ only$ a$ small$ number$ of$haematological$ malignancies$ arise$ from$ an$ inherited$ mutation$ (Segel$ &$Lichtman,$ 2004).$ However,$ the$ risk$ factors$ for$ a$ small$ proportion$ of$ subjects$have$ been$ identified$ (Vineis$ et# al,$ 1996).$ These$ can$ be$ of$ genetic$ or$environmental$influence$and$can$affect$both$children$and$adults.$Risk$factors$can$range$ from$ exposure$ to$ materials$ such$ as$ benzene,$ pesticides,$ and$ past$chemotherapy,$which$are$mostly$thought$to$have$immunosuppressive$qualities,$
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to$ smoking,$ drinking,$ being$ overweight$ and$ even$ using$ particular$ hair$ dyes$(Vineis$ et# al,$ 1996,$Woolf,$ 1998$ &$ Lightfoot$ &$ Roman,$ 2004).$ The$majority$ of$children$that$are$diagnosed$with$a$haematological$malignancy$would$most$likely$not$have$been$exposed$to$risk$factors$such$as$these$so$early$in$life.$It$may$be$that$the$ parents$ have$ been$ exposed$ to$ such$ risks$ and$ Lightfoot$ &$ Roman$ (2004)$suggest$ that$exposure$ to$either$parent$may$create$germ$cell$mutations$ in$ their$children.$$$It$has$been$suggested$by$Smith$et#al$(2009)$that$the$risk$of$leukaemia$occurring$in$ childhood$ is$ higher$ in$ girls$ and$ in$ those$ that$were$ overweight$ at$ birth,$ and$their$work$supports$the$theory$that$leukaemia$originates$prenatally.$However,$a$previous$ report$ by$ Lightfoot$ &$ Roman$ (2004)$ stated$ that$ haematological$malignancies$ are$more$ commonly$ seen$ in$boys$ than$girls,$with$ the$majority$ of$lymphomas$ occurring$ in$ boys.$ It$ has$ also$ been$ reported$ that$ there$ is$ a$ higher$risk$ of$ NHL$ developing$ in$ people$ with$ low$ immunity,$ such$ as$ human$immunodeficiency$virus$(HIV)$sufferers$(Vineis$et#al,$1996).$According$to$Vineis$








































$Identifies$ cancer$according$ to$ symptoms,$e.g.$ enlarged$ lymph$nodes.$$$$Identifies$ abnormalities$in$H&E$stained$samples.$$$Histological$identification$of$enlarged$lymph$nodes$and$tissues.$$Identifies$ spread$ of$cancer$to$bone$marrow.$$Identifies$specific$genetic$abnormalities.$$Uses$ antibodies$ to$identify$ presence$ of$ cell$specific$ proteins$ related$to$ cancer.$ Can$specifically$ identify$stages$of$cancer.$$$






















Identify$specific$subtypes$of$ cancer$ utilising$ their$gene$expression.$$$$$Uses$ radiolabelled$glucose$ to$ identify$presence$ of$ disease$following$treatment.$$Used$in$conjunction$with$PET,$ identifies$ spread$ of$cancer$to$other$organs.$$Identify$ changes$ in$biochemical$composition,$ non^destructive,$ quick,$reliable,$ easily$interpretable.$










Figure#1.5.$Process#of#Diagnostic#Analysis#of#Haematological#Malignancies;$(a)$ repeated$ flow$ cytometry$ or$ immunohistology$ required,$ (b)$ initial$ results$obtained$may$ suggest$ further$molecular$ investigations,$ (c)$ results$ checked$ by$senior$member$ of$ team,$ (d)$ haematological$malignancy$ diagnoses$ are$ checked$by$ a$ further$ member$ of$ team$ to$ ensure$ correct$ diagnosis,$ (e)$ another$ report$produced$to$highlight$additional$information$regarding$the$malignancy$(adapted$from$Richards$&$Jack,$2003)$$$Within$ GHNHSFT$ a$ document$ has$ been$ drawn$ up$ for$ patients$ to$ indicate$ the$timescale$ from$ hospital$ referral$ and$ initial$ diagnosis$ to$ cancer$ treatment$ and$after$ care$ (Figure$ 1.6).$ Referrals$ are$ generally$ made$ by$ a$ GP$ (General$Practitioner)$ to$ the$hospital,$which$can$take$up$to$14$days$(stage$1).$Following$this,$the$initial$services$are$provided.$This$involves$diagnostic$tests$ranging$from$blood$tests$to$biopsies$and$X^rays$or$other$scans.$The$type$and$number$of$tests$carried$ out$ determines$ the$ length$ of$ time$ taken$ and$ can$ significantly$ alter$ the$cost$ (stage$ 2).$ The$ diagnosis$ and$ treatment$ plan$ is$ then$ reviewed$ at$ a$multidisciplinary$team$(MDT)$meeting,$involving$all$of$the$medical$professionals$that$will$work$with$the$patient$(stage$3),$before$it$is$discussed$with$the$patient.$It$is$at$this$point$that$a$maximum$of$31$days$is$allowed$before$the$first$treatment$
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must$ be$ provided.$ The$ type$ of$ treatment$ can$ range$ from$ surgery$ to$chemotherapy$or$radiotherapy$(stage$4).$The$overall$time$allowed$for$an$urgent$case,$such$as$an$acute$form$of$ leukaemia,$ from$referral$to$the$first$treatment$ is$62$days,$or$two$months,$which$can$be$longer$if$non^urgent.$The$patient$pathway$then$ continues$ with$ follow^up$ appointments,$ and$ support,$ which$ can$ be$provided$in$a$variety$of$ways$(stage$5)$(Three$Counties$Cancer$Network,$2005).$$$
$$




1.2.8.#Clinical#Need$The$ current$ diagnostic$ techniques$ are$ unable$ to$ diagnose$ haematological$malignancies$ independently.$ Morphological$ analysis$ must$ be$ combined$ with$other$ secondary$ techniques$ in$ order$ to$ generate$ accurate$ and$ specific$ results.$This$ can$ be$ expensive,$ as$ multiple$ techniques$ and$ medical$ professionals$ are$required$ and$ it$ can$ be$ inefficient,$ as$ a$ small$ percentage$ of$ cases$ still$ remain$undiagnosed.$$There$ is$ a$ diverse$ range$ of$ leukaemia$ and$ lymphoma$ subtypes,$which$ require$individual$ and$ specific$ treatment$ plans,$ making$ the$ process$ complex.$ Thus$misdiagnosing$ a$ blood$ cancer$ can$ cause$ major$ setbacks$ when$ providing$ a$treatment$ plan$ to$ a$ patient.$ Treatments$ for$ haematological$ malignancies$ are$dependent$on$the$type$and$stage$of$the$cancer.$Currently,$for$early$stage$Hodgkin$lymphoma,$ short^duration$ chemotherapy$ is$ combined$ with$ a$ low$ dose$ of$involved$ field$ irradiation,$which$ is$ sufficient$ to$ cure$ the$disease$ (Santoro$et#al,$2006).$Treatment$ for$more$ advanced$haematological$malignancies$ can$be$ very$invasive,$such$as$chemotherapy$(Santoro$et#al,$2006)$or$bone$marrow$transplant,$which$ has$ been$ adopted$ since$ the$ early$ 1980’s$ (Burnett$ &$ Eden,$ 1997,$ Kuby,$1997$&$Hoffbrand$et#al,$2010).$Approximately$50$%$of$patients$with$advanced$stage$lymphomas$relapse$following$high$dose$chemotherapy$treatment$(Santoro$
et# al,# 2006).$ The$ earlier$ the$ cancer$ is$ detected$ and$ correctly$ diagnosed,$ the$earlier$ it$ can$ be$ treated$ and$ thus$ the$ type$ of$ treatment$ required$ should$theoretically$ be$ less$ demanding$ on$ the$ patient.$ It$ therefore$ follows$ that$ the$earlier$the$diagnosis$the$better$the$prognosis$as$the$treatment$can$be$provided$prior$ to$ the$ cancer$ advancing$ to$ an$ untreatable$ level.$ If$ treatments$ such$ as$chemotherapy$can$be$avoided$or$the$need$for$them$reduced,$a$patient’s$way$of$life$ can$ be$ improved.$ There$ is$ therefore$ a$ need$ to$ replace$ the$ current$ “gold$standard”$techniques$with$methods$that$are$less$time$consuming,$more$accurate,$
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and$ less$ invasive$with$ the$ potential$ to$ be$ overall$ cost$ effective$with$ a$ smaller$combination$of$techniques$being$required.$$$$
1.3.#Optical#Diagnostic#Methods#Recent$ research$ has$ explored$ the$ potential$ of$ optical$methods$ as$ new$ tools$ in$clinical$ diagnosis.$ Such$ methods$ include$ fluorescence,$ Raman$ and$ infrared$spectroscopy,$ which$ utilise$ radiation$ from$ the$ electromagnetic$ spectrum$ to$probe$ molecules$ and$ obtain$ information$ regarding$ biochemical$ composition.$These$methods$have$the$potential$to$be$rapid,$non^invasive,$and$provide$highly$accurate$ real^time$ information$ thus$ eliminating$ the$ need$ for$ histological$ and$surgical$methods$ that$ are$ currently$used$ in$diagnosis.$Diagnoses$ can$ therefore$be$made$at$a$faster$rate,$with$treatment$provided$earlier,$reducing$the$emotional$distress$caused$to$patients$and$potentially$the$costs$involved$(Bigio$&$Mourant,$1997).$$$






1.3.2.#The#Interaction#of#Light#with#Matter#The$ interaction$of$ light$with$matter$ can$ cause$a$photon$ (a$ light$particle)$ to$be$emitted,$ absorbed$or$ scattered.$ Spectroscopy$ is$ the$ study$of$ spectra$ generated$by$ this$ emission,$ absorption$ or$ scattering$ (elastic$ and$ inelastic)$ of$electromagnetic$radiation$by$a$molecule,$which$ is$undertaken$to$determine$the$molecular$ composition$ of$ a$ sample.$ Emission# spectroscopy$ is$ the$ molecular$transition$ from$a$ state$ of$ high$ energy$ to$ a$ state$ of$ low$energy$ resulting$ in$ the$emission$of$a$photon.$Absorption#spectroscopy$measures$the$incident$radiation$at$varied$frequencies.$Upon$radiation,$both$absorption$and$emission$occur,$and$the$difference$ (or$ net$ absorption)$measured$ by$ a$ detector.$ Examples$ of$molecular$absorption$ of$ electromagnetic$ radiation$ are$ infrared$ and$ fluorescence$spectroscopies.$ When$ electromagnetic$ radiation$ is$ scattered$ there$ are$ three$different$ types$ of$ radiation$ that$ can$ be$ emitted:$ Stokes$ Raman,$ anti^Stokes$Raman$and$Rayleigh$radiation.$Both$Stokes$and$anti^Stokes$Raman$radiation$are$a$form$of$inelastic#scattering.$In$Stokes$radiation,$photons$and$molecules$collide$and$ energy$ is$ released.$ Lower$ frequency$ radiation$ is$ then$ emitted$ from$ the$sample$as$a$result$of$a$loss$in$photon$energy.$In$anti^Stokes$radiation$the$photons$gain$ energy$ from$ already$ excited$ molecules$ thus$ causing$ a$ higher$ frequency$radiation$to$be$emitted$from$the$sample.$In$Rayleigh$radiation$there$is$no$change$
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in$ frequency$ when$ molecules$ and$ photons$ collide,$ this$ is$ a$ form$ of$ elastic#
scattering.$(Griffiths$&$de$Haseth,$2007,$Smith$&$Dent,$2008$&$Atkins$&$de$Paula,$2010).$$$A$molecule$in$space$can$interact$with$photons$in$a$variety$of$ways.$This$is$due$to$the$vibrational$motions$of$the$chemical$bonds$produced$when$molecules$absorb$infrared$ light.$ Linear$ molecules$ have$ 3n55$ vibrational$ modes$ and$ non^linear$molecules$have$3n56,$where$n$ accounts$ for$ the$number$of$ atoms$ in$a$molecule$(Griffiths$&$de$Haseth,$2007).$Different$ types$of$vibrational$motions$ can$occur,$such$as$bending;$which$ can$entail$ scissoring,$ rocking,$wagging$or$ twisting,$ and$





Figure# 1.8.# Energy# Level# Diagram# of# MidSIR,# Rayleigh,# Stokes# and# AntiS
Stokes#Raman#$$
1.3.3.#Infrared#Absorption#Spectroscopy##Infrared$ absorption$ spectroscopy$ utilises$ mid^infrared$ radiation$ from$ a$polychromatic$ light$ source$ in$ order$ to$ probe$ the$ molecular$ vibrations$ within$molecules.$ These$ vibrations$ are$ not$ random$ but$ specific$ to$ the$ biochemical$constituents$of$the$molecule$and$are$subject$to$influences$from$interactions$with$other$ bonds$ and$ biochemical$ groups$ as$well$ as$ the$ surrounding$ environment.$The$ information$obtained$from$this$ technique$allows$the$biochemical$structure$to$ be$ identified$ from$ an$ infrared$ spectrum.$ This$ spectrum$ displays$ the$frequencies$ of$ the$ vibrational$ modes,$ which$ in$ turn$ provides$ a$ characteristic$signature$of$the$molecule$and$its$biochemical$structure.$Infrared$spectroscopy$is$a$ rapid,$ non^destructive$ and$ reproducible$ technique$ that$ is$ valuable$ in$ the$clinical$ environment$ particularly$ in$ disease$ diagnosis.$ It$ has$ been$ utilised$ as$ a$biomedical$application$in$the$diagnosis$and$assessment$of$the$prognosis$of$many$cancers$(Ramesh$et#al$2002,$Ramesh$et#al,$2003,$Sahu$&$Mordechai,$2005,$Ellis$&$Goodacre,$2006$&$Sahu$et#al,$2006).$$$
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This$method,$although$able$to$characterise$the$complex$structures$of$molecules$independently,$ is$ often$ used$ in$ combination$ with$ other$ complementary$techniques$ in$ order$ to$ gain$ a$ broader$ perspective$ on$ the$ structure$ of$compounds.$It$is$also$inhibited$by$water,$which$limits$in#vivo$study;$therefore$it$is$commonly$used$alongside$Raman$spectroscopy,$as$water$does$not$influence$the$spectra$ as$ strongly.$ These$ techniques$ also$ have$ sensitivities$ to$ different$functional$groups$allowing$a$broader$knowledge$of$the$biochemical$constituents$of$ the$ compounds$ (Ellis$ &$ Goodacre,$ 2006,$ Babrah$ et# al,$ 2007,$ Griffiths$ &$ De$Haseth,$2007,$Babrah$et#al,$2009$&$Siebert$&$Hildebrandt,$2008).$$$
1.3.4.#Fluorescence#Spectroscopy#Tissue$ contains$ a$ variety$ of$ chromophores,$ which$ can$ be$ fluorescent$ or$ non^fluorescent$ in$ nature.$ Fluorescent$ chromophores,$ such$ as$ collagen$ and$ elastin,$emit$ fluorescence$ following$ absorption$of$ light$ of$ a$different$wavelength.$Non^fluorescing$ chromophores,$ such$ as$ haemoglobin$ have$ the$ ability$ to$ absorb$ the$incident$light$without$fluorescing,$which$can$cause$a$reduction$in$energy$in$the$spectra$ (Bigio$ &$ Mourant,$ 1997).$ Aside$ from$ the$ aforementioned$ endogenous$fluorophores$found$within$tissue$that$are$fluorescent$in$nature,$fluorescence$can$also$ be$ induced$ in$ tissues$ using$ precursor$ molecules.$ Commonly,$ 5^aminolevulinic$ acid$ (ALA)$ is$ used$ to$ induce$ the$ fluorophore$ protoporphryn$ IX$(PpIX).$ Fluorophores,$ such$ as$ fluorescein$ and$ Hematoporphyrin$ derivative$(HPD),$ can$ also$ be$ administered$ in$ the$ form$ of$ drugs;$ these$ are$ generally$referred$to$as$exogenous$fluorophores$(Wagniѐres$et#al,$1998).$$$Often$ UV$ and$ visible$ light$ are$ used$ to$ excite$ the$ molecules$ in$ Fluorescence$spectroscopy.$When$subjected$to$the$incident$light,$fluorophores$become$excited$and$ emit$ their$ characteristic$ fluorescence.$ Differences$ in$ the$ fluorescence$emitted$ in$ cancerous$ tissue,$ compared$ to$ normal,$ are$ due$ to$ changes$ in$ the$structure$ and$ or$ concentration$ of$ the$ absorbing$ fluorophores.$ Fluorescence$spectroscopy$ has$ been$ utilised$ in$ the$ diagnosis$ of$ several$ cancers$ including$breast,$ lung$ (Alfano$ et# al,$ 1987)$ and$ oesophageal$ (Endlicher$et# al,$ 2001),$ thus$highlighting$ its$ diagnostic$ potential$ in$ other$ cancers$ (Choi$ et# al,$ 2007).$
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Advantages$of$this$technique$are$that$it$has$the$ability$to$be$used$in#vivo,$unlike$IR$which$ is$ subject$ to$ interference$ from$water.$Also$ fluorophores$ such$as$HPD$are$ sensitive$ to$ cancerous$ tissue,$ providing$ great$ visualisation$ of$ the$ contrast$between$ tumour$ and$ surrounding$ tissue$ in$ the$ observation$ of$ cancer$ during$treatment# (Choi$ et# al,$ 2007).$ However,$ HPD$ has$ the$ ability$ to$ interact$ with$normal$tissue$thus$it$has$been$known$to$generate$false$positives$and$has$a$lower$rate$of$sensitivity$and$specificity$compared$to$other$similar$techniques$such$as$IR$and$Raman$(Alfano$et#al,$1984).$#
#
#
1.3.5.#Elastic#Scattering#Spectroscopy##Elastic$ scattering$ spectroscopy$ (ESS)$ uses$ the$ UV/visible$ region$ of$ the$electromagnetic$spectrum$covering$ the$wavelengths$ from$300^900$nm.$Light$ is$directed$ towards$ a$ sample$ and$once$ it$ interacts$with$ tissue,$ back$ scattering$of$the$photons$occurs,$resulting$in$no$change$to$the$wavelength$(Anandasabapathy,$2008).$The$way$in$which$light$becomes$scattered$in$tissue$depends$on$both$the$structure$ of$ the$ tissue$ and$ the$ wavelength$ of$ light$ directed$ towards$ it.$ The$incident$ light$ may$ be$ subject$ to$ multiple$ scattering$ episodes$ before$ being$detected$(Swinson$et#al,$2006).$In$such$a$case,$information$can$be$obtained$from$deeper$ tissue.$ It$ can$ also$ undergo$ single$ scattering$ events,$ which$ are$ a$ less$common$and$is$more$often$referred$to$as$light$scattering$spectroscopy$(LSS).$In$LSS,$morphological$ information$ is$ generally$ only$ obtained$ from$ the$ surface$ of$tissue.$ The$ type$ and$ number$ of$ scattering$ events$ in$ ESS$ is$ dependent$ on$ the$scattering$particles$having$a$similar$size$to$the$wavelength$of$the$photons$(Bigio$&$Mourant,$1997).$$The$signal$obtained$from$ESS$is$significantly$more$intense$than$that$from$other$methods$ such$ as$ Raman$ and$ fluorescence$ spectroscopy.$ This$ is$ due$ to$ the$increased$ number$ of$ collisions$ that$ occur$ between$ the$ photons$ and$ the$scattering$ particles$ and$ thus$ allows$ the$ technique$ to$ be$ more$ rapid$ and$potentially$a$more$cost^effective$method$in$the$diagnosis$of$cancer$(Jerjes$et#al,$2004$ &$ Swinson$ et# al,$ 2006).$ However,$ ESS$ differs$ from$ the$ other$ optical$methods$ discussed$ here$ in$ that$ it$ provides$ structural$ and$ morphological$
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information$ from$ tissue$ rather$ than$ biochemical$ due$ to$ the$ fact$ that$ it$ is$sensitive$ to$ changes$ in$ size$ and$ structure$ (Bigio$&$Mourant,$ 1997,$ Jerjes$ et# al,$2004$&$Swinson,$2006).$$$
#
#
1.3.6.#Inelastic#Scattering#Spectroscopy#(Raman)#Inelastic$ scattering$ spectroscopy$ (ISS),$ as$ its$ name$ suggests,$ is$ the$ inelastic$scattering$ of$ photons$ from$ a$ monochromatic$ light$ source.$ The$ inelastically$scattered$photons$have$a$different$energy$to$the$incident$photons$as$a$result$of$the$ transition$ of$ the$ molecules$ from$ one$ energy$ state$ to$ another$ (Siebert$ &$Hildebrandt,$2008).$This$change$in$energy$is$referred$to$as$a$Raman$shift$and$is$complementary$ to$ an$ IR$ absorption$ spectrum$ as$ the$ spectra$ have$ peaks$ of$similar$shapes$and$positions$relating$to$the$molecular$groups$(Ellis$&$Goodacre,$2006).$$$Raman$ spectroscopy$ is$ a$ very$ sensitive$ and$ accurate$ method,$ however$ the$Raman$ shift$ is$ extremely$ weak$ due$ to$ the$ photons$ undergoing$ approximately$only$one$in$106$–$108$scattering$events$(Ellis$&$Goodacre,$2006$&$Swinson,$2006).$Due$to$this,$longer$irradiation$times$are$required$in$order$to$enhance$the$Raman$signal.$ This$ can$ cause$ over^heating$ and$ damage$ to$ the$ sample,$ but$ it$ can$ be$overcome$ by$ having$ shorter$ exposure$ times$ and$ repeated$ accumulations$ of$scans$ (Lin$ et# al,$ 2007).$ Another$ factor$ that$ can$ affect$ Raman$ spectra$ is$ that$organic$tissue$can$be$subject$to$interference$from$fluorescence$when$excited$by$light$ in$ the$ visible$ region$ of$ the$ electromagnetic$ spectrum.$ This$ has$ been$overcome$by$the$use$of$either$near$IR$light$or$deep$UV$light.$However,$UV$light$has$a$tendency$to$induce$photo^degradation$thus$near$IR$is$the$better$source$of$radiation$to$use$(Krafft$&$Sergo,$2006).$$$The$ advantages$ of$ using$ Raman$ spectroscopy$ alongside$ IR$ are$ that$ it$ is$ not$subject$to$interference$from$water$as$water$has$a$weak$scattering$property,$thus$it$has$the$advantage$that$it$can$be$used$for$fluid$samples$or$even$in#vivo.$It$also$has$higher$specificities$to$certain$biochemical$groups$that$IR$does$not$and$thus$the$ benefit$ of$ using$ the$ techniques$ together$ allows$ for$ a$ broader$ range$ of$
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information$ to$ be$ obtained.$ (Krafft$ &$ Sergo,$ 2006,$ Lin$ et# al,$ 2007$ &$ Swinson,$2006.)$$$
1.3.7.#Conclusion#There$ are$ several$ advantages$ in$ using$ optical$ techniques$ for$ the$ diagnosis$ of$cancers.$Firstly,$using$histological$methods$where$the$morphological$changes$to$tissue$are$detected$is$time$consuming$and$the$samples$analysed$are$not$always$a$true$ representative$ of$ the$ pathology.$ Optical$ techniques$ allow$ you$ to$ collect$biochemical$information$rapidly$and$have$the$potential$to$be$minimally$invasive.$In$using$these$techniques$rather$than$the$current$“gold$standard”$methods,$it$is$anticipated$ that$ costs$ can$be$ reduced$ owing$ to$ the$ speed$ of$ diagnosis$ and$ the$reduced$number$of$medical$professionals$ required.$By$decreasing$ the$need$ for$biopsies$and$reducing$the$waiting$time$for$a$diagnosis,$the$emotional$trauma$to$the$patient$can$be$reduced$as$treatment$can$be$provided$within$a$shorter$period$of$time.$$Although$ all$ of$ the$methods$mentioned$ have$ been$ utilised$ in$ cancer$ diagnosis$they$have$different$advantages$and$disadvantages$to$one$another:$$
• Infrared$ spectroscopy$ is$ hindered$ by$ the$ interference$ of$ water$ thus$ in#
vivo$experimentation$is$almost$impossible,$however$this$disadvantage$can$be$ overcome$ by$ using$ it$ in$ combination$ with$ other$ techniques$ such$ as$Raman.$Although$withdrawing$blood$from$patients$is$invasive,$it$is$less$so$than$other$biopsy$or$surgical$methods.$$$
• In$ fluorescence$ spectroscopy$ the$ administration$ of$ a$ fluorescent$ drug$allows$it$to$be$used$in#vivo;$however$this$advantage$renders$the$technique$invasive$and$may$result$in$side$effects$(Bigio$&$Mourant,$1997).$The$low$sensitivity$ and$ specificity$ of$ this$method$ also$ renders$ it$ less$useful$ as$ a$diagnostic$ tool$ for$ leukaemia$ and$ lymphoma$ than$ the$ other$ optical$techniques$described.$
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• Although$elastic$scattering$spectroscopy$is$relatively$inexpensive$and$can$be$utilised$in#vivo,$the$main$disadvantage$of$it$is$that$it$does$not$probe$the$biochemical$ information$ of$ the$ sample,$ only$ the$morphological$ changes$that$occur$(Swinson$et#al,$2006).$$$
• Raman$spectroscopy$is$an$extremely$sensitive$technique$that$is$hindered$by$its$weak$signal$and$fluorescence$interference.$However,$increasing$the$irradiation$ time$ of$ the$ laser$ and$ using$ near$ IR$ as$ a$ light$ source$ can$overcome$these$inefficiencies.$$Raman$ and$ IR$ are$ the$ methods$ of$ choice$ in$ this$ thesis$ owing$ to$ their$complementary$ nature;$ they$ have$ the$ ability$ to$ obtain$ a$ wider$ range$ of$biochemical$ information$ from$ samples$ owing$ to$ their$ specificities$ toward$different$ functional$ groups.$ Raman$ can$ also$ be$ used$ to$ overcome$ water$interference$in$IR,$whilst$IR$can$be$used$to$overcome$the$weak$signal$in$Raman.$Recently$ more$ studies$ have$ utilised$ these$ techniques$ in$ combination,$particularly$in$cancer$(Sahu$&$Mordechai,$2005,$Ellis$&$Goodacre,$2006,$Krafft$&$Sergo,$2006,$Krishna$et#al,$2006,$Swinson$et#al,#2006,$Lin$et#al,$2007,$Isabelle$et#
al,$2008$&$Kendall$et#al,$2009).$$$
1.4.#Aims#and#Objectives#This$is$a$continuation$of$a$previous$PhD$undertaken$by$Jaspreet$Babrah$(2009)$who$ analysed$ the$ different$ blood$ fractions$ from$ CLL$ samples$ prepared$ via$cytospin$ centrifugation.$ This$ thesis$ compares$ the$ performance$ of$ the$ cytospin$centrifugation$ samples$ with$ Drop$ Coating$ Deposition$ Raman$ Spectroscopy$(DCDRS)$in$diagnosing$leukaemia,$as$ it$ is$a$much$quicker$method$of$depositing$whole$blood$samples$onto$slides.$This$method,$along$with$FTIR$and$Raman$are$explored$further$in$chapter$2.$$$With$the$help$of$multivariate$statistical$analysis,$the$main$aim$of$this$thesis$is$to$identify$the$performance$and$application$of$Raman$and$FTIR$spectroscopy$as$a$diagnostic$tool$for$leukaemia$and$lymphoma$and$by$comparing$healthy$samples$
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to$ cancer$ samples$ the$ biochemical$ changes$ that$ take$ place$ during$ cancer$ can$hopefully$be$detected.$$$This$thesis$aims$to$achieve$these$aims$with$the$following$objectives:$1. DCDRS$
• Determine$ the$ optimal$ parameters$ for$ the$ DCDRS$method$ using$blood$proteins$and$extending$it$for$use$in$FTIR.$2. Leukaemia$
• Assessing$ the$ value$ of$ different$ blood$ fractions$ prepared$ by$ two$different$ methods$ (cytospin$ centrifugation$ and$ DCDRS)$ in$leukaemia$diagnosis.$
• Identifying$ the$ biochemical$ differences$ between$ normal$ and$leukaemia$samples$by$interpreting$Raman$and$FTIR$spectra$of$the$different$blood$fractions.$
• Developing$ classification$ models$ using$ multivariate$ statistical$analysis$ and$ determining$ the$ performance$ of$ these$ models$ in$diagnosing$leukaemia.$3. Lymphoma$
• Assessing$ the$ ability$ of$ FTIR$ and$ Raman$ to$ obtain$ spectra$ from$fine$needle$aspirate$biopsies$from$normal$and$lymphoma$samples.$




#$The$use$of$vibrational$spectroscopies$for$the$analysis$of$biological$materials$has$become$ a$ well^established$ tool$ for$ biochemical$ analysis$ (Mantsch$ et# al,$ 2002,$Ellis$&$Goodacre,$ 2006,$ Filik$&$ Stone,$ 2008,$ Filik$&$ Stone,$ 2009,$ Kendall$ et# al,$2009).$ In$ recent$years$optical$methods,$ such$as$Raman$and$Fourier$Transform$Infrared$(FTIR),$have$successfully$been$used$in$the$detection$of$several$diseases,$including$a$variety$of$cancers.$These$techniques$look$at$changes$to$biochemical$composition,$such$as$protein,$carbohydrate,$nucleic$acid$and$lipid$make^up$and$aim$to$identify$particular$markers$of$the$different$stages$of$cancer$(Dukor,$2002).$The$detection$of$cancer$according$to$the$biochemical$changes$allows$them$to$be$identified$ prior$ to$ morphological$ changes$ being$ apparent,$ thus$ having$ the$potential$to$provide$an$earlier$diagnosis$(Kendall$et#al,$2009).$$$Numerous$studies$have$been$performed$into$the$use$of$FTIR$and$Raman,$which$show$them$to$be$viable$techniques$for$distinguishing$the$stages$of$blood$cancers.$These$techniques$may$also$be$used$to$deduce$the$sensitivity$of$cancer$treatment$(Andrus,$ 2006).$ They$ are$ more$ reliable$ and$ accurate$ than$ current$ diagnostic$methods$as$well$as$being$more$rapid$and$significantly$ less$ invasive.$With$these$advantages$ in$ mind,$ it$ is$ hoped$ that$ these$ new$ technologies$ will$ change$ and$improve$ the$ way$ in$ which$ blood$ cancers$ are$ diagnosed,$ thus$ aiding$ with$prognosis$ and$ treatment$ for$ cancer$ patients.$ This$ chapter$ reviews$Raman$ and$Fourier$ Transform$ Infrared$ spectroscopy$ and$ their$ biomedical$ applications$ as$well$as$the$use$of$chemometrics$for$data$analysis.$$$
2.1.#Fourier#Transform#Infrared#Spectroscopy#FTIR$ is$ an$ absorption$ spectroscopy$ technique$ that$ utilises$ the$ mid^infrared$(MIR)$ region$ of$ the$ electromagnetic$ spectrum$ and$ studies$ the$ interaction$ of$infrared$light$with$a$sample.$A$range$of$frequencies$of$infrared$light$are$directed$towards$a$sample$and$absorption$takes$place$when$the$frequency$of$the$incident$radiation$is$equal$to$that$of$a$molecule’s$vibrational$mode.$Due$to$the$absorption$
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of$the$incident$radiation$by$the$sample,$the$loss$of$frequency$from$the$radiation$is$ detected.$ What$ is$ generated$ is$ a$ unique$ ‘biochemical$ fingerprint’$ of$ the$functional$ groups$ present,$ owing$ to$ the$ induction$ of$ molecular$ vibrations.$Information$can$be$obtained$from$molecular$vibrations$across$the$entire$infrared$(IR)$ spectrum$ with$ most$ techniques$ focussing$ on$ the$ 800^2000$ cm^1$wavenumber$ range$ owing$ to$ the$ presence$ of$ strong$ absorption$ bands$ of$functional$ groups$ in$ this$ region.$Biological$material$ can$ therefore$be$ identified$by$its$biochemical$fingerprint$making$it$possible$to$differentiate$between$healthy$and$cancerous$tissue$according$to$its$composition$(Babrah$et#al,$2007).$$$In$ practise,$ MIR$ light$ is$ passed$ from$ a$ light$ source$ to$ an$ interferometer.$ The$interferometer$used$in$an$FTIR$spectrometer$was$designed$by$Michelson$in$the$late$19th$century$(Figure$2.1).$It$acts$as$a$beam$splitter$as$it$divides$the$infrared$light$ into$ two$ separate$ beams$ of$ differing$ path$ length.$ One$ beam$ is$ reflected$towards$a$ fixed$mirror$and$ the$other$ is$ transmitted$ to$a$moving$mirror$before$being$ recombined$back$ at$ the$beam$splitter.$The$purpose$of$ this$ is$ to$produce$interference$due$to$the$difference$in$path$length$of$the$two$beams$generated$by$the$differing$mirrors.$Once$the$beams$have$recombined$it$is$passed$through$the$sample$and$Fourier$ transform$information$about$ the$sample$ is$detected$before$being$converted$to$a$spectrum$by$a$computer$(Griffiths$&$de$Haseth,$2007).$$The$spectrum$ is$ a$ plot$ of$ the$ wavenumber$ against$ the$ absorption$ intensity,$ or$percentage$(%)$transmittance$(T).$Transmittance$ is$a$ratio$of$ the$ incident$ light$(I0)$to$the$radiated$light$that$comes$out$of$the$sample$(I),$(equation$1)$which$is$converted$to$absorbance$(A)$using$equation$2:$$
Equation!1:##
€ 




A = 2 − log10%T $$In$order$to$eliminate$any$background$interference$that$may$be$produced$by$the$instrument$ or$ the$ substrate$ upon$ which$ the$ sample$ is$ set,$ a$ background$
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spectrum$ is$ taken$ from$ a$ clear$ area$ of$ the$ substrate,$ i.e.$ where$ there$ is$ no$sample.$This$is$then$removed$from$the$sample$spectra.$$$
$
#
Figure# 2.1.$ Structural# Layout# of# a# Common# FTIR# Spectrometer;$ the$Michelson$Interferometer$is$indicated$in$the$dotted$area$$$Infrared$ spectroscopy$has$ improved$greatly$ in$ the$ last$ forty$ years.$ Its$primary$purpose$ was$ to$ determine$ molecular$ structures$ with$ the$ aid$ of$ a$monochromator,$ however$ since$ the$ introduction$ of$ the$ Michelson$Interferometer$and$thus$the$FTIR$Spectrometer$in$the$late$1960’s,$the$technique$of$structural$elucidation$has$become$significantly$quicker,$cheaper,$and$easier$to$use$ (Griffiths$ &$ de$ Haseth,$ 2007).$ A$ monochromatic$ infrared$ spectrometer$simply$ uses$ a$ monochromator,$ either$ a$ prism$ or$ a$ grating,$ to$ split$ all$wavelengths$ of$ the$ infrared$ radiation$ thus$ allowing$ only$ one$ wavelength$ at$ a$time$to$pass$through$to$the$detector.$This$therefore$allows$measurement$of$only$one$wavelength$at$a$time.$An$interferometer$however$allows$the$user$to$scan$all$
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wavelengths$simultaneously$thus$reducing$the$time$needed$to$scan$an$entire$set$of$wavelengths$from$minutes$to$seconds.$This$is$known$as$the$Felgett$Advantage.$Another$advantage$of$using$an$interferometer$is$that$more$energy$is$allowed$to$pass$ through,$ as$ there$ is$ no$ monochromator$ to$ narrow$ down$ its$ path.$ More$energy$means$higher$sensitivity$and$better$quality$spectra.$This$is$known$as$the$Jacquinot$Advantage$(Griffiths$&$de$Haseth,$2007).$A$disadvantage$of$FTIR$is$the$interference$of$water,$particularly$when$analysing$tissue$samples,$as$80$%$of$the$body$ is$ composed$ of$ water.$ This$ can$ however$ be$ overcome$ in$ most$ cases$ by$simply$ allowing$ a$ sample$ to$ dry$ on$ a$ slide$ before$ analysing$ it.$ Problems$ arise$however$ when$ in# vivo$ analysis$ is$ required$ as$ water$ cannot$ be$ removed$ from$inside$the$body.$$$$




(Schultz$ et# al,$ 1996,$ Boydston^White$ et# al,$ 1999,$ Boydston$White$ et# al,#2006).$Boydston^White$et#al$(1999$&$2006)$studied$myeloid$leukaemia$HeLa$cell$ lines$and$identified$that$at$different$stages$of$the$cell$cycle$spectral$changes$could$be$seen$in$the$DNA,$amide$I$and$amide$II$protein$structures$due$to$the$biochemical$differences$ that$ exist$ when$ cells$ undergo$ maturation,$ differentiation$ and$proliferation.$Other$studies$have$shown$that$dried$biofluids$such$as$whole$blood$(Low^Ying$et#al,$2002$&$Shen$et#al,$2003),$serum$(Shaw$et#al,$1998,$Petibois$et#al,$1999$&$Liu$et#al,$ 2002)$and$urine$ (Shaw$et#al,$ 2000)$ can$also$be$measured$by$FTIR,$ which$ shows$ great$ potential$ for$ FTIR$ to$ be$ used$ in$ blood$ cancer$diagnostics,$particularly$for$blood$and$serum$analysis.$$Babrah$et#al$(2007$&$2009)$recently$carried$out$highly$reproducible$studies$into$the$ use$ of$ infrared$ spectroscopy$ to$ diagnose$ leukaemias$ and$ lymphomas.$ In$ a$small$preliminary$study$using$ lymphoma,$ lymphoid$and$myeloid$cell$ lines$ they$successfully$identified$FTIR$as$a$viable$technique$for$diagnosing$haematological$malignancies.$FTIR$with$the$aid$of$multivariate$statistical$analysis$was$shown$to$be$able$to$identify$different$cancers$according$to$very$small$spectral$differences.$A$principal$ componant$Analysis$ (PCA)$ followed$by$ linear$discriminant$analysis$(LDA)$classification$model$was$used,$the$efficiency$of$which$was$validated$using$leave$ one$ out$ cross$ validation$ (LOOCV).$ A$ total$ of$ 83.6$ %$ of$ the$ data$ was$correctly$classified$with$the$methods$achieving$between$80^100$%$sensitivities$and$specificities.$The$cell$lines$used$were$of$pure$cancer$and$thus$more$specific$and$more$observable$biochemical$compositions,$which$would$have$been$easier$to$ distinguish$ than$ actual$ cells$ that$ may$ contain$ other$ structures$ and$ less$obvious$biochemical$differences.$One$of$the$advantages$of$using$cell$lines$was$the$ability$ to$ dry$ the$ samples$ prior$ to$ being$ subjected$ to$ the$ infrared$ light,$which$would$be$more$difficult$with$ in# vivo$ studies.$ The$use$ of$multivariate$ statistical$analysis$was$ shown$ to$ be$ successful$ in$ differentiating$ the$ cancer$ types$ as$ the$different$ cell$ lines$ clustered$ into$ their$ separate$ populations,$ highlighting$ the$potential$of$using$similar$analyses$in$future$investigations.$However,$in$order$for$this$study$to$show$its$full$potential$it$would$be$advantageous$for$the$techniques$to$be$carried$out$on$actual$human$cells$and$the$results$compared,$thus$indicating$its$viability$in$differentiating$not$only$cancer$and$non^cancer$but$also$the$stages$
40 
 
of$ particular$ blood$ cancers.$ It$ has$ even$ been$ suggested$ by$ the$ authors$ that$further$work$needs$to$be$carried$out$at$a$cellular$level$in$order$to$see$if$FTIR$can$still$differentiate$the$cancers$when$using$more$complex$compositions.$$Several$groups$have$identified$Biochemical$variations$in$the$FTIR$spectra$of$CLL$samples.$In$a$preliminary$study$by$Benedetti$et#al$(1985)$differences$in$the$DNA$peak$at$966$cm^1$were$observed,$which$was$assumed$to$be$specific$for$lymphoid$leukaemias.$ Using$ peripheral$ mononuclear$ cells$ Shultz$ et# al$ (1996)$ identified$this$ DNA$ peak$ to$ be$ a$ biomarker$ for$ CLL$ too.$ They$ also$ discovered$ that$ the$amide$I$peak$at$1656$cm^1$was$more$intense$in$the$normal$data$compared$to$CLL$and$that$this$peak$shifted$to$1652$cm^1$ in$the$CLL$spectra.$Erukhimovitch$et#al,$2006$discovered$ that$peaks$at$1056$cm^1,$1270$cm^1$ and$1592$cm^1$ relating$ to$carbohydrates,$ amide$ III$ and$NH2$ vibrations$ of$ amino$ acids$ respectively,$were$significantly$decreased$in$leukaemia$samples.$$$FTIR$microspectroscopy$has$been$successfully$utilised$by$Ramesh$et#al$(2002$&$2003)$ in$ identifying$ the$ presence$ of$ cancer$ following$ chemotherapy$ in$ child$acute$lymphoblastic$leukaemia$(ALL)$patients.$The$aims$of$these$studies$were$to$show$ the$ success$ of$ the$ treatment$ provided$ and$ to$ inspire$ the$ use$ of$ FTIR$ in$other$aspects$of$leukaemia$research.$Their$results$show$that$specific$biochemical$changes$occur$upon$chemotherapy$treatment,$which$can$be$identified$in$spectra$owing$to$a$reduction$in$the$number$of$immature$blood$cells$present.$High$levels$of$ these$ immature$cells$are$ indicative$of$acute$ leukaemias.$Although$they$were$able$to$differentiate$those$who$still$had$successful$chemotherapy$and$those$who$did$not,$they$were$unable$to$identify$biological$markers$to$aid$in$the$prognostic$prediction$of$chemotherapy.$Another$similar$study$by$Sahu$et#al$ (2006)$ looked$at$FTIR$in$both$acute$myeloid$leukaemia$(AML)$and$ALL$patients.$They$looked$at$the$ biochemistry$ of$ white$ blood$ cells$ rather$ than$ blasts$ during$ chemotherapy$treatment$ to$ identify$ if$ they$ returned$ to$ normal$ following$ successful$chemotherapy$treatment.$It$was$shown$that$the$biochemical$profile$of$the$white$blood$ cells$ following$ chemotherapy$ did$ return$ to$ the$ normal$ state,$ as$ seen$ in$control$samples,$suggesting$the$immune$system$had$recovered$and$the$patients$
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were$in$remission.$They$therefore$successfully$discovered$potential$biomarkers$to$use$in$the$identification$of$a$return$to$normalcy$following$chemotherapy.$$$Although$FTIR$has$not$been$utilised$ in$ these$studies$as$a$diagnostic$ technique,$the$ fact$ that$ it$ can$ be$ used$ to$ differentiate$ between$ patients$ who$ have$ had$successful$chemotherapy$and$not$indicates$that$FTIR$may$potentially$be$used$to$differentiate$these$acute$blood$cancers.$The$majority$of$the$work$carried$out$into$the$use$ of$ FTIR$ in$ blood$ cancer$ diagnosis$ has$ looked$ at$ chronic$ lymphoblastic$leukaemia$ (CLL)$owing$ to$ the$ fact$ that$ it$ is$a$more$common$ type$of$ leukaemia$and$its$slow$progressive$nature$allows$it$to$be$more$easily$studied.$These$studies$have$proven$successful$in$identifying$useful$biomarkers$for$leukaemia$detection$(Schultz$et#al,$1996$&$1997$&$Erukhimovitch$et#al,$2006).$Other$FTIR^$leukaemia$studies$have$been$shown$to$identify$whether$a$cancer$is$high$grade$or$low$grade,$however$ it$ has$ not$ been$ used$ in$ the$ classification$ of$ these$ cancers$ (Andrus$&$Strickland,$1998).$It$would$be$advantageous$if$this$technique$could$be$utilised$for$the$ classification$ of$ all$ types$ of$ blood$ cancers.$ However$ acute$ forms$ of$ the$disease$are$more$difficult$to$analyse$as$once$they$are$diagnosed$they$need$to$be$urgently$ treated$ owing$ to$ their$ aggressive$ nature.$ It$ is$ also$ difficult$ for$researchers$to$obtain$consent$from$acute$patients$to$use$them$in$such$studies$as$they$would$not$have$ very$ long$ to$decide$whether$ they$would$ like$ to$ take$part$and$many$of$the$patients$would$be$children.$
#
#
2.2.#Raman#Spectroscopy#Raman$spectroscopy,$unlike$FTIR,$utilises$ the$near$ infrared$(NIR)$region$of$ the$electromagnetic$ spectrum.$ Monochromatic$ laser$ light$ is$ directed$ towards$ the$sample$ from$ a$ light$ source.$ The$ light$ first$ gets$ reflected$ off$ several$ mirrors$towards$an$edge$filter,$which$directs$the$laser$light$towards$the$sample$placed$on$an$ attached$ microscope.$ Once$ the$ laser$ light$ hits$ the$ sample,$ photons$ in$ the$incident$ light$ collide$ with$ molecules$ in$ the$ sample$ and$ become$ inelastically$scattered.$This$leads$to$a$change$in$energy$of$the$photon$and$thus$a$change$in$its$wavelength,$which$ is$ otherwise$ known$ as$ a$ Raman$ shift$ (Kendall$ et# al,$ 2009).$Both$ Raman$ shifted$ light$ and$ laser$ light$ are$ reflected$ back$ towards$ the$ edge$
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filter$ where$ the$ laser$ light$ is$ reflected$ away$ but$ the$ Raman$ shifted$ light$ is$allowed$to$pass.$The$Raman$light$is$then$passed$through$a$slit$to$remove$off$axis$light$and$is$focussed$onto$the$diffraction$grating$by$a$lens.$The$diffraction$grating$splits$the$light$into$its$component$parts$where$it$is$captured$by$a$charge^coupled$device$(CCD)$detector,$which$measures$photons$across$the$whole$spectral$range$at$ once.$ (Smith$ &$ Dent,$ 2008.)$ A$ common$ Raman$ spectrometer$ layout$ can$ be$seen$in$Figure$2.2.$$
$$
Figure#2.2.#Structural#Layout#of#a#Common#Raman#Spectrometer$$$Raman$ spectroscopy$ can$ be$ used$ as$ an$ alternative$ to$ FTIR$ as$well$ as$ being$ a$complementary$ technique$ to$ it.$ The$ main$ difference$ between$ them$ is$ that$ in$Raman$ a$ monochromatic$ light$ source$ is$ used$ to$ achieve$ scattering$ whereas$polychromatic$ light$ is$ used$ in$ FTIR$ to$ achieve$ absorption.$ The$ incident$ light,$which$equals$the$energy$required$for$a$molecule$to$change$from$the$ground$state$to$the$virtual$state,$causes$the$molecules$to$vibrate.$As$the$energy$level$starts$to$fall$ photons$ in$ the$ incident$ light$ become$ scattered$ providing$ different$
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Figure 23- Demonstration of how the distortion of the molecules electron cloud by stretch vibrations will 
alter the volume and thus the  polarisability of the molecule.  
 
By contrast some vibrational mode changes will only alter the dipole moment and not 
the polarisability of the molecule (Figure 24). 
 
 
Figure 24- Demonstration of how asymmetrical stretching of a molecule alters the dipole moment of the 
molecule.   Following   the   stretch   part   of   the  molecule   (shaded   red)   becomes  more   “negative”   and  part  
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Required$$$800^4000$$$MIR$ absorption$ with$polychromatic$light$$$Fast$$$Dipole$moment$$$$Strong$polar$bonds$ (OH$&$CO)$and$amide$bonds$$$High$$$Mirror,$ (CaF2),$ barium$fluoride$(BaF),$Low^e,$zinc$selenide$(ZnSe)$$$Strong$$None$$Good$$Strong$absorption$and$CO2$contribution$$None$$Spectral$ saturation$ can$occur$ at$ sample$ thickness$of$>15µm$
None$required$$400^4000$$$NIR$ inelastic$ light$ scattering$with$ monochromatic$ light$excitation$at$830nm$$Slow$$$Polarisability$$$Non^polar$ bonds$ (C^C$ double$&$ triple$ bonds)$ and$ aromatic$rings$$Low$$$CaF2,$BaF,$quartz$$$$None$$Very$strong$$Fair$$Weak$scattering$$$$Strong$$Point$spectra$can$be$obtained$at$ >15µm,$ maps$ at$ 10^20µm$sections$ $Table$adapted$from$Lin$et#al,#2007$&$Kendall$et#al,$2009$$$$
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An$ advantage$ of$ Raman$ is$ that$ it$ requires$ very$ little$ sample$ preparation,$ as$water$does$not$ interfere$with$the$spectra$making$it$quick$and$simple$to$use.$ $A$major$disadvantage$of$Raman$spectroscopy$is$that$only$one$in$106$–$108$photons$are$ scattered,$ which$ makes$ it$ very$ weak.$ Increased$ laser$ power$ is$ therefore$required$ in$ order$ to$ increase$ the$ sensitivity$ of$ the$ technique$ and$ reduce$irradiation$ time.$ Increasing$ the$ laser$ power$ also$ increases$ the$ heat$ that$ is$focused$ on$ the$ sample,$ causing$ it$ to$ burn,$ irreversibly$ damaging$ it$ and$preventing$spectral$information$being$obtained.$By$reducing$the$irradiation$time$and$increasing$the$number$of$spectral$acquisitions,$ the$heat$destruction$can$be$minimised$whilst$sensitivity$increased$(Lin$et#al,$2007).$In$recent$years$the$weak$property$ of$ Raman$ has$ also$ been$ overcome$ with$ the$ introduction$ of$monochromators,$ which$ increase$ sensitivity.$ There$ are$ a$ number$ of$ other$techniques$ available$ which$ enhance$ the$ Raman$ signal,$ however$ they$ are$currently$limited$to$research$applications$and$are$not$intended$to$be$used$in$this$thesis.$Examples$include$coherent$anti^Stokes$Raman$scattering$(CARS),$surface$enhanced$ Raman$ scattering$ (SERS)$ and$ Resonant$ Raman$ Scattering$ (RRS)$microscopy$which$are$much$more$sensitive$than$traditional$Raman$spectroscopy$(Burkacky$ &$ Zambusch,$ 2008$ &$ Naumann,$ 2008).$ CARS$ spectroscopy$ uses$ a$higher$ frequency$ wavelength,$ minimising$ the$ interference$ from$ fluorescence$(Chan,$ 2009$&$Hutchings,$ 2009).$ SERS$ enhances$ the$Raman$ signal$ by$ utilising$gold$or$silver$particles$upon$which$samples$are$adsorbed.$This$allows$it$to$detect$single$molecules$(Hutchings,$2009$&$Horsnell,$2012).$RRS$allows$photons$to$be$scattered$upto$106$ times$more$ than$ in$ traditional$Raman$ spectroscopy.$This$ is$because$the$incident$light$corresponds$to$the$energy$required$for$an$electron$to$be$excited$to$a$virtual$state$(Horsnell,$2012).$The$ increased$sensitivity$of$ these$techniques$ allows$ for$ both$ faster$ and$ more$ efficient$ real$ time$ analysis.$ For$ a$more$ detailed$ description$ of$ these$ techniques$ please$ refer$ to$ Lasch$ &$ Kneipp$(2008)$or$Smith$&$Dent$(2008).$$The$ choice$ of$ light$ source$ can$ also$ be$ a$ problem$ in$ Raman$ spectroscopy.$ For$example,$ the$ depth$ at$ which$ ultraviolet$ (UV)$ light$ can$ penetrate$ a$ sample$ is$much$lower$than$NIR$owing$to$its$shorter$wavelength.$Thus$the$focus$of$UV$light$on$ the$ surface$ of$ a$ sample$ is$ more$ intense$ and$ may$ cause$ heat$ destruction$
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(Dukor,$2002$&$Lin$et#al,$2007).$Another$disadvantage$of$Raman$spectroscopy$is$fluorescence$ interference,$ particularly$ in$ tissue.$ This$ is$ due$ to$ the$ fluorescing$nature$ of$ certain$ cellular$ components$ when$ subject$ to$ visible$ light.$ Since$fluorescence$is$reduced$more$quickly$at$longer$excitation$wavelengths$NIR$light$can$be$used$as$an$alternative$in$order$to$minimise$this$(Dukor,$2002,$Griffiths$&$de$ Haseth,$ 2007$ &$ Smith$ &$ Dent,$ 2008).$ Selection$ of$ the$ excitation$laser$wavelength$ (lo)$ therefore$ depends$ on$ several$ factors.$ The$ Raman$differential$scattering$cross^section$(s$'(cm2/sr))$varies$inversely$with$the$fourth$power$of$the$excitation$wavelength$by$the$proportionality$formula$as$shown$in$equation$3:$$
Equation!3:$$
€ 
" s µ(n0 − nvib )4 $Where:$$ no$is$the$wavenumber$of$the$incident$radiation$(1/lo)$nvib$is$the$wavenumber$of$the$vibrational$mode$(nvib/c)$c$is$the$speed$of$light$$Selecting$ a$ shorter$ laser$wavelength$ can$ increase$ the$ Raman$ scattering$ cross^section.$ However,$ as$ laser$ energies$ reach$ into$ the$ shorter$ visible$ and$ UV$wavelength$ range,$ fluorescence$ can$ become$ pronounced,$ which$ may$ interfere$with$weaker$Raman$signals.$In$addition,$the$Raman$shift$is$constant$with$regard$to$ vibrational$ energy,$ hence$ constant$ in$ wavenumber,$ but$ not$ wavelength.$ A$greater$ Raman$ shift$ makes$ separating$ the$ elastically$ scattered$ and$ Raman$scattered$light$much$easier,$possibly$resulting$in$improved$signal^to^noise$ratios$and$ the$ ability$ to$ measure$ smaller$ Raman$ shifts.$ Thus,$ the$ Raman$ excitation$wavelength$ should$be$ selected$ in$ consideration$of$ the$Raman$ scattering$ cross^section,$ the$magnitude$of$ the$Raman$ shift$ in$wavelength,$ and$ the$potential$ for$fluorescence.$$$
2.2.1.#Biomedical#and#Haematological#Applications#of#Raman#Raman$spectroscopy$has$been$utilised$ in$ the$early$detection$of$ several$cancers$including$ lymph$ node,$ gastrointestinal,$ lung,$ cervical,$ brain$ and$ breast$ cancer$(Krafft$&$Sergo,$2006,$Lyng$et#al,$2007,$Taylor$et#al,$2007,$Kendall$et#al,$2009,$Orr$
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et#al,$2010).$It$would$be$advantageous$if$it$could$also$be$used$in$the$diagnosis$of$blood$ cancers$ alongside$ FTIR$ owing$ to$ its$ complimentary$ nature$ and$ the$ fact$that$FTIR$has$already$been$successfully$utilised$for$this$purpose.$Little$work$has$been$carried$out$into$the$use$of$Raman$spectroscopy$of$cells$compared$to$FTIR$and$ thus$ Krishna$ et# al$ (2005)$ carried$ out$ some$ preliminary$work$with$mixed$cancer$cell$ lines$showing$ its$potential$ to$ identify$ the$different$spectral$ features$that$ exist$ in$ the$ different$ cancers.$ One$ small$ study$ recently$ carried$ out$ by$Kendall$et#al#(2009)$on$myeloid$ leukaemia$cell$ lines$ indicated$ the$ feasibility$of$Raman$in$identifying$the$biochemical$compositions$of$the$cancer.$Although$they$have$ suggested$ that$ Raman$ could$ be$ used$ alongside$ FTIR,$ little$ information$ is$reported$ into$ the$ nature$ of$ the$ experiment$ and$ it$ would$ appear$ that$ a$ vast$amount$ of$ work$ is$ still$ required.# Looking$ at$ other$ research$ undertaken$ into$Raman$ spectroscopy$ with$ lymph$ nodes$ would$ be$ quite$ informative$ as$ to$ the$ability$ of$ Raman$ in$ leukaemia$ and$ lymphoma$diagnosis.$ Orr$ et# al$ (2010)$ have$recently$ studied$ lymph$ nodes$ and$ successfully$ compared$ the$ results$ obtained$through$ Raman$ spectroscopy$ of$ Hodgkin$ and$ non^Hodgkin$ lymphoma.$ Using$their$model$ to$predict$nodes$with$and$without$cancer$ they$obtained$over$80%$accurate$ spectral$ prediction,$ again$ highlighting$ the$ potential$ of$ Raman$spectroscopy$in$replacing$the$current$“gold$standard”$morphological$techniques.$As$with$FTIR,$Raman$Spectroscopy$has$been$exploited$for$tissue,$cell$and$biofluid$analysis.$ Pully$ et# al$ (2010)$ obtained$ 32$ x$ 32$ pixel$ images$ of$ single$ living$peripheral$blood$ lymphocytes$with$collection$times$of$ two$minutes$using$time^lapse$Raman$imaging$(TLRI).$Other$Raman$imaging$studies$of$cancerous$tissues$include$lung$(Krafft#et#al,$2008),$cervical$(Mantsch$et#al,$2002),$skin$(Mantsch$et#









Figure#2.4.#Image#of#a#Typical#Droplet#Deposited#on#a#CaF2#Slide#$$Using$ droplets$ to$ form$ rings$ of$ highly$ concentrated$ solutes$ can$ be$ utilised$ for$biological$analysis.$Raman$and$Fourier$Transform$Infrared$spectroscopy$(FTIR)$require$ samples$of$a$ limited$ thickness$and$concentration$ for$ information$ to$be$obtained.$By$using$drop$drying$ to$ concentrate$ solutes,$ an$ increased$amount$of$information$can$be$obtained$from$low$volume,$dilute$samples.$Zhang$et#al$(2003)$first$ coined$ the$drop$coating$deposition$Raman$spectroscopy$ (DCDRS)$ term$by$depositing$droplets$onto$a$slide,$forming$a$ring$pattern$of$concentrated$solution,$and$ obtaining$ protein$ spectra$ using$ Raman$ spectroscopy$ (Ortiz$ et# al,$ 2006).$Since$then,$several$studies$have$been$carried$out$into$its$use$for$protein$analysis$due$ to$ its$ high$ sensitivity$ and$ reproducibility$ (Filik$&$ Stone,$ 2007,$ Ortiz$ et# al,$2006).$$$Using$a$series$of$dilutions$of$ the$most$common$proteins$ found$in$human$blood$(albumin,$ fibrinogen$ and$ globulin),$ the$ DCDRS$ technique$ is$ explored$ and$extended$for$use$with$FTIR$in$order$to$identify$the$upper$and$lower$limits$of$the$technique.$Thus$from$here$onwards$it$will$be$referred$to$as$DCDS.$$$In$chapter$5$the$DCDS$technique$is$utilised$for$biological$analysis$of$whole$blood$samples$ for$ leukaemia$ diagnosis,$ which$ have$ unknown$ or$ uncontrollable$concentrations$of$components.$A$major$drawback$of$whole$blood$analysis$is$the$
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low$ concentration$ of$ components$ which$ have$ weak$ signals$ that$ are$ easily$masked$by$the$strong$absorption$and$scattering$properties$of$the$red$blood$cells$themselves$(Enejder$et#al,$2002).$$Using$this$technique$allows$this$problem$to$be$overcome$ as$ the$ components$ of$ the$ blood$ cells$ spill$ out$ into$ solution$ forming$rings$that$are$evenly$dispersed$and$highly$concentrated.$$
#
#
2.3.#Data#Analysis#Interpretation$ of$ individual$ IR$ and$ Raman$ spectra$ can$ prove$ challenging$ and$subjective$due$to$the$complexity$of$the$peaks$and$the$very$small$differences$that$arise$ from$ the$ various$ vibrational$ modes$ of$ molecules.$ Thus$ the$ use$ of$chemometrics,$ or$ multivariate$ statistics,$ to$ develop$ classification$ models$ to$identify$spectral$variance$is$vital$for$the$analysis$of$the$vast$amounts$of$data$that$will$be$obtained.$The$techniques$used$in$this$thesis$are$described$below.$$$
2.3.1.#Spectral#PreSProcessing#Both$ Raman$ and$ IR$ spectra$ need$ to$ be$ pre^processed$ prior$ to$ chemometric$analysis.$ This$ can$ involve$ several$ methods,$ which$ aim$ to$ reduce$ interference$from$background$noise$so$that$the$relevant$peaks$are$not$suppressed$or$masked$by$other$artefacts.$$$
Normalisation#Normalisation$ removes$ differences$ between$ spectra$ due$ to$ signal$ intensity$ or$absorbance.$ This$ can$ be$ achieved$ using$ an$ internal$ standard$ such$ as$ a$ peak$within$ the$ spectra,$ however$ the$ shape$ and$ position$ of$ the$ peak$ must$ not$ be$overlapped$by$the$signals$of$other$compounds.$Alternatively$it$can$be$normalised$according$to$the$area$under$the$curve,$although$this$can$be$affected$by$negative$values.$Here,$vector$normalisation$is$used$where$the$sum$of$the$squared$values$is$equal$to$1.$$$$$
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Mean#Centring#Mean$centring$the$data$involves$subtracting$the$mean$of$the$entire$dataset$from$each$ spectrum$ so$ that$ the$ intensity$ of$ the$ spectra$ is$ to$ the$ same$ scale.$ This$allows$the$differences$from$the$mean$value$to$be$explored.$$$$
2.3.2.#Peak#Ratio#Analysis#Peak$ratio$analysis$was$carried$out$in$order$to$remove$any$saturated$or$weak$IR$spectra$ according$ to$ the$ ratio$ of$ the$ amide$ I$ and$ amide$ II$ peaks.$ In$ FTIR$spectroscopy,$ samples$ thicker$ than$15$µm$are$more$highly$absorbing$and$ thus$the$ intensity$of$ the$ light$ emitted$ from$ the$ sample$ is$much$ lower.$According$ to$equation$1,$this$causes$the$%T$to$be$very$high$and$thus$the$spectra$obtained$is$highly$saturated$(Kendall$et#al,$2009).$More$incident$ light$ is$absorbed$and$thus$the$intensity$of$the$light$emitted$from$the$sample$is$very$low$causing$the$%T$to$be$very$high.$It$is$therefore$not$a$true$representation$of$the$biochemical$make^up$of$ the$ sample.$ To$ eliminate$ these$ spectra,$ ratios$ of$ the$ amide$ I$ and$ amide$ II$peaks$were$identified$from$various$sources,$and$any$ratios$that$were$lower$than$a$specified$value$were$removed$from$the$data$sets.$$$$
2.3.3.#Chemometric#Analysis#
#
Difference#Spectra#Difference$spectra$were$produced$to$ identify$ the$main$differences$between$the$data$ groups.$ By$ subtracting$ the$mean$ spectra$ of$ one$ group$ from$ the$mean$ of$another$ the$ similarities$ between$ the$ groups$ are$ removed,$ leaving$ behind$ only$the$ differences.$ The$ remaining$ peaks$ were$ then$ identified$ to$ look$ for$ any$changes$ between$ the$ pathologies$ due$ to$ protein,$ DNA$ and$ other$ biochemical$constituents.$ In$order$to$ identify$the$peaks$a$table$of$Raman$peak$shifts$and$IR$peak$intensities$was$created$from$various$references$(Appendix$B).$$$$
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Principal#Component#Analysis#(PCA)#PCA$ is$used$to$reduce$or$simplify$ large$datasets$ into$smaller$more$manageable$variables,$which$better$represent$the$differences$in$the$data$and$thus$the$data$as$a$whole.$It$looks$at$the$significant$peak$differences$and$separates$spectra$based$on$ their$ variance.$ Principal$ components$ (PC)$ are$ generated,$ with$ PC1$representing$ the$ largest$ variance,$ followed$ by$ PC2,$ then$ PC3$ etc,$ with$ noise$appearing$ in$ later$ PCs.$ The$most$ significant$ PCs$ are$ then$ plotted$ against$ each$other$ to$ identify$ any$natural$ separation$ that$ occurs$ (Ellis$&$Goodacre,$ 2006$&$Brereton,$2009).$This$is$as$an$unsupervised$technique.$$$
Linear#Disciminant#Analysis#(LDA)#The$ PCs$ generated$ can$ then$ be$ fed$ into$ LDA,$which$maximises$ the$ separation$between$the$groups$according$to$a$linear$function$and$is$therefore$a$supervised$technique.$ LDA$ is$ used$ to$ reduce$ the$ variance$ within$ each$ group$ whilst$maximising$the$variance$between$the$different$groups.$It$therefore$separates$the$groups$ according$ to$ their$ pathology$ creating$ a$ model$ that$ future$ data$ can$ be$inserted$ into$ and$ its$ pathology$ predicted.$ The$ number$ of$ PCs$ used$ must$ be$minimal$ in$ order$ to$prevent$ any$over^fitting$of$ the$data.$ PCA$ followed$by$LDA$has$ been$ used$ by$ several$ groups$ for$ the$ analysis$ of$ both$ IR$ and$ Raman$ data$(Kendall$et#al,$2003,$Lyng$et#al,$2007,$Babrah$et#al,$2009$&$Babrah,$2009).$$$
Leave#One#Sample#Out#Cross#Validation#(LOSOCV)#Finally,$LOSOCV$looks$at$the$quality$of$the$data$and$the$classification$method.$All$of$ the$data$ from$one$ sample$ (the$ test$ set)$ is$ removed$ from$ the$model$ and$ the$analysis$rerun$using$the$remaining$data$(the$training$set)$to$identify$if$the$model$can$classify$the$remaining$samples$as$accurately.$This$is$repeated$with$all$of$the$data$ for$ each$ sample$ and$ sensitivities$ and$ specificities$ are$ calculated$ and$ a$contingency$ table$ produced.$ Sensitivity$ is$ a$ measure$ of$ the$ number$ of$ true$positives$ that$are$correctly$ identified$and$ is$calculated$as$shown$ in$equation$4,$whereas$ specificity$ is$ a$ measure$ of$ the$ number$ of$ true$ negatives$ that$ are$correctly$ identified$ and$ is$ calculated$ as$ shown$ in$ equation$ 5.$ By$ generating$sensitivities,$specificities$and$contingency$tables$(which$displays$the$distribution$
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Specificity = no.truenegativesno.truenegatives+ no. false positives x100%#$$Although$ there$ is$ a$ plethora$ of$ statistical$ techniques$ available,$ all$ of$ these$techniques$ are$ accepted$ and$ sufficient$ for$ this$ thesis.$ There$ may$ be$ other$techniques$that$are$more$optimal$but$their$use$is$beyond$the$scope$of$this$work.$$ $
2.4.#Conclusion#The$use$of$vibrational$spectroscopies,$such$as$Raman$and$FTIR,$ in$early$cancer$diagnosis$ has$ advanced$ significantly$ in$ the$ last$ 15^20$ years$ (Griffiths$ &$ de$Haseth,$ 2007).$ Preliminary$ studies$ have$ been$ carried$ out$ into$ a$ vast$ array$ of$cancers,$which$have$shown$them$to$have$great$diagnostic$potential.$However,$in$nearly$all$cases$more$research$is$needed$to$prove$that$they$are$highly$accurate$and$ cost^effective$ to$ use$ as$ a$ medical$ diagnostic$ tool$ in$ replacement$ of$ the$methods$ already$ available.$ These$ techniques$ were$ originally$ used$ as$ separate$tools$but$ they$have$shown$great$potential$ to$be$used$ in$combination$with$each$other.$ Kendall$ et# al$ (2009)$ have$ reviewed$ several$ preliminary,$ combinatorial$studies$ on$ FTIR$ and$ Raman$ in$ cancers$ such$ as$ lung,$ lymph,$ brain,$ breast$ and$cervical.$The$success$of$this$research$has$not$only$identified$the$future$potential$but$has$also$aided$ in$encouraging$ the$ techniques$ to$be$used$ in$ replacement$of$the$current$morphological$ones.$Krishna$et#al$(2006)$have$used$Raman$and$FTIR$together$to$identify$drug$resistance$in$leukaemia$cell$lines$thus$highlighting$the$capability$of$these$techniques$to$identify$unique$spectral$changes$that$can$occur$within$similar$samples$and$thus$characterise$the$status$of$the$cells.$
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A$key$ advantage$of$ using$FTIR$and$Raman$ together$ is$ that$ they$have$different$sensitivities$ to$ particular$ molecular$ entities$ (Table$ 2.1).$ For$ example,$ FTIR$ is$highly$ sensitive$ to$ polar$ functional$ groups$ such$ as$ C=O,$ C^O,$ C^H$ and$ O^H,$whereas$Raman$is$more$sensitive$to$C=C$and$carbon$triple$bonds.$$Therefore$not$all$the$vibrations$within$a$molecule$may$be$both$IR$and$Raman$active;$thus$using$the$techniques$together$can$provide$a$better$overall$biochemical$composition$of$the$molecules.$Other$benefits$of$using$these$techniques$in$combination$allow$the$disadvantages$of$water$ in$FTIR$to$be$overcome.$(Kendall$et#al,$2009$&$Smith$&$Dent,$2008.)$$$Both$Raman$and$FTIR$can$be$used$ to$ identify$ the$morphological$as$well$as$ the$biochemical$ structure$of$a$ sample.$With$ the$attachment$of$a$microscope$ to$ the$instrumentation$ they$ can$ be$ used$ to$ image$ the$ samples$ in$ real^time$ thus$providing$ even$ more$ information$ than$ the$ current$ diagnostic$ “gold$ standard”$techniques$do.$A$vast$range$of$biological$molecules$can$be$studied$owing$to$the$combinatorial$ nature$ of$ these$ techniques.$ The$ major$ components$ of$ tissues$(nucleic$ acids,$ proteins,$ lipids$ and$ carbohydrates)$ have$ unique$ biochemical$fingerprints,$ which$ can$ be$ easily$ identified$ in$ both$ Raman$ and$ FTIR$ spectra$(Dukor,$ 2002).$ Along$ with$ their$ non^subjective,$ complementary$ nature,$ their$speed$and$ease$of$use,$they$are$able$to$provide$accurate$and$reproducible$results$and$have$great$potential$ to$be$used$as$the$future$“gold$standard”$techniques$ in$the$diagnosis$of$blood$cancers.$However,$future$work$into$the$in#vivo#capabilities$of$ these$ techniques$ is$ required$ in$ order$ to$ show$ that$ they$ are$ better$ than$ the$current$methods$employed.$$Currently$ an$ insufficient$ amount$ of$ research$ has$ been$ carried$ out$ into$ the$potential$ of$ FTIR$ and$ Raman$ in$ diagnosing$ haematological$ malignancies.$Although$many$research$groups$have$successfully$used$them$for$the$diagnosis$of$other$cancers$in$the$last$ten$years,$more$research$is$needed$into$their$accuracy$and$viability$as$a$medical$application$(Sahu$&$Mordechai,$2005).$ In$some$cases$where$controlled$studies$have$been$carried$out,$FTIR$appears$to$have$an$80$%$prediction$rate.$However$these$results$seem$to$be$less$promising$in$uncontrolled$studies$ thus$ identifying$ the$ need$ for$ more$ in^depth$ research$ (Dukor,$ 2002).$
55 
 
There$appears$to$be$very$little$literature$available$on$Raman$and$blood$cancers$analysis$using$patient$blood$samples,$thus$it$has$been$beneficial$to$look$at$lymph$node$ studies$ in$ order$ to$ gain$ some$ perspective$ on$ its$ use$ in$ haematological$malignancies.$Isabelle$et#al$(2008)$have$used$Raman$and$FTIR$in$combination$to$differentiate$between$cancerous$and$non^cancerous$lymph$nodes.$Although$they$have$ not$ used$ the$ techniques$ to$ differentiate$ between$ cancers$ and$ their$subtypes,$they$have$shown$potential$for$the$techniques$to$be$used$to$identify$the$chemical$compositions$of$lymph$node$cancers$such$as$Hodgkin$and$non^Hodgkin$lymphomas.$$$
2.5.#Summary#In$ this$ chapter$ the$ vibrational$ spectroscopies$ FTIR$ and$ Raman$ and$ their$diagnostic$applications$have$been$explored.$The$methods$that$will$be$used$in$this$thesis$for$the$diagnosis$of$Leukaemia$and$Lymphoma$have$also$been$introduced.$In$ the$ following$ chapters$ these$methods$ are$ described$ in$more$ detail$ and$ the$results$of$the$investigations$are$presented.$$$This$thesis$ follows$on$from$the$work$carried$out$by$Jaspreet$Babrah$(2009)$on$leukaemia$cell$lines.$Thus$her$thesis$should$be$referred$to$for$more$information$regarding$the$initial$work$that$was$undertaken$into$these$methods.$$$$Unfortunately,$ due$ to$ the$ limited$number$ of$ samples$ obtained$ throughout$ this$PhD$the$work$involving$the$use$of$lymphoma$samples$can$only$be$described$as$a$feasibility$study.$$$$$$$$$$$$
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3.#MATERIALS#AND#METHODS#$$Analysing$ the$ Raman$ and$ Infrared$ (IR)$ spectra$ of$ four$ different$ sample$ types$obtained$ from$ two$ different$ sample$ preparation$methods$ for$ the$ diagnosis$ of$leukaemia$ is$ the$ main$ focus$ of$ this$ research.$ The$ first$ method,$ Drop$ Coating$Deposition$ Spectroscopy$ (DCDS),$ is$ explored$with$ blood$ proteins$ in$ chapter$ 4$prior$ to$ the$ analysis$ of$ whole$ blood,$ buffy$ coat$ and$ plasma$ samples$ from$leukaemia$patients$ and$healthy$volunteers$ in$ chapter$5.$This$method$has$been$utilised$as$it$has$the$ability$to$gain$information$from$a$small$sample$volume$and$involves$minimal$sample$preparation$(Filik$&$Stone,$2007).$If$ leukaemia$can$be$accurately$ diagnosed$ from$ a$ small$ sample$ volume$ combined$ with$ a$ rapid$analytical$ technique,$ there$ is$ potential$ for$ this$ method$ to$ give$ almost$instantaneous$diagnostic$results$to$patients$thus$avoiding$up$to$a$two^week$wait$for$results$(Three$Counties$Cancer$Network,$2005).$$$Also$in$chapter$5$the$second$method,$Cystospin$Centrifugation,$is$explored.$This$method$is$currently$used$in$haematology$laboratories$to$separate$blood$fractions$(Hoffbrand$et#al,$2010).$The$plasma,$buffy$coat$(containing$the$white$blood$cells)$and$the$red$blood$cells$can$be$extracted$and$analysed$spectroscopically$to$obtain$information$ across$ all$ three$ fractions$ that$ may$ not$ be$ available$ from$ the$fractions$individually.$This$method$has$been$used$previously$with$the$buffy$coat$fraction$ achieving$ 99.5$ %$ correct$ classification,$ plasma$ achieving$ 80.6$ %$ and$whole$ blood$ 70$%$with$ Infrared$ Spectroscopy$ (Babrah,$ 2009).$ Although$ buffy$coat$has$been$shown$to$give$the$best$results,$separating$the$blood$fractions$prior$to$spectroscopic$analysis$ is$ laborious,$taking$up$to$two$hours$and$utilises$more$resources$and$medical$professionals.$Analysing$whole$blood$and$obtaining$both$FTIR$ and$ Raman$ spectra$ alongside$ may$ be$ valuable$ in$ identifying$ differences$that$may$not$be$seen$in$the$buffy$coat$spectra$alone.$The$whole$blood$cytospin$sample$can$also$be$compared$to$the$whole$blood$DCDS$sample.$$
#Other$methods$have$been$explored$for$the$preparation$of$blood$samples$but$are$appropriate$ or$ advantageous$ over$ the$ methods$ described.$ For$ example$ blood$
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smears$could$be$used$to$analyse$whole$blood.$However,$the$process$of$obtaining$a$blood$smear$is$highly$specialised$and$takes$time$and$practise$often$resulting$in$high$wastage$of$slides.$This$makes$the$method$expensive$owing$to$the$nature$of$the$Calcium$Fluoride$(CaF2)$slides$required$for$these$spectroscopic$methods$and$their$individual$cost.$It$therefore$holds$no$benefit$over$cytopsin$centrifugation$of$whole$blood,$which$ is$ a$much$quicker$ and$more$practical$method$of$ obtaining$whole$cells.$$Fine$needle$aspirate$biopsies$(FNAB)$were$obtained$for$spectroscopic$analysis$of$lymphoma.$ The$ results$ from$ the$ lymphoma$ feasibility$ study$ are$ displayed$ in$chapter$6.$$$





















SNR# No.#Scans# SNR# Aperture#
(µm)#
SNR#1$ 1:44$ 1$ 1:344$ 10$x$10$ 1:327$2$ 1:12$ 2$ 1:365$ 15$x$15$ 1:150$4$ 1:209$ 4$ 1:167$ 20$x$20$ 1:165$8$ 1:370$ 8$ 1:181$ 30$x$30$ 1:354$16$ 1:123$ 16$ 1:353$ 50$x$50$ 1:310$32$ 1:96$ 32$ 1:157$ 100$x$100$ 1:281$64$ 1:336$ 64$ 1:250$ $ $
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SNR#X$5$ 1:6$ 1$ 1:9$ 1$ 1:12$X$20$ 1:4$ 2$ 1:8$ 2$ 1:10$X$50$ 1:5$ 5$ 1:8$ 5$ 1:7$X$80$ 1:6$ 10$ 1:5$ 10$ 1:6$$ $ 20$ 1:2$ $ $$ $ 30$ 1:2$ $ $$ $ 50$ 1:2$ $ $$$Raman$ parameters$ need$ to$ be$ adjusted$ to$ suit$ the$ sample$ type$ in$ order$ to$generate$ good$ quality$ spectra$ in$ an$ efficient$ manner.$ The$ resolution$ is$dependent$ on$ the$ objective$ used.$ The$ higher$ the$ objective$ magnification,$ the$higher$ the$ numerical$ aperture,$ and$ the$ better$ the$ resolution.$ As$ in$ FTIR,$ high$
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the# Effect# of# Different# Objectives# on# Quality# of# Spectra;$ x5$ (blue),$ x20$(green),$x50$(red)$and$x80$(turquoise)$objective$lens$$$
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the#Effect#of#Spectral#Acquisition#Time#on#Quality#of#Spectra;$1$second$(blue),$2$ seconds$ (green),$5$ seconds$ (red),$10$ seconds$ (turquoise),$20$ seconds$ (pink),$30$seconds$(yellow)$and$50$seconds$(black)$acquisition$time$$$$$$$
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3.1.3.#Raman#System#Calibration#The$ Raman$ spectrometer$ requires$ calibration$ at$ the$ beginning$ of$ each$ day.$Calibrating$the$system$allows$a$comparison$to$be$made$between$measurements$in$ order$ to$ avoid$ any$ deviation$ over$ time,$ this$ is$ particularly$ important$ in$medical$ applications.$ Should$ there$be$ any$ change$ in$ accuracy$or$precision$ this$can$be$accounted$ for$and$adjusted$at$ the$ time.$ If$ left$ these$deviations$could$be$mistaken$ for$ clinical$ differences$ in$ the$ spectra$ rather$ than$ technical.$ The$calibration$standards$used$have$known$characteristic$peaks$and$are$listed$below$with$Figure$3.7$displaying$some$examples$of$the$spectra$obtained:$$
• Silicon,$ which$ has$ a$ very$ strong$ peak$ at$ 520.4$ cm^1,$ is$ measured$ to$identify$any$shift$in$the$spectra.$Should$there$be$any$shift$from$this$peak$the$system$is$recalibrated$ in$order$ to$centre$ the$silicon$peak$at$520.4±1$cm^1$(Figure$3.7A).$$
• Cyclohexane$also$has$precise$characteristic$peaks,$which$are$distributed$across$the$spectral$range.$It$is$measured$daily$to$identify$any$drifts$in$the$spectra$(Figure$3.7B).$$
• A$ neon^argon$ lamp$ has$ narrow$ emission$ lines$ at$ precise$ wavelengths,$which$ are$ equally$ distributed$ across$ the$ spectral$ range,$ which$ again$ is$used$ as$ a$ check$ over$ time$ to$ identify$ if$ the$ system$ has$ drifted$ (Figure$3.7C).$$
• Plastic$pipette$ tip$ is$also$measured$daily$as$ it$has$a$characteristic$peaks$distributed$across$the$spectral$range$(Figure$3.7E).$$$









Figure# 3.7.# Spectra# of# Raman# Calibration# Standards;$ A)$ silicon,$ B)$cyclohexane,$C)$neon^argon,$D)$green$glass,$E)$pipette$tip$
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3.2.# Evaluating# Drop# Coating# Deposition# Spectroscopy# (DCDS)# for#
Microanalysis#of#Protein#Solutions#
#

























3.2.2.# Raman,# Infrared# Transmittance# and# Infrared# Reflectance#
Spectroscopy##Line$maps$of$the$samples$were$acquired,$where$each$pixel$of$the$map$represents$one$ spectrum.$ Infrared$ line$ maps$ were$ collected$ using$ the$ Perkin$ Elmer$Spectrum$One$FTIR$spectrometer$coupled$to$a$Spotlight$400$molecular$imaging$microscope$described$ in$section$3.1.1.$White$ light$ images$were$created$using$a$charge^couple$ device$ (CCD)$ camera,$ located$ in$ the$ microscope.$ For$ both$reflectance$and$transmittance$IR$spectroscopy,$16$scans$per$6.25$µm$pixel$were$obtained$at$a$resolution$of$4$cm^1,$and$2.2$cm^1$interferometer$speed.$$$Raman$ line$ maps$ were$ produced$ using$ a$ customised$ Renishaw$ Streamline$System$1000$micro^spectrometer$as$described$ in$section$3.2.2.$A$x50$objective$lens$ was$ used$ to$ create$ line$ maps$ with$ 10$ µm$ step$ size$ with$ each$ spectra$acquired$for$thirty$seconds.$$$
3.2.3.#Identifying#the#Position#and#Absorbance#of#the#Amide#I#Peak##The$amide$I$peak$position$and$absorption$across$the$samples$were$analysed$and$identified$ using$ an$ in^house$ line$ profile$ analysis$ tool$ for$ Matlab.$ The$ peak$position$was$determined$by$selecting$the$wavenumber$of$maximum$absorbance$in$the$1600^1700$cm^1$range.$Colour$maps$of$the$spectral$data$were$produced$to$
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3.3.3#Amide#I#Peak#Analysis#The$position$and$intensity$of$the$amide$I$peak$was$measured$across$the$diameter$of$each$ring.$Any$peak$shifts$or$scattering$effects$that$may$occur$at$the$edges$of$the$rings$were$then$identified.$The$average$amide$I$peak$position$for$each$of$the$seven$ albumin$ rings$ (A1^A7)$ was$ plotted$ to$ identify$ the$ most$ suitable$concentration$ for$each$ technique.$The$optimum$area$ for$spectral$acquisition$ to$avoid$scattering$and$hence$shifts$in$the$peak$position$was$then$calculated.$$
#
3.4.# Comparing# DCDS# and# Cytospin# Centrifugation# as# Blood# Sample#
Preparation#Methods#in#the#Diagnosis#of#Leukaemia#Using#FTIR#and#Raman#
Spectroscopy#$
3.4.1.#Ethics#Ethical$approval$was$obtained$from$the$South$West$5$Research$Ethics$Committee$(REC)$ (formerly$ Frenchay$ REC)$ for$ the$ analysis$ of$ an$ unspecified$ number$ of$post^analysed$ samples$ of$ leukaemia$ whole$ blood,$ providing$ they$ were$anonymously$ supplied.$ Approval$was$ also$ granted$ for$ fifty$ samples$ of$ healthy$whole$blood$ from$volunteers,$provided$ that$ they$ consented$ to$ take$part$ in$ the$study$ after$ reading$ and$ fully$ understanding$ a$ patient$ information$ sheet$ (PIS)$outlying$the$reasons$for$the$study,$the$methods$used$and$any$risks$that$may$be$involved.$ The$ REC$ reference$ number$ for$ ethical$ approval$ is$ 06/Q2005/120#(Appendix$C).$$$
3.4.2.#Sample#Collection#Anonymous,$ post^analysed$ leukaemia$ blood$ samples$ were$ obtained$ from$Cheltenham$ General$ Hospital;$ their$ pathologies$ identified$ and$ kept$ on$ a$password^protected$ database$ by$ associated$ haematologists.$ All$ samples$ were$obtained$from$a$new$patient$clinic$so$that$samples$involved$were$less$likely$to$be$influenced$ by$ factors,$ such$ as$ chemotherapy,$ that$would$ alter$ the$ biochemical$fingerprints$ of$ the$ cancers.$ Samples$ were$ supplied$ in$ standard$ 5ml$ethylenediaminetetracetic$ acid$ (EDTA)$ blood$ collection$ tubes$ to$ ensure$ the$
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samples$did$not$clot.$Simultaneously,$whole$blood$from$healthy$volunteers,$who$consented$to$taking$part$in$the$study,$were$also$collected$in$standard$5$ml$EDTA$blood$ collection$ tubes$ by$ phlebotomists.$ Samples$ were$ then$ screened$ by$ the$associated$haematologists$to$ensure$their$suitability$in$the$study.$$$$
3.4.3.#Sample#Preparation#The$protocol$(Appendix$D)$was$adapted$and$developed$from$the$Sigma^Aldrich$Histopaque®^1077$ Product$ Information$ page$ (Sigma^Aldrich,$ 2011).$ Once$obtained,$all$ samples$were$maintained$at$2^8$°C,$prepared$and$ fixed$within$six$hours$of$collection$and$analysed$within$36$hours$of$preparation.$For$each$sample$collected,$3$ml$of$whole$blood$was$required$for$centrifugation.$A$further$150$μl$was$kept$ for$cytospin$centrifugation$and$remaining$blood$was$diluted$for$Drop$Coating$Deposition$Spectroscopy$(DCDS)$(see$section$3.4.4.2).$$$
3.4.4.#Methods#$
3.4.4.1.# Isolating#Mononuclear#Cells# from#AntiSCoagulated#Whole#Blood#by#












Figure# 3.11.# The# Cytospin#Mounts;# CaF2$ slide$ inserted$ into$ base$ holder$ (1),$filter$paper$(2)$lies$on$top$of$slide$to$absorb$excess$fluid,$fluid$chamber$(3)$clips$on$top$and$cap$(4)$is$tightened$to$hold$sample$securely$$$
3.4.4.2.#Drop#Coating#Deposition#Spectroscopy#100$%,$50$%$and$25$%$dilutions$of$whole$blood$and$plasma$were$made$and$1.5$μl$droplets$of$these$solutions$were$deposited$onto$CaF2$slides$with$a$calibrated$micropipette.$ The$ droplets$were$ left$ to$ dry$ as$ the$ solutes$were$ pushed$ to$ the$outer$ edge$ in$ order$ to$ provide$ a$more$ concentrated$ sample$ for$ spectroscopic$analysis.$Slides$were$left$for$sixty$minutes$at$22$°C$in$an$air$condition$controlled$laboratory.$$$
3.4.4.3.#Spectroscopic#Analysis#Point$ spectra$ of$ the$ samples$ were$ acquired$ using$ the$ Perkin$ Elmer$ Spectrum$One$ FTIR$ spectrometer$ coupled$ to$ a$ Spotlight$ 400$ molecular$ imaging$microscope$ described$ in$ section$ 3.1.1.$ Images$ were$ created$ under$ white$ light$using$ a$ charge^couple$ device$ camera,$ located$ in$ the$ microscope.$ Thirty$ point$spectra$ were$ taken$ from$ each$ sample$ type$ with$ 16$ scans$ per$ 6.25$ µm$ pixel$obtained$at$a$resolution$of$4$cm^1,$and$2.2$cm$interferometer$speed.$Background$measurements$ of$ the$ CaF2$ slides$ were$ taken$ and$ ratioed$ against$ each$ point$
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spectra$in$order$to$minimise$any$interference.$Point$spectra$were$also$acquired$from$ the$ customised$ Raman$ Renishaw$ Streamline$ System$ 1000$ micro^spectrometer$ as$ described$ in$ section$ 3.1.2.$ A$ x50$ objective$ lens$ was$ used$ to$obtain$thirty$point$spectra$from$each$sample$for$thirty$seconds.$$$




3.5.1.#Ethics#An$application$was$ also$made$ to$ the$ South$West$5$Research$Ethics$Committee$(REC)$ (formerly$ Frenchay$ REC)$ for$ the$ analysis$ of$ an$ unspecified$ number$ of$post^analysed$ samples$ of$ lymphoma$ fine$ needle$ aspirate$ biopsies$ (FNAB),$providing$they$were$anonymously$supplied.$Ethical$approval$was$also$obtained$for$fifty$lymph$node$tissue$biopsy$samples$providing$consent$was$obtained$from$the$volunteer$patients$involved.$The$REC$reference$number$for$ethical$approval$is$also$06/Q2005/120#(Appendix$C).$$
3.5.2.#Sample#Collection#&#Preparation#Anonymous,$ FNABs$ were$ obtained$ from$ Cheltenham$ General$ Hospital$ and$placed$in$PBS.$No$lymph$node$tissue$biopsies$were$obtained.$$$
3.5.3.#Methods#$
3.5.3.1.#Cytospin#Centrifugation#Once$ samples$were$ obtained,$ they$were$ subject$ to$ the$ cytospin$ centrifugation$method$utilised$for$the$leukaemia$blood$samples.$150$μl$of$the$aspirate$solutions$were$ placed$ into$ cytospin$ mounts$ and$ cytospun$ for$ 2$ mins$ at$ 500$ rpm.$ The$slides$ were$ left$ to$ dry$ on$ the$ bench$ for$ a$ minimum$ of$ two$ hours$ prior$ to$spectroscopic$analysis.$$





4.#RESULTS#AND#DISCUSSION:#BLOOD#PROTEIN#ANALYSIS#$$In$ preparation$ for$ the$ analysis$ of$ leukaemia$ blood$ samples,$ drop$ coating$deposition$ spectroscopy$ (DCDS)$ has$ been$ explored$ using$ both$ Raman$ and$Fourier$ Transform$ Infrared$ (FTIR)$ spectroscopy$ to$ compare$ the$ limitations$ of$the$techniques$for$biological$analysis$of$samples$with$low$protein$concentration.$The$ first$ section,$ 4.1,$ explores$ the$ results$ from$ the$ initial$ study$ involving$ the$three$blood$proteins;$ albumin,$ fibrinogen$and$γ^globulin.$The$main$ focus$being$on$the$variation$of$the$amide$I$peak$across$the$samples.$Any$shifts$in$the$amide$I$peak$position$will$determine$whether$scattering$has$occurred,$whilst$differences$in$ absorption$ of$ the$ amide$ I$ peak$ will$ identify$ whether$ the$ sample$ deposits$within$a$ ‘coffee^ring’$pattern.$Scattering$may$cause$peaks$to$shift,$which$can$be$problematic$ as$ this$may$ be$mistaken$ for$ a$ change$ in$ the$ biochemistry$ due$ to$disease.$The$second$section,$4.2,$explores$the$DCDS$method$further$with$albumin$solutions$ only.$ The$ aim$ of$ this$ study$ was$ to$ identify$ what$ effect$ sample$concentration$ has$ on$ droplet$ formation$ and$ spectral$ data$ with$ the$ aim$ of$reducing$ sample$ volume$ whilst$ maintaining$ sensitivity$ of$ the$ techniques.$ By$comparing$ the$ data$ obtained$ from$FTIR$ and$Raman$ it$ is$ hoped$ that$ the$DCDS$method$can$be$used$across$complementary$platforms$whilst$achieving$consistent$results.$$
#
#
4.1.# Evaluating# Drop# Coating# Deposition# Spectroscopy# (DCDS)# for#
Microanalysis#of#Protein#Solutions#$
4.1.1.#Sample#Preparation#Using#DCDS#The$ DCDS$ method,$ as$ described$ in$ section$ 3.2.1,$ works$ by$ capillary$ flow,$ a$process$of$sample$drying$previously$described$by$Deegan$et#al$(1997).$Once$the$droplets$ have$ been$ micropipetted$ onto$ a$ slide,$ they$ dry$ from$ the$ outside$ in$creating$ a$ flow$ of$ solutes$ to$ the$ outer$ edge,$ which$ then$ becomes$ highly$concentrated$ compared$ to$ the$ solution$ in$ the$ centre.$ Once$ the$ sample$ has$completely$ dried,$ the$ solutes$ should$ theoretically$ be$ located$ in$ a$ ‘coffee^ring’$
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pattern$ on$ the$ slide,$ thus$ making$ spectroscopic$ analysis$ easier$ due$ to$ the$concentration$ increase.$ The$ effect$ that$ occurs$ can$ be$ seen$ in$ the$ white$ light$images$in$Figures$4.1^4.3.$$$
#















4.1.2.# Raman,# Infrared# Transmittance# and# Infrared# Reflectance#
Spectroscopy#Using$ the$ parameters$ described$ in$ section$ 3.2.2,$ spectra$ were$ obtained$ from$Raman,$ IR$ transmittance$ and$ IR$ reflectance$ in$ order$ to$ explore$ drop$ coating$deposition$spectroscopy$(DCDS)$as$a$viable$method$for$blood$sample$analysis.$It$is$already$known$that$measuring$the$buffy$coat$(the$leucocyte$fraction$of$blood)$by$ infrared$ spectroscopy,$ chronic$ lymphoblastic$ leukaemia$ (CLL)$ can$ be$diagnosed$ to$ a$ high$ sensitivity,$ with$ 99.5$ %$ of$ samples$ correctly$ classified$(Babrah,$2009).$However,$the$process$of$separating$out$the$different$fractions$of$blood$is$time$consuming$and$if$DCDS$can$generate$the$same$quality$of$results$it$could$be$used$as$an$alternative$as$it$is$quick$and$easily$repeatable.$In$chapter$5$both$of$these$methods$are$explored$with$blood$samples$to$diagnose$leukaemia.$$In$using$ this$method,$ the$ interference$of$Mie$scattering$needs$ to$be$addressed.$This$dispersion$artefact$occurs$when$the$wavelength$of$incident$light$is$equal$to$the$ diameter$ of$ a$ particle,$ or$ object$ of$ interest.$ When$ light$ collides$ with$ the$object$ it$ is$ scattered$ away$ from$ the$ detector$ causing$ a$ decrease$ in$ signal$intensity$and$an$artificial$shift$in$the$spectra,$noticeably$around$the$amide$I$peak.$Any$change$to$this$peak$in$the$past$was$thought$to$be$due$to$a$change$in$protein$conformation$ (Bassan$ et# al,$ 2010).$ If$ this$ scattering$ were$ to$ arise$ and$ not$ be$accounted$ for$ in$ the$ leukaemia$ blood$ samples,$ the$ spectra$ could$ be$misinterpreted,$ potentially$ leading$ to$ a$ misdiagnosis$ of$ cancer.$ Shultz$ et# al,#(1996)$compared$the$spectra$of$normal$and$CLL$cells#using$FTIR.$They$identified$a$shift$in$the$amide$I$peak$from$1656$cm^1$in$normal$lymphocytes$to$1652$cm^1$in$
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CLL$ cells.$ Had$ there$ been$ a$ shift$ in$ the$ spectra$ due$ to$ Mie$ scattering,$ the$diagnosis$may$have$been$falsely$made,$or$not$made$at$all.$Thus$in$this$study$we$have$concentrated$the$analysis$of$scattering$to$this$region$of$the$spectra.$$$Mie$ scattering$ is$ most$ commonly$ observed$ in$ IR$ reflectance$ spectra$ due$ to$ a$change$ in$ the$ trajectory$of$ the$radiation$caused$by$differences$ in$ the$refractive$index$between$a$ sample$and$ its$ surrounding$medium,$ as$well$ as$ the$ increased$intensity$observed$when$radiation$passes$through$a$sample$and$back$(Romeo$et#

































































Figure# 4.5.# Peak# Absorption# and# Position# Plots# of# the# Amide# I# Peak# for#















Figure# 4.7.# 3D# Spectral# Plots# of# Albumin# Rings# A# and# A2#Measured# in# IR#
Transmittance;$A)$ring$A,$B)$ring$A2$$$The$ line$ profile$ plots$ for$ the$ albumin$ rings$measured$ by$ Raman$ spectroscopy$can$ be$ seen$ in$ Figure$ 4.8.$ As$with$ the$ IR$ transmittance$ data,$ the$ areas$where$there$ are$ cracks$ in$ the$ rings$ can$ be$ seen$ by$ variation$ in$ the$ intensity$ and$position$ of$ the$ amide$ I$ peaks.$ Although$ there$ appears$ to$ be$ less$ variation$ or$interference$ from$ cracks,$ this$ is$ just$ due$ to$ the$ line$ maps$ being$ measured$ in$different$ places$ across$ the$ rings.$ The$ intensity$ of$ the$ peaks$ decreases$ as$ the$concentration$ of$ albumin$ in$ the$ ring$ decreases$ suggesting$ that$ better$ quality$Raman$spectra$can$be$obtained$with$higher$concentrations$of$albumin,$from$25$mg/ml$up.$As$with$the$IR$transmittance$line$profiles$it$is$clear$that$albumin$has$
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For$ completeness,$ and$ in$ order$ to$ compare$ the$ data$ between$ the$ three$spectroscopic$methods,$ the$ line$ profile$ for$ albumin$ ring$ A$ in$ IR$ reflectance$ is$shown$in$Figure$4.9.$It$can$be$seen$that$within$the$ring$the$position$of$the$amide$I$peak$is$much$higher$than$in$the$other$two$methods,$residing$between$1680^1690$cm^1.$This$consistent$shift$in$the$peaks$is$caused$by$scattering$and$confirms$the$lack$ of$ scattering$ present$ in$ both$ IR$ transmittance$ and$ Raman$ spectroscopy.$Again$ spectra$ measured$ in$ cracks$ in$ the$ rings$ can$ be$ observed$ where$ the$absorbance$and$peak$position$is$low$within$the$rings.$$$
$$





















$$1656^58$1680^92$1680^90$1680^90$$$1664$1658$1664^6$1658$$$1672^74$1688^94$1688^94$1688^92$$$According$to$Socrates$(2001),$ the$amide$I$peak$for$an$α^helical$protein$such$as$albumin,$ should$ reside$ between$ 1645^1655$ cm^1$ in$ both$ infrared$ and$ Raman.$The$Raman$data$showed$that$it$actually$resided$at$1657$cm^1,$which$although$is$slightly$higher$this$is$due$to$the$instrument$itself.$The$pure$protein$data$confirms$this$ as$ does$ the$ consistency$ of$ the$ data$ across$ the$ different$ concentrations$suggesting$ that$ it$ is$ a$ technical$ difference$ rather$ than$ an$ error$ in$ the$ DCDS$method$(Appendix$E).$At$the$lowest$concentration,$A2,$there$appears$to$be$some$variation$in$the$peak$position.$From$the$spectra$it$was$clear$that$the$droplet$was$too$thin$for$the$weak$Raman$signal$and$thus$this$variation$may$be$due$to$some$small$degree$of$scattering$from$cracks$in$the$droplet.$The$average$peak$position$was$also$shown$to$be$1657$cm^1$by$the$IR$transmittance$method,$which$is$again$slightly$higher$but$does$coincide$with$the$pure$albumin$data.$This$ is$consistent$across$ all$ three$ droplets.$ The$ IR$ reflectance$ profiles$ identified$ a$ shift$ in$ the$amide$I$peak$of$20$to$30$wavenumbers.$This$was$expected$due$to$the$dispersive$effects$ that$ take$ place$ when$ the$ incident$ radiation$ is$ equal$ to$ the$ change$ in$
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refractive$ index$at$ the$edge$of$ the$droplet.$The$fibrinogen$and$globulin$profiles$appear$to$further$confirm$the$scattering$in$the$reflectance$data.$$$Fibrinogen$ is$ a$ random$ chain$ protein,$ which$ should$ have$ an$ amide$ I$ peak$between$1660^1670$cm^1,$whereas$globulin$has$a$β^sheet$ structure$and$should$have$an$amide$I$peak$between$1665^1675$cm^1$(Socrates,$2001).$The$poor$ring$structure$and$ the$uneven$distribution$of$ the$protein$ throughout$ the$ fibrinogen$and$ globulin$ droplets$ make$ it$ difficult$ to$ conclude$ the$ accuracy$ of$ the$ DCDS$method$both$physically$and$spectrally.$$The$proteins$did$not$deposit$in$a$ring$and$the$ position$ and$ absorption$ of$ the$ amide$ I$ peak$ was$ highly$ varied$ due$ to$scattering.$
#
#





of#Albumin#Solutions#In$order$to$study$the$protein$droplets$and$their$formation$on$the$slides$further$a$series$ of$ albumin$ dilutions$ covering$ a$ larger$ range$ of$ concentrations$ were$analysed.$The$purpose$of$ this$was$to$ identify$ the$upper$and$ lower$ limits$of$ the$DCDS$technique$using$both$Raman$and$FTIR$with$the$future$aim$being$to$utilise$the$technique$for$biological$analysis$of$samples$with$unknown$or$uncontrollable$concentrations,$such$as$blood.$$$$
4.2.1#Physical#properties#The$ white$ light$ images$ show$ a$ severe$ loss$ of$ shape$ and$ structure$ as$ the$concentration$of$albumin$decreases$(Figure$4.10).$At$the$highest$concentration,$both$ the$diameter$of$ the$droplet$and$ the$width$of$ the$ring$are$ larger.$At$ lower$concentrations,$more$cracks$are$visible$in$the$rings.$The$white$light$images$were$used$to$explore$the$relationship$between$ring$width$and$albumin$concentration,$which$ in$ Figure$ 4.11$ are$ shown$ to$ be$ directly$ proportional$ at$ the$ higher$concentrations.$At$more$dilute$concentrations,$rings$A0$to$A5,$the$rings$have$not$properly$ formed$suggesting$ that$at$concentrations$below$25$mg/ml$(below$the$normal$concentration$range$of$albumin$in$human$blood)$the$technique$is$limited$(Martini,$2006).$ Interestingly,$ a$ linear$ fit$of$ the$data$ indicated$ that$at$0$mg/ml$there$should$be$a$droplet$with$a$ring$width$of$22.9$µm.$This$was$tested$with$a$1.5$















































































Figure# 4.13.$Line# Profile# Plot# of# Ring# A7;# showing$ the$ peak$ absorption$ and$position$of$the$amide$I$peak$measured$in$IR$transmittance$$$$From$ these$ results$ it$ was$ necessary$ to$ identify$ where$ within$ the$ ring$ is$appropriate$to$take$spectra$to$eliminate$spectral$shifts$and$therefore$to$identify$the$minimum$ring$width$for$accurate$results.$$$






























































In$ IR$ transmittance$ (Figure$4.14A)$ the$ SD$ is$ slightly$ raised$at$ the$ edges$of$ the$ring.$As$ two$data$points$were$ removed$ from$the$edges$ the$SD$decreased$ to$an$acceptable$ level,$ below$ two.$ The$ width$ of$ the$ ring$ was$ 211.9$ µm,$ which$ was$divided$ by$ the$ number$ of$ pixels$ in$ the$ ring$ (81.5)$ to$ identify$ the$ number$ of$microns$per$pixel$(2.6$µm/pixel).$This$was$then$multiplied$by$the$number$of$data$points$ to$ identify$ how$ far$ from$ the$ edge$ of$ the$ ring$was$ acceptable$ to$ obtain$spectral$measurements.$Thus$two$data$points$equates$to$a$distance$of$5.2$µm.$In$the$ centre$ of$ the$ ring$ the$ SD$ remained$ low$ suggesting$ the$ results$ remain$consistent$regardless$of$the$number$of$data$points$averaged.$$$ $The$SD$was$on$average$higher$in$the$Raman$data$(Figure$4.14B)$but$as$the$outer$four$data$points$were$removed$the$SD$dropped$below$2.5$and$remained$between$2^2.5$ throughout$ the$ ring.$ Using$ the$ same$ calculation,$ it$ was$ determined$ that$spectral$measurements$should$be$taken$at$a$minimum$of$15.3$µm$from$the$edge$of$ the$ ring$ in$order$ to$ ensure$ that$ any$effects$of$ scattering$ are$ avoided.$ In$ the$centre$of$the$ring$the$SD$is$increased$suggesting$that$several$measurements$are$required$ in$order$ to$obtain$an$accurate$ result.$ In$ IR$ reflectance$ (Figure$4.14C)$the$SD$is$very$high$due$to$the$scattering.$$$
4.2.4.#Summary#Both$Raman$and$IR$transmittance$spectroscopy$were$able$to$detect$the$albumin$spectra$ at$ each$ concentration$ with$ little$ background$ interference.$ As$ the$concentration$ of$ the$ rings$ decreased$ the$ absorbance$ of$ the$ IR$ spectra$ was$slightly$reduced$but$the$signal$to$noise$ratio$remained$low.$Raman,$however,$was$better$ at$ detecting$ the$ spectra$ of$ the$more$ concentrated$ rings,$with$ increased$intensity$and$sensitivity.$This$technique$is$therefore$limited$to$detecting$protein$concentrations$ above$ 25$ mg/ml.$ However,$ the$ IR$ transmittance$ spectra$remained$consistent$at$each$concentration,$even$below$25$mg/ml$when$the$ring$had$deteriorated.$It$is$important$to$note$that$in$section$4.1$saturation$occurred$at$50$ mg/ml$ and$ thus$ this$ would$ appear$ to$ be$ the$ maximum$ concentration$ of$protein$to$use$for$IR$transmittance.$These$results$show$the$potential$of$DCDS$as$a$tool$for$micro^analysis$of$biological$samples$with$low$protein$concentration.$
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DCDS$ has$ been$ shown$ to$ be$ a$ useful$ tool$ for$ detecting$ low$ concentrations$ of$proteins.$Both$FTIR$and$Raman$results$indicate$the$use$of$the$technique$to$detect$levels$ of$ albumin$ much$ lower$ than$ found$ in$ the$ blood.$ However,$ it$ has$ been$shown$ that$ a$ minimum$ ring$ width$ is$ required$ for$ reducing$ the$ effects$ of$scattering$ and$ that$ this$ ring$width$ is$ affected$ by$ sample$ concentration.$ As$ the$albumin$ concentration$ is$ decreased$ the$ ring$ width$ reduces$ thus$ lowering$ the$number$of$possible$ spectral$measurements.$ It$ also$causes$ the$ ring$structure$ to$become$less$stable$and$crack.$$$$
4.3.#Discussion##The$method$of$DCDS$has$been$utilised$for$protein$analysis$by$several$groups$and$enabled$ the$ detection$ of$ changes$ to$ protein$ conformation,$ binding$ and$ purity$(Ortiz$ et# al,$ 2006)$ as$well$ as$ aided$ in$ the$ diagnosis$ of$ ocular$ disease$ (Filik$ &$Stone,$2007).$Tear$fluid$has$been$used$to$diagnose$ocular$abnormalities,$not$just$from$the$spectra$obtained,$but$from$the$fern^like$drying$patterns$that$arise$upon$deposition$ (Pearce$ &$ Tomlinson,$ 2000).$ In$ chapter$ 4$ some$ of$ these$ ferning$patterns$were$seen$in$the$solutions$containing$fibrinogen,$which$could$simply$be$due$ to$ the$ protein$ not$ dissolving$ in$ the$ solutions$ or$ from$ the$ interference$ of$saline.$However,$ if$ it$ is$ due$ to$ a$ characteristic$ of$ the$ protein$ itself,$ it$ could$ be$used$to$ identify$the$presence$of$an$abnormality$prior$to$spectroscopic$analysis.$Should$these$ferning$patterns$be$seen$in$blood$this$could$potentially$be$used$in$the$ diagnosis$ of$ leukaemia$ if$ it$ could$ be$ proven$ that$ these$ drying$ patterns$related$to$the$presence$of$disease.$$$The$results$obtained$ indicate$ that$Raman$ is$ the$better$spectroscopic$ technique$for$higher$protein$concentrations.$The$higher$the$concentration,$the$thicker$the$ring$ therefore$ a$ better$ signal$ is$ achieved.$ However$ this$may$ only$ be$ true$ to$ a$certain$degree$as$it$has$been$identified$that$multiple$pinning$of$the$contact$line$can$occur$ in$higher$ concentration$ solutions$ (Esmonde^White$et# al,$ 2009).$ This$may$ cause$ interference$ in$ the$ spectra,$ again$ limiting$ the$ DCDS$method.$ In$ IR$transmittance$ too$ thick$ a$ sample$prevents$ light$passing$ through$ thus$ reducing$the$quality$of$the$spectra$as$they$become$saturated.$IR$transmittance$should$be$
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the$ method$ of$ choice$ for$ lower$ protein$ concentrations$ as$ indicated$ by$ the$results.$ Although$ the$ absorbance$ at$ lower$ concentrations$ is$ reduced,$ the$technique$is$sensitive$enough$to$detect$the$peaks$of$interest.$$In$the$next$chapter$the$DCDS$method$is$explored$with$blood$samples.$Although$it$has$ potential$ to$ be$ used$ with$ biological$ samples$ where$ unknown$ and$uncontrollable$concentrations$of$proteins$are$found,$variability$in$ring$formation$is$still$a$factor$that$is$difficult$to$overcome.$From$this$work$and$from$the$work$of$other$ research$ groups$ into$ the$ DCDS$ technique,$ forming$ droplets$ in$ which$qualitative$ spectra$ can$ be$ obtained$ is$ fairly$ difficult$ and$ the$ best$ way$ to$overcome$ this$would$be$ to$use$a$ series$of$dilutions$and$visually$ inspecting$ the$droplets$ under$ a$ microscope$ prior$ to$ spectral$ acquisition.$ Rings$ that$ are$ too$dilute$and$do$not$form$properly$should$be$avoided,$as$should$droplets$of$too$high$concentration$which$ suffer$ interference$ due$ to$multiple$ pinning$ of$ the$ contact$line.$It$has$therefore$been$determined$from$this$study$that$the$following$should$be$taken$into$consideration$for$optimising$the$DCDS$method$for$leukaemia$blood$analysis:$$
• Sample$preparation:$$make$a$series$of$dilutions$of$the$sample$in$water$and$pipette$these$all$onto$a$CaF2$slide.$
• Physical$ properties:$ prior$ to$ spectroscopic$ analysis$ ensure$ successful$deposition$ has$ occurred.$ Check$ for$ bubbles$ and$ cracks.$ Minimum$ ring$width$ must$ account$ for$ the$ distance$ at$ the$ edges$ of$ the$ ring$ where$scattering$may$occur.$




#$This$ chapter$outlines$ the$ results$ obtained$ from$Raman$and$Fourier$Transform$Infrared$(FTIR)$Spectroscopy$of$blood$specimens$for$the$diagnosis$of$Leukaemia.$For$ each$ sample,$whole$ blood$ and$ plasma$were$ deposited$ onto$ CaF2$ slides$ by$drop$coating$deposition$spectroscopy$(DCDS)$and$whole$blood$and$buffy$coat$by$cytospin$centrifugation.$The$spectra$were$pre^processed,$as$described$in$section$3.4.4.4,$ to$ remove$ any$ differences$ in$ the$ data$ that$ may$ be$ mistaken$ for$biochemical$variances.$Any$saturated$infrared$(IR)$spectra$were$also$eliminated.$The$data$was$then$analysed$by$univariate$(mean$spectra$and$difference$spectra)$and$ multivariate$ (principal$ component$ analysis$ (PCA)$ followed$ by$ linear$discriminant$ analysis$ (LDA))$ analysis$ to$ create$ a$ classification$ model.$ The$performance$of$ the$ classification$model$was$ assessed$by$ leave$one$ sample$out$cross$validation$(LOSOCV).$$$













5.1.1.#Morphological#Analysis#Using$the$information$obtained$from$the$blood$protein$droplet$studies$in$chapter$4,$ all$ samples$ were$ initially$ morphologically$ examined$ using$ the$ white$ light$cameras$ in$ order$ to$ identify$ the$ most$ appropriate$ droplets$ for$ the$ two$spectroscopic$ techniques.$ Poor$ quality$ samples$ that$ were$ small$ or$ had$ weak$structures$filled$with$cracks$were$also$avoided.$$$$
5.1.2.#Empirical#Analysis#Using$ the$ parameters$ described$ in$ section$ 3.4.4.3,$ thirty$ Raman$ and$ thirty$ IR$point$ spectra$ were$ collected$ from$ each$ of$ the$ four$ sample$ types$ from$ each$patient.$This$number$of$spectra$was$selected$based$on$power$calculations$from$Babrahs$work$(2009).$Measurements$were$taken$from$the$central$regions$of$the$ring$ in$ the$ blood$ droplet$ samples,$ at$ least$ 5.2$ µm$ (for$ IR)$ and$ 15.3$ µm$ (for$Raman)$from$the$edge$or$any$cracks.$All$FTIR$and$Raman$spectra$were$loaded$in$
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to$Matlab$and$were$normalised$and$mean$centred.$Some$of$the$samples$were$too$thick$ for$ IR$ transmittance$ analysis$ and$ thus$ the$ transmission$ of$ light$ was$saturated$ causing$ the$maximal$ absorbance$ value$ to$ be$ reached.$ This$ data$was$therefore$ subject$ to$ empirical$ screening$ to$ remove$ any$ of$ these$ saturated$spectra$from$the$dataset.$This$was$done$using$the$ratio$of$the$amide$I$and$amide$II$peaks,$identified$by$the$largest$peak$in$the$1600^1700$cm^1$and$1500^1600$cm^1$regions$respectively.$The$ratios$were$selected$based$on$a$mixture$of$references$(Table$5.2).$$$$
Table#5.2.#Amide#I/#Amide#II#Ratios#




Appendix$E$Appendix$E$Appendix$E$Isabelle$et#al,$2008$Isabelle$et#al,$2008$Babrah,$2009$Babrah,$2009$Babrah,$2009$Babrah,$2009$$$Histograms$of$the$amide$I/$amide$II$ratio$of$all$ the$spectra$for$each$of$the$four$different$pathology$groups$were$ then$plotted$(Figure$5.1).$From$the$sources$ in$Table$5.2$it$is$clear$that$the$amide$I/$amide$II$ratio$is$highly$variable,$depending$on$what$is$being$measured.$It$can$also$be$seen$in$the$histograms$that$there$is$a$difference$ between$ sample$ types,$ even$ between$ the$ blood$ cytospin$ and$ the$blood$droplet.$In$order$to$eliminate$saturated$spectra,$all$of$the$data$with$a$ratio$of$1$were$initially$removed$and$the$spectra$reassessed$for$saturation.$A$ratio$of$1$was$ chosen$ at$ first$ as$ all$ of$ the$ references$ indicated$ that$ the$ ratio$ of$ the$ two$peaks$was$always$above$this$value.$If$saturated$spectra$were$still$present$in$the$data,$ all$ spectra$with$ a$ ratio$ of$ 1.1$were$ removed$ and$ the$ spectra$ reassessed.$
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Table# 5.3.# Number# of# Spectra# Removed# From# Each# Sample# Due# to#
Saturation#
#










TOTAL$ # 2# 8# 25# 103#$$$
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A$high$proportion$of$the$spectra$from$six$plasma$samples$(highlighted$in$red$in$Table$ 5.3)$ were$ saturated$ and$ thus$ the$ entire$ data$ from$ those$ samples$ was$eliminated.$Several$spectra$from$the$remaining$samples$had$a$large$peak$at$1585$cm^1$between$the$amide$I$and$amide$II$peaks.$This$has$previously$been$identified$as$C=C$of$fibrinogen$in$blood$plasma$by$Poon$et#al$(2012)$however,$due$to$it$not$being$ present$ in$ all$ spectra$ in$ all$ samples$ it$may$ be$mistaken$ for$ pathological$variation$and$thus$the$plasma$IR$data$was$excluded$from$all$further$analysis.$$At$this$stage$it$was$also$decided$that$owing$to$the$varying$sizes$of$each$pathology$group$ that$ some$were$ too$ small$ for$multivariate$ statistical$ analysis.$ Therefore$only$CLL$(PUP),$CLL$(PTP)$and$healthy$groups$were$analysed$further.$$$
5.2.#Mean#Spectra#Mean$ IR$ and$ Raman$ spectra$ of$ the$ four$ sample$ types$ (blood$ cytospin,$ blood$droplet,$buffy$coat$cytospin$and$plasma$droplets)$were$plotted$using$the$healthy$data$ to$ identify$ any$ differences$ in$ peak$ positions$ or$ absorbance.$ Peaks$ were$identified$ according$ to$ a$ visual$ inspection$ and$ manual$ selection$ using$ an$ in$house$Matlab$tool,$which$were$then$assigned$according$to$literature.$A$full$list$of$peak$assignments$for$IR$and$Raman$are$displayed$in$Appendix$B.$$$
$$
Figure# 5.3.#Mean#Healthy# IR# Spectra# of# All# Four# Sample# Types;$ dark$ blue:$buffy$coat,$green:$blood$cytospin,$red:$blood$droplet,$light$blue:$plasma.$
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Across$all$ four$samples,$peaks$of$varying$intensities$are$observed$at$1400$cm^1,$1452$cm^1,$1548$cm^1$and$1655$cm^1$corresponding$to$amino$acids,$lipids,$amide$II$ and$ amide$ I$ respectively$ (Lie$ et# al,$ 1997,$ Liu$ et# al,$ 2002$ &$ Mourant$ et# al,#2003b).$ In$ the$ buffy$ coat$ spectrum$ (dark$ blue),$more$ prominent$ peaks$ can$ be$seen$ at$ 966$ cm^1,$ 1056$ cm^1,$ 1088$ cm^1,$ and$1240$ cm^1$ corresponding$ to$DNA,$carbohydrates,$ nucleic$ acids$ and$ amide$ III$ respectively$ (Schultz$ et# al,$ 1996,$Lasch$et#al,$2002,$Liu# et#al,#2002$&$Erukhimovitch$et#al,$2006).$A$peak$at$1307$cm^1$ is$ also$present$ in$ the$ buffy$ coat$ spectrum$as$well$ as$ in$ the$ blood$droplet$(red)$ and$ blood$ cytospin$ (green)$ spectra.$ This$ peak$ corresponds$ to$ amide$ III$(Chiriboga$ et# al,$ 1998a).$ In$ addition,$ peaks$ at$ 1100$ cm^1$ and$ 1170$ cm^1,$ both$relating$ to$nucleic$ acids,$ are$observed$ in$ the$blood$droplet$ and$blood$ cytospin$spectra$(Mourant$et#al,$2003b).$The$plasma$data$was$also$analysed$to$identify$if$any$extra$ information$may$be$ lost$by$not$using$ this$ sample$group.$The$plasma$spectra$ (light$ blue)$ did$ not$ appear$ to$ identify$ any$ other$ contributions$ from$biochemical$components$apart$from$those$already$noted.$$$
$
#
Figure# 5.4.# Mean# Healthy# Raman# Spectra# of# All# Four# Sample# Types;$ dark$blue:$buffy$coat,$green:$blood$cytospin,$red:$blood$droplet,$light$blue:$plasma.$$$$
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Similarly$there$are$peaks$observed$in$the$mean$Raman$spectra$of$all$four$sample$types.$At$1002$cm^1,$1250$cm^1$and$1447$cm^1$peaks$are$present$which$relate$to$phenylalanine$ (an$ amino$ acid),$ amide$ III$ and$ CH2$ vibrations$ from$ lipids/$proteins$ respectively$ (Stone$ et# al,$ 2002$&$ Pully$ et# al,$ 2010).$ In$ the$ buffy$ coat$spectra$(dark$blue)$peaks$can$be$seen$at$1095$cm^1$relating$to$PO2^$vibrations$in$DNA/$RNA$and$1657$cm^1$relating$to$the$C=O$stretch$of$amide$I$(Lyng$et#al,$2007$&$Poon$et#al,$2012).$The$amide$I$peak$is$also$present$in$the$plasma$spectra$(dark$blue)$but$is$masked$in$both$the$blood$cytospin$(green)$and$blood$droplet$spectra$(red)$ by$ a$ series$ of$ peaks$ at$ 1560$ cm^1,$ 1578$ cm^1$ (pyrimidine$ ring/$ haem$protein),$ and$ 1616$ cm^1$ (C=C$ vibrations$ of$ the$ amino$ acids$ tryptophan/$tyrosine)$(Stone$et#al,$2002$&$Poon$et#al,$2012).$The$peaks$at$1560$cm^1$and$1369$cm^1$ cannot$be$ identified$ from$ the$ literature.$However$peaks$ corresponding$ to$amino$acids$have$been$identified$in$similar$regions,$such$as$tryptophan$at$1361$cm^1$ and$ 1560$ cm^1$ and$ tyrosine$ at$ 1375$ cm^1$ (Fredericks,$ 1995,$Mahadevan^Jansen$&$Richards^Kortum,$1996$&$Pully$et#al,$2010).$Another$peak$at$1126$cm^1$can$be$seen$in$the$blood$cytospin$and$blood$droplet$data$only$which$is$caused$by$C^C/$C^N$vibrations$of$lipids/$proteins$(Stone$et#al,$2002$&$Bonnier$et#al,$2012).$$Mean$spectra$of$ the$ three$pathologies,$healthy,$CLL$(PUP)$and$CLL$(PTP)$were$also$plotted.$The$mean$buffy$coat$IR$spectra$of$the$three$pathologies$is$shown$in$figure$5.5.$The$peaks$of$the$main$biochemical$component$have$been$highlighted.$It$can$be$seen$that$there$are$some$subtle$differences$between$the$spectra,$caused$by$ variations$ in$ the$ absorption$ and$ positions$ of$ the$ peaks.$ However$ these$differences$ are$ very$ difficult$ to$ identify$ without$ the$ use$ of$ further$ statistical$analysis$and$thus$the$mean$spectra$for$the$other$datasets$are$shown$in$Appendix$F.$$$The$peaks$at$966$cm^1$and$1088$cm^1$are$caused$by$the$PO2^$stretching$vibrations$of$the$nucleic$acids$in$DNA$(Schultz$et#al,$1996$&$Liu$et#al,$2002).$The$peaks$at$1056$ cm^1$ and$ 1452$ cm^1$ are$ attributed$ to$ vibrations$ from$ the$ C^OH$ of$carbohydrates$ (Erukhimovitch$et#al,$ 2006)$and$ the$asymmetric$deformation$of$CH2$ and$ CH3$ of$ lipids$ (Liu$ et# al,$ 1997)$ respectively.$ The$ remaining$ peaks$ are$caused$ by$ the$ absorption$ modes$ of$ proteins,$ with$ the$ most$ prominent$ peaks$
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observed$in$the$spectra$due$to$the$C=O$stretching$vibrations$of$amide$I$at$1656$cm^1$and$ the$N^H$deformation$of$amide$ II$at$1546$cm^1$ (Liu$et#al,$2002).$Other$protein$peaks$are$observed$at$1240$cm^1$due$to$the$C^N$stretch$and$N^H$bending$of$amide$III$(Lasch$et#al,$2002)$and$at$1400$cm^1$due$to$the$bending$vibrations$of$NH2$in$amino$acids$(Mourant$et#al,$2003b).$$$$
$$











C^C$ vibrations$ α^helical$ protein$backbone$CH3$deformation$Symmetric$ring$breathing$phenylalanine$C^H$vibrations$phenylalanine$Weak$C=O$stretch$Glycogen$PO2^$DNA/RNA$$C^N$stretch$protein$$C^N$stretch$proteins$NH3$$$C6H5$tryptophan$and$phenylalanine$C^N$vibrations$amide$III$CH2CH3$deformation$lipids$CH2CH3$ deformation$ nucleic$ acids/$proteins$Ring$breathing$modes$DNA$CH2$bending$proteins/$lipids$N^H$ deformation/$ C^N$ vibration$ amide$II/$tryptophan$Pyrimidine$ring/$haem$protein$C=C$vibrations$tyrosine/$tryptophan$C=O$stretch$amide$I/$C=C$stretch$lipid$
Mahadevan^Jansen$ &$Richards^Kortum$1996$Poon$et#al,$2012$Stone$et#al,$2002$Poon$et#al$2012$Kendall,$2002$Mahadevan^Jansen$ &$Richards^Kortum$1996$Bonnier$ et# al,$ 2012$Fredericks,$1995$Bonnier$et#al,#2012$$Poon$et#al,$2012$Pully$et#al,$2010$Stone$et#al,#2002$Stone$ et# al,#2002$&$ Pully$ et#



































Figure# 5.8.# Difference# Spectra# for# Blood# Cytospin# IR;# A)$ CLL$ (PUP)$ –$ CLL$(PTP),$B)$CLL$(PUP)$–$Healthy,$C)$CLL$(PTP)$^$Healthy$$$$
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Figure# 5.9.# Difference# Spectra# for# Blood# Droplet# IR;# A)$ CLL$ (PUP)$ –$ CLL$(PTP),$B)$CLL$(PUP)$–$Healthy,$C)$CLL$(PTP)$^$Healthy$$$$
122 
 




$1025$ C^OH$carbohydrates$1080$PO2^$DNA$(nucleic$acids)$$1155$C^OH$carbohydrates$1240$C^N$stretch/$N^H$ bending$ of$ amide$III$$1390$$1452$ CH3CH2$ fatty$acids/$phospholipids$$1546$N^H$amide$II$$1638$1682$C=O$amide$I$
966$DNA$1025$C^OH$carbohydrates$1080$PO2^$DNA$(nucleic$acids)$$$$1240$C^N$stretch/$N^H$bending$of$amide$III$$$1407$CH3CH2$fatty$acids/$phospholipids$1530$N^H$amide$II$$$1592$$1682$C=O$amide$I$
$$$1080$PO2^$DNA$(nucleic$acids)$1121$PO2^$DNA$(nucleic$acids)$$$$$$1410$ CH3CH2$ fatty$acids/$phospholipids$$$$1592$1655$C=O$amide$I$$1708$C^CO$RNA$













































Table# 5.9.$ Assignment# of# Difference# Spectra# Peaks# for# Blood# Cytospin#
Raman#


























Table# 5.10.$ Assignment# of# Difference# Spectra# Peaks# for# Blood# Droplet#
Raman#


































925$proline$ring$$972$C^C$proline$1030$phenylalanine$1048$C=O$glycogen$1271$C^N$ stretch/$N^H$ bending$ of$ amide$III$$1350$glucose$$









It$can$be$seen$that$there$are$higher$DNA,$nucleic$acid$and$protein$contributions$in$the$two$CLL$pathologies,$which$corresponds$with$high$cell$proliferation.$There$also$ appears$ to$ be$ higher$ lipid$ and$ carbohydrate$ contributions$ in$ the$ healthy$data.$However$ there$are$ some$discrepancies$between$ the$protein$ content$with$higher$ amide$ I$ and$ amide$ III$ contributions$ seen$ in$ the$ CLL$ data,$ and$ higher$amide$ II$ in$ the$ healthy$ data.$ Although$ certain$ biochemical$ differences$ can$ be$identified$ by$ this$ peak$ assignment,$ there$ is$ still$ a$ lot$ of$ variation$ and$disagreement$between$biochemical$contributions$in$the$three$pathologies.$Peak$assignment$ is$ only$ speculative$ as$ the$ data$ obtained$ from$ literature$ is$ highly$varied.$Peaks$may$also$represent$a$variety$of$biochemical$constituents$and$thus$may$be$masked$or$shifted$due$to$other$components.$Baseline,$signal$strength$and$noise$ also$ varies$ between$ the$ spectra$ causing$ any$ small$ differences$ to$ be$exaggerated.$All$ of$ the$ sample$ types$ and$pathologies$will$ display$ fairly$ similar$and$complex$biochemistry,$with$variation$surrounding$small$peak$shifts$as$well$as$ the$ absorbance/$ intensity$ of$ certain$ components$ being$ the$ main$ source$ of$differentiation.$However,$ these$mean$ spectra$ appear$ to$ indicate$ that$ there$ are$not$ very$ strong$ differences$ between$ the$ two$ CLL$ pathologies.$ It$ is$ therefore$necessary$ to$ use$multivariate$ statistical$ analysis$ in$ order$ to$ analyse$ the$ entire$data$rather$than$individual$peaks.$$$











































































Figure# 5.17.# PC# Score# Plots;#A)$ buffy$ coat$ IR,$ B)$ blood$ cytospin$ IR,$ C)$ blood$droplet$ IR,$ D)$ buffy$ coat$ Raman,$ E)$ blood$ cytospin$ Raman,$ F)$ blood$ droplet$Raman,$G)$plasma$Raman,$purple:$healthy,$dark$blue:$CLL$(PUP),$light$blue:$CLL$(PTP)$$It$can$be$seen$in$the$IR$buffy$coat$PC$score$plot$(Figure$5.17A)$that$there$is$some$separation$ between$healthy$ (purple)$ and$ the$ two$CLL$datasets$ (light$ blue$ and$dark$blue).$The$purple$data$points$lie$in$the$positive$region$of$PC4$and$thus$are$separated$by$amide$I,$amide$II$and$carbohydrate$contributions,$as$ indicated$by$the$positive$peaks$ in$ the$PC$ load$(Figure$5.16).$CLL$(PUP)$(dark$blue)$and$CLL$(PTP)$ (light$blue)$overlap$and$ trend$ towards$ the$negative$region$of$PC4$ in$ the$scatter$plot.$These$are$therefore$separated$from$healthy$according$to$changes$in$DNA$and$RNA$as$shown$by$the$negative$peaks$in$the$PC$load.$Separation$can$also$be$ seen$ between$ the$ healthy$ and$ the$ two$ CLL$ pathologies$ in$ the$ buffy$ coat$Raman$plot$using$PC4$(Figure$5.17D).$However$there$is$less$obvious$separation$in$the$other$datasets.$$Although$ these$ score$ plots$ show$ some$ natural$ separation$ in$ the$ data,$ ANOVA$only$uses$ the$ two$most$ significant$PCs$ to$ generate$ scores$plots.$ It$ can$be$ seen$from$ the$ plots$ in$ Figure$ 5.14$ that$ more$ than$ two$ PCs$ contribute$ to$ the$differences$in$the$data.$ANOVA$also$separates$the$data$based$on$averages$of$the$
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means.$ If$ there$are$any$outliers$ in$ the$data,$as$can$be$seen$ in$several$of$ the$PC$score$ plots,$ the$mean$will$ be$ shifted$ and$ the$ ability$ of$ the$ PC$ to$ separate$ the$groups$will$be$distorted$by$these$outliers.$In$order$to$improve$the$separation$of$the$pathologies$LDA$was$used.$$$






























# # PREDICTED# #
# # CLL#(PUP)# CLL#(PTP)# Healthy# TOTAL#
# SN#%# 59$ 36$ 77$ $
# SP#%# 69$ 82$ 87$ $
CLL#(PUP)# 161# 81$ 30$ 272$
CLL#(PTP)# 101$ 75# 34$ 210$#TRUE#
Healthy# 48$ 15$ 207# 270$
# # $ $ $ 752#59$%$of$the$spectra$were$correctly$classified$$$
Table#5.14.#LOSOCV#Results#for#Blood#Cytospin#IR#
# # PREDICTED# #
# # CLL#(PUP)# CLL#(PTP)# Healthy# TOTAL#
# SN#%# 17$ 45$ 19$ $
# SP#%# 67$ 57$ 65$ $
CLL#(PUP)# 47# 116$ 107$ 270$
CLL#(PTP)# 55$ 95# 59$ 209$#TRUE#
Healthy# 102$ 114$ 51# 267$




# # PREDICTED# #
# # CLL#(PUP)# CLL#(PTP)# Healthy# TOTAL#
# SN#%# 31$ 36$ 57$ $
# SP#%# 75$ 87$ 49$ $
CLL#(PUP)# 79# 34$ 138$ 251$
CLL#(PTP)# 34$ 75# 97$ 206$#TRUE#
Healthy# 83$ 34$ 158# 276$
# # $ $ $ 733#43$%$of$the$spectra$were$correctly$classified$$
Table#5.16.#LOSOCV#Results#for#Buffy#Coat#Raman##
# # PREDICTED# #
# # CLL#(PUP)# CLL#(PTP)# Healthy# TOTAL#
# SN#%# 36$ 20$ 80$ $
# SP#%# 69$ 74$ 79$ $
CLL#(PUP)# 95# 119$ 47$ 261$
CLL#(PTP)# 113$ 42# 53$ 208$#TRUE#
Healthy# 33$ 21$ 215# 269$
# # $ $ $ 738#48$%$of$the$spectra$were$correctly$classified#
#
Table#5.17.#LOSOCV#Results#for#Blood#Cytospin#Raman##
# # PREDICTED# #
# # CLL#(PUP)# CLL#(PTP)# Healthy# TOTAL#
# SN#%# 55$ 29$ 49$ $
# SP#%# 74$ 77$ 66$ $
CLL#(PUP)# 149# 51$ 71$ 271$
CLL#(PTP)# 60$ 61# 92$ 213$#TRUE#
Healthy# 67$ 71$ 131# 269$
# # $ $ $ 753#45$%$of$the$spectra$were$correctly$classified#
#
Table#5.18.#LOSOCV#Results#for#Blood#Droplet#Raman##
# # PREDICTED# #
# # CLL#(PUP)# CLL#(PTP)# Healthy# TOTAL#
# SN#%# 70$ 48$ 66$ $
# SP#%# 89$ 80$ 74$ $
CLL#(PUP)# 178# 46$ 31$ 255$
CLL#(PTP)# 19$ 98# 88$ 205$#TRUE#
Healthy# 32$ 59$ 179# 270$




# # PREDICTED# #
# # CLL#(PUP)# CLL#(PTP)# Healthy# TOTAL#
# SN#%# 49$ 41$ 64$ $
# SP#%# 71$ 78$ 80$ $
CLL#(PUP)# 137# 84$ 57$ 278$
CLL#(PTP)# 84$ 86# 42$ 212$#TRUE#
Healthy# 58$ 39$ 173# 270$












































The$blood$droplet$Raman$and$buffy$coat$ IR$methods$show$better$separation$of$the$two$individual$CLL$pathologies$compared$to$the$other$methods.$This$can$be$seen$ by$ the$ higher$ sensitivities$ and$ specificities,$ however$ classification$ is$ still$poor$with$less$than$50$%$of$the$CLL$(PTP)$correctly$classified.$Throughout$it$has$been$clear$that$there$is$poor$separation$between$the$two$CLL$populations$with$patients$who$had$previously$been$treated$for$CLL$and$patients$who$were$newly$diagnosed$showing$little$biochemical$variance.$Because$of$this$the$classification$model$was$rerun,$with$the$two$CLL$populations$grouped$together.$$$$
5.7.#Two#Group#Model#All$ data$ from$ the$ two$ CLL$ pathologies$ were$ combined$ and$ the$ classification$model$ rerun$ as$ before.$ The$ sensitivities$ and$ specificities$ of$ the$ two$ group$classification$models$are$displayed$in$Tables$5.20$to$5.26.$$$
Table#5.20.#Two#Group#LOSOCV#Results#for#Buffy#Coat#IR#$ # PREDICTED# #$ # CLL# Healthy# TOTAL#
# SN#%# 83$ 76$ $
# SP#%# 76$ 83$ $
CLL# 398# 85$ 483$TRUE#
Healthy## 64$ 206# 290$
# # $ # 773#78$%$of$the$spectra$were$correctly$classified$$
Table#5.21.#Two#Group#LOSOCV#Results#for#Blood#Cytospin#IR#$ # PREDICTED# #$ # CLL# Healthy# TOTAL#
# SN#%# 54$ 28$ $
# SP#%# 28$ 54$ $
CLL# 259# 220$ 479$TRUE#
Healthy## 191$ 76# 267$
# # # # 746#45$%$of$the$spectra$were$correctly$classified$$$
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Table#5.22.#Two#Group#LOSOCV#Results#for#Blood#Droplet#IR#$ # PREDICTED# #$ # CLL# Healthy# TOTAL#
# SN#%# 45$ 60$ $
# SP#%# 60$ 45$ $
CLL# 206# 251$ 457$TRUE#
Healthy## 107$ 163# 270$
# # $ # 727#51$%$of$the$spectra$were$correctly$classified$$
Table#5.23.#Two#Group#LOSOCV#Results#for#Buffy#Coat#Raman#$$ # PREDICTED# #$ # CLL# Healthy# TOTAL#
# SN#%# 77$ 82$ $
# SP#%# 82$ 77$ $
CLL# 359# 110$ 469$TRUE#
Healthy## 49$ 220# 269$
# # $ # 738#78$%$of$the$spectra$were$correctly$classified$$
Table#5.24.#Two#Group#LOSOCV#Results#for#Blood#Cytospin#Raman##$ # PREDICTED# #$ # CLL# Healthy# TOTAL#
# SN#%# 54$ 54$ $
# SP#%# 54$ 54$ $
CLL# 260# 224$ 484$TRUE#
Healthy## 124$ 145# 269$
# # $ # 753#54$%$of$the$spectra$were$correctly$classified$$
Table#5.25.#Two#Group#LOSOCV#Results#for#Blood#Droplet#Raman##$ # PREDICTED# #$ # CLL# Healthy# TOTAL#
# SN#%# 69$ 76$ $
# SP#%# 76$ 69$ $
CLL# 316# 144$ 460$TRUE#
Healthy## 66$ 204# 270$
# # $ # 730#71$%$of$the$spectra$were$correctly$classified$$$
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Table#5.26.#Two#Group#LOSOCV#Results#for#Plasma#Raman##$ # PREDICTED# #$ # CLL# Healthy# TOTAL#
# SN#%# 69$ 66$ $
# SP#%# 66$ 69$ $
CLL# 335# 155$ 490$TRUE#
Healthy## 93$ 177# 270$








































































# SN%# SP%# SN%# SP%# SN%# SP%#
CLL# 78$ 93$ 52$ 18$ 58$ 66$










# SN%# SP%# SN%# SP%# SN%# SP%# SN%# SP%#
CLL# 77$ 80$ 54$ 54$ 65$ 81$ 65$ 68$
Healthy## 80$ 77$ 54$ 54$ 81$ 65$ 68$ 65$
#
#
Table# 5.30# Comparison# of# the# Performance# of# the# Complete# and#
Conservative#Two#Group#Models#









5.8.#Discussion#The$ difference$ spectra$ showed$ that$ significant$ spectral$ differences$ existed$between$ the$ three$pathology$ groups,$ particularly$between$ the$CLL$pathologies$and$the$healthy$group.$The$major$differences$seen$between$the$CLL$and$healthy$groups$ being$ attributed$ to$ biochemical$ contributions$ from$ proteins$ and$ DNA.$PCA$identified$some$natural$separation$between$the$two$CLL$pathologies$and$the$healthy$ group,$ which$was$ further$ separated$ using$ all$ 20$ PCs$ in$ LDA.$ LOSOCV$showed$ that$ the$ initial$ three$group$model$was$unable$ to$differentiate$between$the$two$CLL$pathologies$very$well.$When$these$pathology$groups$were$combined$in$ the$ two$ group$ model,$ the$ classification$ of$ CLL$ from$ healthy$ was$ greatly$improved$ across$ all$ sample$ types,$ identifying$ that$ misclassification$ due$ to$ a$patient$having$previously$been$treated$for$CLL$is$not$very$likely.$In$order$to$try$to$ improve$ the$ classification$model$ further$ by$ reducing$ the$ influence$ of$ noise,$the$ two$ group$model$ was$ rerun$ using$ 12$ PCs.$ This$ moderately$ improved$ the$performance$ of$ some$ of$ the$ datasets$ suggesting$ that$ beyond$ 12$ PCs$ noise$ is$more$likely$to$be$contributing$to$the$variance$than$biochemical$differences.$$It$ must$ be$ highlighted$ that$ in$ the$ previous$ study$ by$ Babrah$ (2009),$ 99.5$ %$correct$ classification$of$ the$buffy$ coat$ IR$model$was$ achieved.$Here$only$83$%$correct$ classification$ was$ achieved$ in$ the$ conservative$ two$ group$ model.$Although$ this$ is$ significantly$ lower,$ in$ the$ previous$ study$ 1438$ spectra$ were$acquired$from$ten$blood$samples,$an$average$of$140$spectra$per$sample,$whereas$here$840$spectra$were$acquired$from$28$samples,$30$spectra$from$each.$As$the$performance$ of$ the$ blood$ droplet$ Raman$model$was$ very$ similar$ to$ the$ buffy$coat$ IR$ in$ this$ study,$ obtaining$ a$ higher$ number$ of$ samples$ and$ spectra$ may$improve$ the$model.$ This$ could$ be$ tested$ by$ rerunning$ the$models$ and$ leaving$two$or$three$samples$out$each$time.$It$was$also$identified$from$these$results$that$cytospinning$ whole$ blood$ samples$ onto$ slides$ was$ not$ a$ very$ good$ method$choice$for$CLL$diagnosis.$Due$to$the$sample$being$a$heterogeneous$layer$of$cells,$the$ cellular$ content$ across$ the$ slide$ was$ highly$ varied$ whereas$ the$ blood$droplets$created$a$homogenous$ ‘soup’$of$biochemical$content$from$which$more$consistent$spectral$collection$could$be$obtained$across$the$sample.$$$
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6.#RESULTS#AND#DISCUSSION:#LYMPHOMA#ANALYSIS#$$Due$ to$ the$ low$ number$ of$ samples$ obtained,$ this$ chapter$ on$ lymphoma$ is$presented$ as$ a$ feasibility$ study$ in$ order$ to$ assess$ the$ methods$ of$ sample$preparation$and$spectroscopic$analysis$that$were$used.$Five$fine$needle$aspirate$biopsies$(FNAB)$were$obtained.$The$first$sample$that$was$collected$was$subject$to$ both$ cytospin$ centrifugation$ and$ drop$ coating$ deposition$ spectroscopy$(DCDS)$measured$by$Raman$and$Fourier$Transform$Infrared$(FTIR)$as$described$in$ section$ 3.5.$ The$ remaining$ samples$ were$ only$ cytospun$ due$ to$ the$interference$ of$ phosphate$ buffered$ saline$ (PBS)$ observed$ in$ the$ white$ light$images$and$potentially$in$the$data.$Unfortunately$a$record$of$the$pathologies$was$not$maintained.$$$$




Figure# 6.1.# White# Light# Images# of# the# First# FNAB# Received;$ A)$ DCDS,$ B)$Cytospin$
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6.3.#Discussion#The$spectra$obtained$show$the$potential$for$lymph$node$aspirate$biopsies$to$be$analysed$by$both$Raman$and$IR$spectroscopy.$Unfortunately,$due$to$difficulties$in$ obtaining$ samples$ and$ the$ limited$ number$ obtained$ with$ unknown$pathologies,$any$further$statistical$analysis$was$not$appropriate.$$$
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FNABs$are$routinely$collected$and$flushed$in$PBS$in$the$hospital.$Although$at$this$stage$ it$ is$ only$ speculation$ that$ there$ is$ spectral$ interference$ from$ PBS,$ the$physical$ structure$ of$ the$ droplets$ is$ poor.$ As$ discovered$ by$ the$ blood$ protein$analysis$in$chapter$4,$the$formation$of$diamond$shapes$is$not$desirable$for$good$spectral$measurements.$ It$would$ therefore$be$ interesting$ to$ see$ if$ the$ samples$could$be$obtained$in$water$for$DCDS.$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
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7.#CONCLUSIONS#$$With$ the$ aid$ of$ multivariate$ statistical$ analysis,$ the$ aim$ of$ this$ thesis$ was$ to$investigate$ the$ application$ of$ Raman$ and$ Fourier$ Transform$ infrared$ (FTIR)$spectroscopy$as$a$rapid$diagnostic$tool$for$leukaemia$and$lymphoma.$The$main$focus$ of$ this$ thesis$ was$ to$ compare$ the$ performance$ of$ the$ different$ blood$fractions$prepared$by$two$different$techniques;$cytospin$centrifugation$and$Drop$Coating$ Deposition$ Spectroscopy$ (DCDS),$ in$ diagnosing$ leukaemia.$ The$ DCDS$method$ was$ explored$ owing$ to$ the$ low$ sample$ volumes$ and$ minimal$ sample$preparation$required$and$thus$is$advantageous$over$the$more$laborious$cytospin$centrifugation$method.$ Unfortunately$ the$ investigation$ of$ FTIR$ and$ Raman$ for$lymphoma$diagnosis$did$not$get$very$far$due$to$the$small$number$of$undiagnosed$fine$needle$aspirate$biopsy$samples$obtained.$$$
7.1.#DCDS#Method#The$ results$ from$ the$ preliminary$ DCDS$ study$ revealed$ it$ to$ be$ a$ powerful$technique$ for$ both$ infrared$ (IR)$ and$ Raman$ spectroscopic$ analysis$ of$ low$concentration$ protein$ solutions.$ It$ was$ identified$ that$ in$ order$ to$ achieve$qualitative$ biochemical$ information$ from$ the$ droplets,$ initial$ morphological$analysis$ of$ the$ formed$ rings$ was$ required$ in$ order$ to$ avoid$ taking$ spectral$measurements$ from$ areas$ in$ the$ ring$ where$ cracks$ had$ formed.$ It$ was$ also$identified$ that$ scattering$ occurred$ at$ the$ very$ edges$ of$ the$ rings$ to$ a$ certain$extent$and$by$taking$spectral$measurements$a$specified$distance$from$the$edge$these$effects$could$be$eliminated$from$the$results.$This$information$was$used$to$develop$a$technique$for$leukaemia$diagnosis$using$whole$blood$samples.$$$$
7.2.#Leukaemia#Classification#Model#Morphological$ analysis$ allowed$ the$ best$ ring$ dilution$ to$ be$measured$ for$ each$spectroscopic$ method.$ Each$ blood$ sample$ obtained$ had$ a$ very$ different$consistency,$ varying$ in$ number$ of$ cells,$ colour$ and$ viscosity$ and$ thus$ diluting$
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blood$ to$ obtain$ a$ specific$ concentration$ or$ appearance$ in$ order$ to$ obtain$ a$precise$droplet$on$the$slide$was$extremely$difficult.$It$may$have$been$beneficial$to$ identify$ the$ concentrations$ of$ some$ of$ the$ analytes$ in$ the$ samples$ for$calibration$purposes.$However$at$ this$early$ stage$ it$was$difficult$ to$know$what$analytes$may$have$been$different$in$the$cancer$and$healthy$samples.$A$full$blood$count$could$have$been$done$to$identify$the$indices$and$aid$in$the$dilution$of$the$samples$for$drop$coating$deposition.$However,$not$only$is$it$time$consuming$but$the$ white$ cell$ count$ is$ very$ high$ in$ leukaemia,$ which$ causes$ a$ reduction$ in$circulating$ red$ blood$ cells$ thus$ making$ comparisons$ between$ healthy$ and$cancerous$ samples$quite$difficult.$Making$ three$dilutions$of$ each$blood$ sample$and$ visually$ assessing$ the$ quality$ of$ the$ droplets$ was$ the$ easiest$ and$ most$practical$ option,$ especially$ if$ the$ technique$ was$ to$ be$ brought$ into$ a$ clinical$environment.$The$accuracy$of$ this$visual$ technique$was$confirmed$in$chapter$4$using$albumin$droplets,$which$aided$in$the$determination$of$acceptable$criteria$for$this$process.$$$A$numerical$screening$method$aided$in$the$semi^automated$removal$of$ IR$data$that$ was$ saturated.$ Although$ some$ poor$ quality$ samples$ can$ be$ removed$visually,$ using$ a$ numerical$ method$ allows$ a$ more$ accurate$ technique$ of$eliminating$ spectra$ that$ has$ interference$ from$ background$ noise$ or$ from$ a$sample$ being$ too$ thick$ for$ the$ light$ to$ pass$ through.$ Although$ this$meant$ that$several$ plasma$ samples$were$ removed,$ the$ spectra$ in$ Figure$5.3$ show$ that$ no$extra$biochemical$information$was$obtained$from$plasma$than$was$identified$in$the$other$blood$fractions.$$$The$principal$component$analysis$(PCA)$followed$by$linear$discriminant$analysis$(LDA)$classification$method$performed$best$in$the$two$group$model$using$12$PCs$for$ both$ the$ buffy$ coat$ infrared$ and$ blood$ droplet$ Raman$ datasets.$ This$ was$shown$by$the$percentage$of$correctly$classified$spectra$as$calculated$by$leave$one$sample$ out$ cross$ validation$ (LOSOCV).$ The$ performance$ of$ the$ classification$model$for$the$buffy$coat$data$was$not$as$good$at$correctly$classifying$the$spectra$as$shown$by$Babrah$(2009),$with$83$%$correctly$classified$compared$to$99.5$%.$
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However,$the$number$of$spectra$per$sample$obtained$here$was$much$lower,$with$hundreds$rather$than$thousands$of$point$spectra$analysed.$$$The$method$ of$ extracting$ the$ buffy$ coat$ layer$ is$ laborious$ and$ thus$ the$ DCDS$method$ using$ whole$ blood$ was$ compared$ in$ order$ to$ minimise$ sample$preparation$and$overall$analysis$time.$The$DCDS$preparation$in$theory$provides$a$ homogenous$ ring$ signal$ so$ only$ a$ few$measurements$ need$ to$ be$made$ that$represent$the$signal$from$the$blood$collected.$From$these$results$it$would$seem$that$the$blood$droplet$Raman$classification$model,$which$achieved$71$%$correct$classification,$was$not$quite$as$successful$as$the$buffy$coat$infrared$model,$which$correctly$ classified$ 83$ %$ of$ the$ spectra,$ at$ diagnosing$ leukaemia.$ With$ the$collection$ and$ analysis$ of$ more$ samples$ and$ further$ development$ of$ the$statistical$model$ used,$ the$DCDS$method$has$potential$ to$ be$ improved$ further,$increasing$ the$ sensitivity$ and$ specificity$of$ the$ technique$ in$diagnosing$ cancer.$The$ advantage$ of$ using$ this$ technique$ over$ buffy$ coat$ infrared$ is$ the$ smaller$sample$volumes$and$minimal$sample$preparation$required.$The$samples$can$also$be$measured$almost$instantly$with$Raman$spectroscopy$as$water$does$not$cause$interference$and$thus$time$could$be$saved$not$having$to$dry$the$samples$first.$It$may$be$possible$ that$droplets$could$be$measured$whilst$still$wet,$although$this$could$be$a$problem$with$ low$concentration$samples.$ It$would$be$ interesting$ to$test$ this$ theory$ out.$ However$ the$ effects$ of$ hydration$ on$ the$ biochemistry$ of$samples$would$also$need$to$be$addressed$in$order$to$avoid$variation$in$hydration$being$mistaken$for$biochemical$differences$due$to$cancer.$$$All$ patients$ used$ for$ this$ study$ were$ newly$ diagnosed$ cases$ of$ Chronic$Lymphoblastic$ leukaemia$ (CLL).$ Both$ populations$ of$ CLL,$ previously$ unseen$patients$(PUP)$and$previously$ treated$patients$(PTP)$showed$ little$biochemical$difference$ and$ thus$when$ the$ classification$models$were$ rerun$with$ these$ two$groups$ combined,$ the$ overall$ performances$ improved.$ It$ is$ therefore$ unlikely$that$misclassification$ due$ to$ a$ patient$ having$ previously$ been$ treated$ for$ CLL$would$occur.$$$
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7.3.#Lymphoma#Insufficient$ samples$ were$ collected$ for$ appropriate$ conclusions$ to$ be$ drawn$regarding$the$use$of$vibrational$spectroscopies$for$the$diagnosis$of$lymphoma.$It$has$been$shown$that$spectra$can$be$taken$from$fine$needle$aspirate$biopsies$and$from$lymph$nodes$and$thus$further$work$is$required$into$the$method$of$sample$preparation,$ identifying$ the$ biochemical$ differences$ between$ normal$ and$lymphoma$ samples$ and$ developing$ a$ classification$ model$ for$ successful$diagnosis.$$$
7.4.#Clinical#Applications#Although$ vibrational$ spectroscopies,$ particularly$ FTIR,$ have$ been$ used$ to$monitor$leukaemias$and$identify$the$effect$of$chemotherapy$treatment,$there$is$a$lack$ of$ evidence$ in$ the$ literature$ that$ different$ sub^types$ of$ leukaemia$ can$ be$diagnosed$by$spectroscopic$analysis.$It$has$been$identified$in$this$study$that$CLL$can$be$differentiated$from$healthy$samples$using$buffy$coat$IR,$buffy$coat$Raman$and$blood$droplet$Raman$classification$models.$Unfortunately$due$to$the$number$of$samples$collected$it$was$not$possible$to$look$at$other$leukaemia$pathologies.$If$these$could$also$be$diagnosed$with$the$same$level$of$sensitivity$and$specificity,$these$techniques$have$the$potential$to$be$applied$to$clinical$practice.$$Having$worked$in$a$hospital$laboratory$for$the$last$year,$at$this$stage$a$realistic$environment$for$drop$coating$deposition$spectroscopy$to$be$employed$is$in$the$laboratory$rather$than$a$GP$surgery.$For$this$technique$to$become$automated$in$a$laboratory$a$method$for$analysing$the$consistency$of$the$blood$for$optimal$ring$formation$ would$ need$ to$ be$ deployed.$ If$ information$ regarding$ the$ cellular$contents$of$blood$could$be$used$to$ identify$the$appropriate$dilution$for$droplet$deposition,$ the$ process$ of$ individually$ assessing$ each$ droplet$ visually$ prior$ to$analysis$could$be$eliminated.$Several$samples$could$be$analysed$simultaneously$by$ depositing$ whole$ blood$ onto$ a$ slide$ using$ an$ automated$ multichannel$micropipette.$ This$ would$ also$ improve$ the$ quality$ of$ the$ droplet$ by$ reducing$manual$ errors.$ Spectroscopic$ measurements$ of$ each$ sample$ could$ be$ taken$within$seconds$and$results$uploaded$onto$the$hospital$database.$From$a$sample$
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being$taken$at$a$GP$surgery,$the$sample$would$be$sent$to$the$laboratory$the$same$day$and$analysed$within$hours.$$$There$is$potential$for$this$technique$to$be$improved$further$so$that$a$hand$held$device$ could$measure$ droplets$ of$ blood$ taken$ directly$ from$ a$ patient$ allowing$the$method$ to$ be$ introduced$ into$ the$ GP$ surgery.$ However$ this$ requires$ a$ lot$more$research,$with$more$samples$and$experimentation.$$$
7.5.#Future#Work#As$already$highlighted,$larger$sample$groups$with$more$spectra$are$required$to$improve$ the$ performance$ of$ the$ classification$models.$ This$ is$ particularly$ true$for$ the$blood$droplet$Raman$model$ in$order$ to$prove$ it$can$perform$as$well$as$the$ buffy$ coat$ IR$ model.$ Due$ to$ the$ small$ number$ of$ samples$ and$ spectra$obtained$it$is$impossible$to$have$accounted$for$variations$in$the$population$that$may$have$contributed$to$biochemical$variances$seen$in$the$data$such$as$gender,$sex,$smoking$habits$and$diet$etc.$It$may$also$be$interesting$to$look$at$a$secondary$control$group$made$up$of$patients$who$have$a$high$white$blood$cell$count$due$to$an$ infection.$ Although$ changes$ in$ the$ concentrations$ of$ certain$ cellular$components$have$been$identified$here$for$leukaemia$diagnosis,$for$example$the$amount$of$DNA$and$protein,$this$would$also$be$apparent$in$an$infection$as$more$white$blood$ cells$ are$produced$ thus$ increasing$ the$number$of$ immature$white$blood$cells$in$circulation.$$$Further$work$to$improve$the$blood$droplet$Raman$model$would$be$to$look$at$the$effects$ of$ hydration$ on$ the$ blood$ droplets$ to$ see$ if$ this$ causes$ any$ detectable$biochemical$changes$that$may$be$mistaken$for$changes$relating$to$pathology.$A$further$ understanding$ of$ the$ consistency$ of$ the$ blood$ samples$ at$ the$ different$dilutions$would$ also$ be$ beneficial$ in$ creating$ a$method$where$ only$ one$ blood$droplet$was$ needed$ for$ qualitative$ spectroscopic$ analysis$ thus$ eliminating$ the$need$for$a$visual$check$of$the$samples.$$$
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In$ order$ to$ evaluate$ the$ use$ of$ the$ blood$ droplet$ Raman$ model$ for$ other$leukaemia$subtypes,$it$would$be$necessary$to$obtain$samples$from$a$wider$range$of$ pathologies.$ It$ would$ be$ particularly$ useful$ to$ look$ at$ chronic$ myeloid$leukaemia$ (CML),$ acute$ lymphoblastic$ leukaemia$ (ALL)$ and$ acute$ myeloid$leukaemia$(AML)$to$identify$the$biochemical$differences$between$cancers$of$the$myeloid$ and$ lymphoid$ progenitors$ as$ well$ as$ between$ acute$ and$ chronic$versions$of$the$same$cancer.$$$For$this$work$to$be$translated$into$a$hospital$laboratory,$multicentre$trials$of$the$method$would$be$required$ in$order$ to$ identify$ the$sensitivity$and$specificity$of$the$method$ in$ different$ populations$ using$ different$ spectrometers.$ The$ cost$ of$the$ method$ is$ also$ very$ important,$ particularly$ in$ today’s$ economic$ climate$where$hospitals$are$continually$trying$to$cut$costs.$The$upfront$cost$of$a$Raman$spectrometer$ is$very$high,$and$ the$CaF2$slides$are$very$expensive$compared$ to$the$ simple$glass$ slides$ that$ are$used$ in$ the$hospital$ laboratory.$Thus$ there$are$many$obstacles$to$overcome$before$clinical$implementation$is$possible.$$$Other$ areas$ where$ this$ method$ could$ be$ deployed$ is$ monitoring$ of$chemotherapy$ treatment$ in$ cancer$ patients.$ By$ identifying$ the$ biochemical$changes$ that$ take$ place$ during$ treatment,$ the$ effectiveness$ of$ it$ could$ be$identified.$$$Future$work$ for$ lymphoma$diagnosis$would$ involve$setting$up$ongoing$sample$collection$with$a$head$and$neck$surgeon$within$the$hospital.$The$pathologies$of$the$ samples$ collected$ would$ need$ to$ be$ recorded$ on$ a$ password^protected$database$by$the$health$professionals$involved,$like$the$leukaemia$samples$were.$Samples$ preparation$ involving$ water$ rather$ than$ phosphate$ buffered$ saline$would$also$have$to$be$explored$and$once$an$appropriate$protocol$is$set$in$place,$IR$and$Raman$analysis$ followed$by$multivariate$statistical$analysis$would$need$to$ be$ carried$ out$ to$ identify$ biochemical$ markers$ for$ the$ diagnosis$ of$lymphomas.$$$
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900^1350$ v(PO2^):$collagen$&$glycogen$ Malignant$non^Hodgkins$Lymphoma$ Andrus$1998$950$ DNA$ Fibroblast$cell$lines$ Mourant$2003b$950^1200$ Glycogen$ Cervical$cells$ Diem$2002$965$ DNA$ ALL$Lymphocytes$ Ramesh$2002$965$ DNA$ ALL$Lymphocytes$ Ramesh$2003$965$ v(C^C)$deoxyribose:$DNA$&$RNA$ Human$promyelocytic$leukaemia$(HL60)$cell$lines$ Gasparri$2003$965$ v(C^O)$ribose$&$(PO2^)$ Nucleic$acids$ Chiriboga$1998a$965$ (PO2^):$DNA$ Myeloid$Leukaemia$$(ML^1)$cell$lines$ Boydston^White$1999$966$ DNA$ CLL$cells$ Schultz$1996$966$ DNA$ Colonic$tissue$ Sahu$2005$966$ Nucleic$acids$&$lipids$ White$blood$cells$ Sahu$2006$966$ DNA$ CLL$cells$ Liu$1997$967$ DNA$(hydrated)$ Myeloid$Leukaemia$$(ML^1)$cell$lines$ Boydston^White$1999$968$ DNA$ Bovine$Liver$Tissue$ Lasch$2002$970$ DNA$ Leukaemic$Lymphocytes$ Benedetti$1997$970$ DNA$ Cervical$Tissue$ Nevilliappan$
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2002$970$ DNA$ Normal$human$skin$$ Boydston^White$2005$983^1116$ α2^macroglobulin$ Sigma$Aldrich$ Déléris$2003$996$ vδ$ring:$uracyl$ Leukaemic$Lymphocytes$ Benedetti$1997$996$ RNA$ Colonic$tissue$ Sahu$2005$997^1062$ v(C^O):$glucose$ Human$serum$ Petibois$1999$1000$ Nucleic$acids$(DNA:RNA)$ Atheroscleratic$Plaques$ Colley$2004$1000^1100$ vsPO2^$$ ALL$Lymphocytes$ Ramesh$2002$1000^1140$ Nucleic$acids$$ Human$promyelocytic$leukaemia$(HL60)$cell$lines$ Gasparri$2003$1000^1150$ vsPO2^$ ALL$Lymphocytes$$ Ramesh$2002$1000^1150$ Nucleic$acids$(in$absence$of$glycogen)$ Nucleic$acids$ Chiriboga$1998a$1000^1200$ Nucleic$acids$(DNA:RNA)$ ALL$Lymphocytes$ Ramesh$2002$1000^1250$ DNA/RNA$ Cervical$cells$ Diem$2002$1015$ v(C^O):$ribose$ Leukaemic$Lymphocytes$ Benedetti$1997$1015$ Glycogen$ Lung$carcinoma$(A549)$cell$lines$ Petibois$2006$1020$ s(PO2^):$$nucleic$acids$(DNA)$ Glycogen^poor$cells$(colonocytes/$lymphocytes)$Malignant$non^Hodgkins$Lymphoma$
Andrus$1998$
1020$ Nucleic$acids$(DNA:RNA)$ ALL$Lymphocytes$ Ramesh$2003$1020$ DNA$ Colonic$tissue$ Sahu$2005$1020^1120$ v(C^O):$sugars$&$complex$carbohydrates$ Astrocytic$glioma$tissue$ Beleites$2005$1025$ Glycogen$ Normal$cervix$tissue$ Andrus$1998$1025$ CH2OH$&$v(C^O)$coupled$to$δ(C^O):$C^OH$of$carbohydrates$(glucose,$fructose,$glycogen$etc.)$
Moloney$murine$sarcoma$virus$transformed$mouse$&$human$fibroblast$cells,$$Mouse$(NIH/3T3)$&$human$(Hep^2)$fibroblast$cell$lines,$Mouse$&$human$malignant$cells$
Erukhimovitch$2002$
1025^1047$ vC^O$or$δC^OH$Glycogen$$ Cervical$Tissue$ Nevilliappan$2002$1028$ Glycogen$ Squamous$(superficial$layer)$cervical$epithelial$ Chiriboga$1997$
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tissue$1028$ v(C^O/$C^C)$&$C^OH$deformation:$glycogen$$ Glycogen$ Chiriboga$1998a$1031$ Collagen$ Normal$epithelial$tissues$ Andrus$1998$1031$ Nucleic$acids$ Squamous$(basal$layer)$cervical$epithelial$tissue$ Chiriboga$1998a$1033$ v(C^O):$D^glucose$ Sigma$Aldrich$ Petibois$1999$1033$ Glucose$ Lung$carcinoma$(A549)$cell$lines$ Petibois$2006$1033^1074$ Cholesterol$ Sigma$Aldrich$ Déléris$2003$1040$ Carbohydrate$moiety$glycoproteins$ Glandular$(columnar)$&$squamous$(superficial$layer)$cervical$epithelial$tissue$
Chiriboga$1997$
1050$ Carbohydrate$ Bovine$Liver$Tissue$ Lasch$2002$1054$ DNA$(hydrated)$ Myeloid$Leukaemia$$(ML^1)$cell$lines$ Boydston^White$1999$1056$ Carbohydrate$ Leukaemia$plasma$ Erukhimovitch$2006$1059$ v(C^O):$D^fructose$ Sigma$Aldrich$ Petibois$1999$1060$ (C^O)$ribose$&$v#(PO2^)$of$DNA$ Myeloid$Leukaemia$$(ML^1)$cell$lines$ Boydston^White$1999$1060$ Nucleic$acids$ Squamous$(basal$layer)$cervical$epithelial$tissue$ Chiriboga$1998a$1063$ vsCO^O^C$$ Bovine$Liver$Tissue$ Lasch$2002$1064$ v(C^O):$D^galactose$ Sigma$Aldrich$ Petibois$1999$1064$ CH2OH$&$v(C^O)$coupled$to$δ(C^O):$C^OH$of$carbohydrates$(glucose,$fructose,$glycogen$etc.)$
Moloney$murine$sarcoma$virus$transformed$mouse$&$human$fibroblast$cells,$$Mouse$(NIH/3T3)$&$human$(Hep^2)$fibroblast$cell$lines,$Mouse$&$human$malignant$cells$
Erukhimovitch$2002$
1065$ v(C^O)$ribose$&$(PO2^)$ Nucleic$acids$ Chiriboga$1998a$1067$ DNA$(dried)$ Myeloid$Leukaemia$$(ML^1)$cell$lines$ Boydston^White$1999$1070$ Nucleic$acids$(DNA:RNA)$ $ Mourant$2003a$1075$ v(C^O):$D^mannose$ Sigma$Aldrich$ Petibois$1999$1076$ Carbohydrate$moiety$glycoproteins$ Glandular$(columnar)$&$squamous$(superficial$layer)$cervical$epithelial$ Chiriboga$1997$
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tissue$1078$ (PO2^):$RNA,$DNA$&$phospholipids$ Normal$human$skin$$ Boydston^White$2005$1078$ Glycogen$ Squamous$(superficial$layer)$cervical$epithelial$tissue$ Chiriboga$1997$1078$ v(C^O/$C^C)$&$C^OH$deformation:$glycogen$$ Glycogen$ Chiriboga$1998a$1078$ DNA$(in$absence$of$glycogen)$ Squamous$(basal$layer)$cervical$epithelial$tissue$ Chiriboga$1998a$1080$ Nucleic$acids$(RNA)$ Myeloid$Leukaemia$$(ML^1)$cell$lines$ Boydston^White$1999$1080$ Nucleic$acids$(DNA:RNA)$ $ Sahu$2005$1080$ Nucleic$acids$(DNA)$ Benign$human$skin$fibroblast$ Diem$2004$1080$ Nucleic$acids$(DNA)$ Cervical$cells$ Diem$2002$1080$ Deoxyribose$(C^O):$DNA$ Astrocytic$glioma$tissue$ Beleites$2005$1080$ Nucleic$acids$(DNA:RNA)$ Atheroscleratic$Plaques$ Colley$2004$1080$ vsPO2^$$ Lung$Cancer$Cells$ Sule^Suso$2005$1080$ vsPO2^$$ Cervical$Tissue$ Nevilliappan$2002$1080$ vs(PO2^):$nucleic$acids$ Human$promyelocytic$leukaemia$(HL60)$cell$lines$ Gasparri$2003$1081$ Nucleic$acids$ Squamous$(basal$layer)$cervical$epithelial$tissue$ Chiriboga$1998a$1081$ Carbohydrates$ Lung$carcinoma$(A549)$cell$lines$ Petibois$2006$1082$ s(PO2^)$&$as(PO2^)$$ Moloney$murine$sarcoma$virus$transformed$mouse$&$human$fibroblast$cells,$$Mouse$(NIH/3T3)$&$human$(Hep^2)$fibroblast$cell$lines,$Mouse$&$human$malignant$cells$
Erukhimovitch$2002$




1085$ (C^O)$ribose$&$v#(PO2^)$of$RNA$ Myeloid$Leukaemia$$(ML^1)$cell$lines$ Boydston^White$1999$1087$ vsPO2^$$ CLL$cells$ Schultz$1996$1087$ vsPO2^$$ CLL$cells$ Liu$1997$1088$ vsPO2^$$ Human$Serum$ Liu$2002$1090$ DNA$(hydrated)$ Myeloid$Leukaemia$$(ML^1)$cell$lines$ Boydston^White$1999$1091^1122$ Triglyceride$ Sigma$Aldrich$ Déléris$2003$1095$ v(PO2^)$ Nucleic$acids$ Chiriboga$1998a$1095$ (C^O)$ribose$&$v#(PO2^)$of$DNA$ Myeloid$Leukaemia$$(ML^1)$cell$lines$ Boydston^White$1999$1099$ vC=O$(ester)$$ Fibroblast$cell$lines$ Mourant$2003b$1100$ Nucleic$acids$(DNA:RNA)$ $ Mourant$2003a$$1115^1134$ Lactate$ Sigma$Aldrich$ Déléris$2003$1120$ Carbohydrate$moiety$glycoproteins$ Cervical$squamous$epithelial$tissue$(superficial$layer)$ Chiriboga$1997$1121$ Nucleic$acids$(DNA:RNA)$ ALL$Lymphocytes$ Ramesh$2003$1121$ v(PO2^):$nucleic$acids$(RNA)$ Glycogen^poor$cells$(colonocytes/$lymphocytes)$Malignant$non^Hodgkins$Lymphoma$
Andrus$1998$
1121$ RNA$ Colonic$tissue$ Sahu$2005$1127$ Lactic$acid$ Lung$carcinoma$(A549)$cell$lines$ Petibois$2006$1147^1186$ Cholesterol$esters$ Sigma$Aldrich$ Déléris$2003$1150$ v(C^C/C^O):$saccharides,$glucose,$lactate,$glycerol$
Bovine$Liver$Tissue$ Lasch$2002$
1151$ Glycogen$ Squamous$(superficial$layer)$cervical$epithelial$tissue$ Chiriboga$1997$1151$ v(C^O/$C^C)$&$C^OH$deformation:$glycogen$$ Glycogen$ Chiriboga$1998a$1155$ vC^OH$carbohydrate$ Cervical$Tissue$ Nevilliappan$2002$1170$ v(C^C/C^O):$saccharides,$glucose,$lactate,$glycerol$
Atheroscleratic$Plaques$ Colley$2004$
1170$ C^OH$groups$of$serine,$threonine$ Cervical$Tissue$ Nevilliappan$2002$
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&$tyrosine$(cell$proteins)$1170^1310$ vsPO2^$$ ALL$Lymphocytes$ Ramesh$2002$1173$ vasCO^O^C$$ Bovine$Liver$Tissue$ Lasch$2002$1200^1245$ vsPO2^$$ ALL$Lymphocytes$$ Ramesh$2002$1200^1330$ v(C^N)$&$δ(N^H):$amide$III$ Leukaemic$Lymphocytes$ Benedetti$1997$1204$ Collagen$ Normal$epithelial$tissues$ Andrus$1998$1206$ Amide$III$ Squamous$(stromal$layer)$cervical$epithelial$tissue$ Chiriboga$1998a$1225$ DNA$(hydrated)$ Myeloid$Leukaemia$$(ML^1)$cell$lines$ Boydston^White$1999$1230$ as(PO2^)$ Nucleic$acids$ Chiriboga$1998a$1230$ v(C^N)$&$δ(N^H):$amide$III$ Thrombocythemic$megakaryocytes$ Benedetti$1998$1230$ DNA$ Colonic$tissue$ Sahu$2005$1230$ (PO2^):$DNA$ Myeloid$Leukaemia$$(ML^1)$cell$lines$ Boydston^White$1999$1234$ Nucleic$acids$(DNA)$ Cervical$cells$ Diem$2002$1235$ Nucleic$acids$(DNA)$ Benign$human$skin$fibroblast$ Diem$2004$1235$ (PO2^):$nucleic$acids$(amide$III)$ Squamous$(basal$layer)$cervical$epithelial$tissue$ Chiriboga$1998a$1236^1242$ Collagen$&$nucleic$acids$ Malignant$non^Hodgkins$Lymphoma$ Andrus$1998$1237$ vasPO2^$$ Atheroscleratic$Plaques$ Colley$2004$1237$ vasPO2^$$ Bovine$Liver$Tissue$ Lasch$2002$1238$ (PO2^):$RNA,$DNA$&$phospholipids$ Normal$human$skin$$ Boydston^White$2005$1238$ Amide$III$ Squamous$(stromal$layer)$cervical$epithelial$tissue$ Chiriboga$1998a$1240$ vasPO2^$$ CLL$cells$ Schultz$1996$1240$ vasPO2^$$ Cervical$Tissue$ Nevilliappan$2002$1240$ vas(PO2^)$ Human$promyelocytic$leukaemia$(HL60)$cell$lines$ Gasparri$2003$1240$ vasPO2^$$ CLL$cells$ Liu$1997$1240$ vasPO2^$$ Lung$Cancer$Cells$ Sule^Suso$2005$1240$ Deoxyribose$$(PO2^):$DNA$ Astrocytic$glioma$tissue$ Beleites$2005$1240$ Collagen$ Malignant$non^Hodgkins$Lymphoma$ Andrus$1998$1240^1340$ vC^N$&$δN^H$ Bovine$Liver$Tissue$ Lasch$2002$
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Amide$III$$1242$ Amide$III$$ Bovine$Serum$Albumin$ Chiriboga$1998a$1242$ vas(PO2^)$ Human$Serum$ Liu$2002$1242$ Amide$III$ Normal$epithelial$tissue$ Andrus$1998$1243$(1200$^1400)$ s(PO2^)$&$as(PO2^)$$ Moloney$murine$sarcoma$virus$transformed$mouse$&$human$fibroblast$cells,$$Mouse$(NIH/3T3)$&$human$(Hep^2)$fibroblast$cell$lines,$Mouse$&$human$malignant$cells$
Erukhimovitch$2002$




δs(CH2)$ Human$Serum$ Liu$2002$1378^1428$ Haptoglobin$ Sigma$Aldrich$ Déléris$2003$1390$ Protein$side$chains$ Myeloid$Leukaemia$$(ML^1)$cell$lines$ Boydston^White$1999$1395$ Aliphatic$side$chains,$amino$acids$ Bovine$Serum$Albumin$ Chiriboga$1998a$1397$ v(C^C/$C^O):$saccharides,$glucose,$lactate,$glycerol$
CLL$cells$ Schultz$1996$
1397$ v(COO^):$amino$acids$ Bovine$Liver$Tissue$ Lasch$2002$1400$ δNH2$(amino$acids)$ Fibroblast$cell$lines$ Mourant$2003b$1400$ Protein$ White$blood$cells$ Sahu$2006$1400^1455$ δas$(CH3),$δas$(CH2):$fatty$acids,$phospholipids$&$triglyceride$$δs$(CH2)$
Cervical$Tissue$ Nevilliappan$2002$











1455$ asCH3$deformation$ CLL$cells$ Schultz$1996$1455$ asCH3$deformation$ Bovine$Liver$Tissue$ Lasch$2002$1455$ Aliphatic$side$chains,$amino$acids$ Bovine$Serum$Albumin$ Chiriboga$1998a$1464^1479$ Immunoglobulin^D$ Sigma$Aldrich$ Déléris$2003$1467$ δas$(CH3),$δas$(CH2):$fatty$acids,$phospholipids$&$triglyceride$$δs$(CH2)$
CLL$cells$ Liu$1997$
1467$ δCH2$lipid$acyl$$ Human$Serum$ Liu$2002$1468$ δCH2$lipid$acyl$$ CLL$cells$ Schultz$1996$1468$ δas$(CH3),$δas$(CH2):$fatty$acids,$phospholipids$&$triglyceride$$δs$(CH2)$
Bovine$Liver$Tissue$ Lasch$2002$
1468$ δ(CH2):$acyl$chain$$ Astrocytic$glioma$tissue$ Beleites$2005$1470$ Peptide$side$chains$ Astrocytic$glioma$tissue$ Beleites$2005$1480^1600$ δ(NH):$amide$II,$




α^helix,$proteins$ Atheroscleratic$Plaques$ Colley$2004$1530$ δ(NH):$amide$II$ Astrocytic$glioma$tissue$ Beleites$2005$1530^1545$ δ(NH):$amide$II,$
α^helix,$proteins$ Leukaemic$Lymphocytes$ Benedetti$1997$1530^1570$ δ(NH):$amide$II,$
α^helix,$proteins$ Bovine$Liver$Tissue$ Lasch$2002$1538$ v(CN)$&$δ(CNH):$amide$II$ Human$promyelocytic$leukaemia$(HL60)$cell$lines$ Gasparri$2003$1540$ δ(NH):$amide$II,$
α^helix,$proteins$ Lung$Cancer$Cells$ Sule^Suso$2005$1540$ Amide$II$ Cervical$Adenocarcinoma$(HeLa)$cell$lines$$ Boydston^White$2005$1541$ Amide$II$ Bovine$Serum$Albumin$ Chiriboga$1998a$1542$ δ(NH):$amide$II,$
α^helix,$proteins$ CLL$cells$ Liu$1997$1544$ v(CN)$&$δ(CNH):$amide$II$ Moloney$murine$sarcoma$virus$transformed$mouse$&$human$fibroblast$cells,$$Mouse$(NIH/3T3)$&$human$(Hep^2)$fibroblast$cell$lines,$Mouse$&$human$malignant$cells$
Erukhimovitch$2002$
1544$ v(C^N)$&$δ(CNH):$amide$II$ Leukaemia$plasma$ Erukhimovitch$2006$1545$ δ(NH):$amide$II,$
α^helix,$proteins$ Cervical$Tissue$ Nevilliappan$2002$1545$ δ(NH):$amide$II,$
α^helix,$proteins$ Colonic$Tissue$ Sahu$2005$1546$ δ(NH):$amide$II,$
α^helix,$proteins$ Human$Serum$ Liu$2002$1546$ δ(N^H)#proteins:$amide$II$ Human$glioblastoma$(U87)$cell$lines$ Petibois$2006$1546$ δ(N^H)#collagen:$amide$II$ Type$I$collagen$ Petibois$2006$1549$ δ(NH):$amide$II,$
α^helix,$proteins$ Thrombocythemic$megakaryocytes$ Benedetti$1998$1550$ δ(NH):$amide$II$ Liver$tissue$ Diem$2000$1550$ Amide$II$ Cervical$cells$ Diem$2002$1550$ Amide$II$ Squamous$(stromal$layer)$cervical$epithelial$tissue$ Chiriboga$1998a$1554$ δ(N^H)#collagen:$ Type$I$collagen$ Petibois$2006$
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amide$II$1560^1630$ δNH2$(amino$acids)$ Plasma$ Déléris$2003$1571$ δ(N^H)#collagen:$amide$II$ Type$I$collagen$ Petibois$2006$1575$ δ(N^H)#proteins:$amide$II$ Human$glioblastoma$(U87)$cell$lines$ Petibois$2006$1580^1700$ Nucleic$acid$aromatic$base$breathing,$v(C=O)$ $ $1592$ δNH2$(amino$acids)$ Leukaemia$plasma$ Erukhimovitch$2006$1592$ δ(NH2)#collagen:$amine$$ Type$I$collagen$ Petibois$2006$1595$ δ(NH2)#proteins:$amine$$ Human$glioblastoma$(U87)$cell$lines$ Petibois$2006$1599^1710$(1640)$ v(C=O)$coupled$to$δ(N^H)$&$v(C^N):$amide$I$ Human$promyelocytic$leukaemia$(HL60)$cell$lines$ Gasparri$2003$1600^1720$ v(C=O):$amide$I,$
β^sheet:$proteins,$turns,$coils$ Plasma$ Déléris$2003$1613^1637$(1633)$ v(C=O):$amide$I,$β^sheet$ Human$promyelocytic$leukaemia$(HL60)$cell$lines$ Gasparri$2003$1615$ v(C=O)$proteins:$
β^turn$ Human$glioblastoma$(U87)$cell$lines$ Petibois$2006$1617$ v(C=O)$collagen:$
β^turn$ Type$I$collagen$ Petibois$2006$1620$ v(C=O)$nucleic$acids$bases$&$ring$breathing$modes$ Nucleic$acids$ Chiriboga$1998a$1620^1690$ v(C=O):$amide$I$ Fibroblast$cell$lines$ Mourant$2003b$1620^1690$ v(C=O):$amide$I$ Bovine$Liver$Tissue$ Lasch$2002$1622^1652$ Immunoglobulin^G2$ Sigma$Aldrich$ Déléris$2003$1628^1652$ Immunoglobulin^G3$ Sigma$Aldrich$ Déléris$2003$1628$ v(C=O)$collagen:$parallel$β^strand$ Type$I$collagen$ Petibois$2006$1630$ v(C=O)$proteins:$parallel$β^strand$$ Human$glioblastoma$(U87)$cell$lines$ Petibois$2006$1632^1652$ Urea$ Sigma$Aldrich$ Déléris$2003$1635$ v(C=O):$amide$I$ Atheroscleratic$Plaques$ Colley$2004$1637^1645$ v(C=O):$amide$I,$coils$ Human$promyelocytic$leukaemia$(HL60)$cell$lines$ Gasparri$2003$
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1638$ v(C=O)$collagen:$triple$helix$ Type$I$collagen$ Petibois$2006$1640^1660$ v(C=O):$amide$I$ Leukaemic$Lymphocytes$ Benedetti$1997$1642$ v(C=O)$proteins:$unordered$structure$$ Human$glioblastoma$(U87)$cell$lines$ Petibois$2006$1643$ v(C=O):$amide$I$ Moloney$murine$sarcoma$virus$transformed$mouse$&$human$fibroblast$cells,$$Mouse$(NIH/3T3)$&$human$(Hep^2)$fibroblast$cell$lines,$Mouse$&$human$malignant$cells$
Erukhimovitch$2002$
1643$ v(C=O):$amide$I$ Leukaemia$plasma$ Erukhimovitch$2006$1645$ Amide$I$ Cervical$Adenocarcinoma$(HeLa)$cell$lines$$ Boydston^White$2005$1645^1662$(1650)$ v(C=O):$amide$I,$α^helix$ Human$promyelocytic$leukaemia$(HL60)$cell$lines$ Gasparri$2003$1647$ v(C=O)$collagen:$unordered$structure$ Type$I$collagen$ Petibois$2006$1650$ v(C=O):$amide$I$ Myeloid$Leukaemia$$(ML^1)$cell$lines$ Boydston^White$1999$1650$ Amide$I$ Benign$human$skin$fibroblast$ Diem$2004$1650$ v(C=O):$amide$I$ Liver$tissue$ Diem$2000$1650$ v(C=O):$amide$I$ Astrocytic$glioma$tissue$ Beleites$2005$1652$ v(C=O):$amide$I$ CLL$cells$ Liu$1997$1652^1656$ v(C=O):$amide$I$ CLL$cells$ Schultz$1996$1654$ v(C=O)$proteins:$
α^helix$ Human$glioblastoma$(U87)$cell$lines$ Petibois$2006$1655$ v(C=O):$amide$I$ Cervical$Tissue$ Nevilliappan$2002$1655$ Amide$I$ Cervical$Cells$ Chiriboga$1998b$1655$ v(C=O):$amide$I$ Human$Serum$ Liu$2002$1655$ v(C=O):$amide$I$ Thrombocythemic$megakaryocytes$ Benedetti$1998$1655$ v(C=O)$nucleic$acids$bases$&$ring$breathing$modes$ Nucleic$acids$ Chiriboga$1998a$1666$ v(C=O)$collagen:$
α^helix$ Type$I$collagen$ Petibois$2006$1657$ v(C=O):$amide$I$ $ Sahu$2005$1658$ Amide$I$ Bovine$Serum$Albumin$ Chiriboga$
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1998a$1660^1676$ Apolipoprotein^C3$ Sigma$Aldrich$ Déléris$2003$1662^1682$ v(C=O):$amide$I,$turns$ Human$promyelocytic$leukaemia$(HL60)$cell$lines$ Gasparri$2003$1666$ v(C=O)$proteins:$
β^turn$$ Human$glioblastoma$(U87)$cell$lines$ Petibois$2006$1668$ v(C=O)$collagen:$






1738$ Phospholipids$ Cervical$Adenocarcinoma$(HeLa)$cell$lines$$ Boydston^White$2005$
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1739$ v(C=O)$proteins:$acid$esters$$ Human$glioblastoma$(U87)$cell$lines$ Petibois$2006$1740$ v(C=O)$lipids,$cholesterol$esters,$triglyceride$
Bovine$Liver$Tissue$ Lasch$2002$
1740$ Lipid$ White$blood$cells$ Sahu$2006$1740$ v(C=O)$lipids$ Malignant$non^Hodgkins$Lymphoma$ Andrus$1998$1740$ vs(PO43^)$&$











Shift#cmS1# Assignment# Tissue#or#Substance# Reference#917$ Deoxyribose$(CH2$deformation)$ DNA$(B)$ Mahadevan^Jansen$1996$920$ Glucose$ Sigma$ Mahadevan^jansen$1998$920$ vC^C$elastin$ Sigma$Aldrich$E1625$ Kendall$2002$$920$ C^C$proline$ring$ Type$I$collagen$(Human$placenta)$and$infiltrating$ductal$carcinoma$(breast)$
Frank$1995$
920$ vC^C$proline$ring$collagen$ Sigma$Aldrich$C7774$ Kendall$2002$$920$ vC^C$proline$ring/glucose/lactate$ Oesophagus$tissue$ Stone$2002$921$ vC^C$proline$ring$ Collagen$ Mahadevan^Jansen$1996$922$ vC^C$$ Cervical$Tissue$ Lyng$2007$928^940$ C^C$proline,$valine$ $ Mahadevan^jansen$1998$930$ vC^C$ Tear$fluid$ Filik$2009$934$ C^C$proline$ring$ Type$I$collagen$(human$placenta)$ Frank$1995$935^945$ (C^C)$skeletal$vibrations,$α^helix$ α^helix$protein$secondary$structure$ Mahadevan^Jansen$1996$935$ vC^C$proline,$valine$&$protein$backbone$(α^helix)/$glycogen$ Oesophagus$tissue$ Stone$2002$936$ vC^C$,$backbone$in$collagen$ Sigma$Aldrich$C7774$ Kendall$2002$937$ Glycogen$ Sigma$Aldrich$G0885$ Kendall$2002$937$ C^C$proline$ring$ Infiltrating$ductal$carcinoma$(breast)$ Frank$1995$938$ C^C$backbone$ Collagen$ Mahadevan^Jansen$1996$938$ v#C^C$protein$backbone$ Human$skin$tissue$ Bonnier$2012$939$ vC^C^N$$ Bovine$serum$albumin$ Fredericks$1995$939$ vC^C$backbone$(α^helix$conformation)$ Blood$Plasma$ Poon$2012$
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940$ vC^C^N$bovine$albumin$ Sigma$Aldrich$A2153$ Kendall$2002$958$ CH3$deformation$ Blood$Plasma$ Poon$2012$966$ Desmosine$&$isodesmosine$(amino$acids)$ Elastin$ Manoharan$1996$972$ C^C$proline$ring$ Normal$breast$tissue,$oleic$acid$methyl$ester$ Frank$1995$975$ Deoxyribose$(CH2$deformation)$ DNA$(B)$ Mahadevan^Jansen$1996$978$ vs#phosphate$ion$$ Phospholipids,$glucose^1^phosphate$ Mahadevan^jansen$1998$978$ vs$phosphate$ion$$ Human$cervix$ Mahadevan^Jansen$1998b$978$ Phosphorylated$proteins$&$nucleic$acids$ Human$cervical$biopsies$ Mahadevan$1995$1000$ Phenylalanine$in$bovine$albumin$ Sigma$Aldrich$A2153$ Kendall$2002$1000^1100$ Glucose$ Blood$ Chaiken$2000$1000^1150$ C^C$skeletal$$ Phospholipid$membrane,$hydrophobic$chains$ Mahadevan^Jansen$1996$1001$ Phenylalanine$$ Sigma$Aldrich$T8324$ Kendall$2002$1001$ s$ring$breathing$phenylalanine$ Oesophagus$tissue$ Stone$2002$1002$ (C^C)$skeletal,$β^sheet$ β^sheet$protein$secondary$structure$ Mahadevan^Jansen$1996$1002$ Hydroxyproline,$tyrosine$ Type$I$collagen$(human$placenta)$ Frank$1995$1002$ Phenylalanine$$ Peripheral$blood$lymphocytes$ Pully$2010$1002$ Phenylalanine$ Tear$fluid$ Filik$2008$1003$ s$ring$breathing$phenylalanine$ Blood$Plasma$ Poon$2012$1004$ Phenylalanine$$ Infiltrating$ductal$carcinoma$(breast)$ Frank$1995$1004$ Phenylalanine$&$tryptophan$aromatic$ring$ Bovine$serum$albumin$ Fredericks$1995$1004$ CC$aromatic$ring$breathing$ Cervical$Tissue$ Lyng$2007$1004$ Phenylalanine$in$collagen$ Sigma$Aldrich$C7774$ Kendall$2002$1004$ Phenylalanine$ Albumin,$chicken$egg$Sigma$A5253$ Kopecky$2006$1004^1006$ CH3$plane$rocking$in$carotenoids$ Peripheral$blood$lymphocytes$ Pully$2010$1005$ β^carotene$ Breast$ Frank$1995$
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1006$ Phenylalanine$$ Collagen,$histones$ Mahadevan^Jansen$1996$1006$ Phenylalanine$phenol$ring$ Tear$fluid$ Filik$2009$1014$ Tryptophan$$ $ Mahadevan^Jansen$1996$1014$ Tryptophan$indole$ring$ Tear$fluid$ Filik$2009$1030$ Collagen$ Sigma$Aldrich$C7774$ Kendall$2002$1030$ δCH$phenylalanine$ Human$skin$tissue$ Bonnier$2012$1031$ δC^H$phenylalanine$ Oesophagus$tissue$ Stone$2002$1032$ Proline$ Type$I$collagen$(human$placenta)$ Frank$1995$1032$ δCH$phenylalanine$ Blood$Plasma$ Poon$2012$1033$ Phenylalanine$ Albumin,$chicken$egg$Sigma$A5253$ Kopecky$2006$1034$ vC^C$$ Cervical$Tissue$ Lyng$2007$1043$ Proline$ Infiltrating$ductal$carcinoma$(breast)$ Frank$1995$1048$ Glycogen$ Sigma$Aldrich$G0885$ Kendall$2002$1065$ vC^N$$ Cervical$Tissue$ Lyng$2007$1066$ vC^C$,Proline$ Normal$breast$tissue$ Frank$1995$1067$ Proline$ Oleic$acid$methyl$ester$ Frank$1995$1069$ Hydroxyapatite$shifted$due$to$environment$ Human$cervix$ Mahadevan^jansen$1998$1070$ vs$phosphate$ion$$ Glucose^1^phosphate,$collagen$ Mahadevan^jansen$1998$1070$ vs#phosphate$ion$$ Human$cervix$ Mahadevan^jansen$1998$1070$ Collagen/$elastin$ $ Mahadevan$1995$1078$ vC^N$$ Benign$breast$tissue$ Alfano$1991$1079$ vC^C$$ Normal$breast$tissue$ Frank$1995$1082$ $ Oleic$acid$methyl$ester$ Frank$1995$1082$ vC^N$ Blood$Plasma$ Poon$2012$1083$ Glycogen$ Sigma$Aldrich$G0885$ Kendall$2002$1083$ vC^N$proteins$(&$lipid)$ Oesophagus$tissue$ Stone$2002$1090$ PO2^$ DNA$(C)$ Mahadevan^Jansen$1996$1090$ vs#PO2^$$ Peripheral$blood$lymphocytes$ Pully$2010$1091$ PO2^$ DNA$(B)$ Mahadevan^Jansen$1996$1095$ vs$of$two$ionised$phosphate$oxygen’s$in$diphosphate$ester$ DNA$(B)$ Mahadevan^Jansen$1996$
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1095$ PO2^$ DNA$(Z),$RNA$(Z)$ Mahadevan^Jansen$1996$1096$ vC^C$$ Cervical$Tissue$ Lyng$2007$1098$ vC^C$$ Cervical$Tissue$ Lyng$2007$1099$ PO2^$ DNA$(A),$RNA$(A)$ Mahadevan^Jansen$1996$1099$ v$C^N$ Human$skin$tissue$ Bonnier$2012$1100$ vs$of$two$ionised$phosphate$oxygen’s$in$diphosphate$ester$ DNA$(A)$ Mahadevan^Jansen$1996$1100^1110$ (C^C)$skeletal$vibrations$ Unordered$protein$secondary$structure$ Mahadevan^Jansen$1996$1002$ vCC$$ Cervical$Tissue$ Lyng$2007$1108$ Desmosine$&$isodesmosine$$ Elastin$ Manoharan$1996$1118$ vC^C$$ Normal$breast$tissue$ Frank$1995$1119$ vC^C$$ Oleic$acid$methyl$ester$ Frank$1995$1123$ Glycogen$ Sigma$Aldrich$G0885$ Kendall$2002$1123$ Glucose$ Sigma$ Mahadevan^jansen$1998$1123$ vC^C$lipids/vC^N$protein$ Oesophagus$tissue$ Stone$2002$1124$ vCC$skeletal$trans$ Cervical$Tissue$ Lyng$2007$1125$ $ Infiltrating$ductal$carcinoma$(breast)$ Frank$1995$1126$ vC^N$protein$ Human$skin$tissue$ Bonnier$2012$1127$ $ Type$I$collagen$(human$placenta)$ Frank$1995$1128$ vC^N$ Blood$Plasma$ Poon$2012$1154$ C^C$carotenoids$ Peripheral$blood$lymphocytes$ Pully$2010$1155$ vC^C$(&$C^N)$protein$$(also$carotenoid)$ Oesophagus$tissue$ Stone$2002$1156$ vC^N$$ Bovine$serum$albumin$ Fredericks$1995$1158$ vC^C,$vC^N$ $ $1160$ Carotenoid$ Blood$plasma$ Larrson$1974$1166$ $ Type$I$collagen$(human$placenta)$ Frank$1995$1167$ $ Infiltrating$ductal$carcinoma$(breast)$ Frank$1995$1170$ δC^H$tyrosine$ Oesophagus$tissue$ Stone$2002$1175$ vC^O$$ Human$cervical$biopsies$ Mahadevan$1995$1175$ δC^H$tyrosine$ Blood$Plasma$ Poon$2012$1177$ NH3$ Human$skin$tissue$ Bonnier$2012$1180$ Tyrosine$ Breast$ Manoharan$1998$
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1205$ Tyrosine$&$phenylalanine$ Bovine$albumin,$Sigma$Aldrich$A2153$ Kendall$2002$1206$ Hydroxyproline,$tyrosine$ Type$I$collagen$(human$placenta)$and$infiltrating$ductal$carcinoma$(breast)$
Frank$1995$
1207$ Tyrosine$&$phenylalanine$$ Bovine$serum$albumin$ Fredericks$1995$1208$ Thymine$ DNA$(B)$ Mahadevan^Jansen$1996$1208$ Tryptophan$&$phenylalanine$n(C^C6H5)$ Blood$Plasma$ Poon$2012$1208$ Tyrosine$&$Phenylalanine$ Albumin,$chicken$egg$Sigma$A5253$ Kopecky$2006$1209$ Tryptophan$&$pheylalanine$v(C^C6H5)$$ Oesophagus$tissue$ Stone$2002$1214$ vCC$backbone$carbon$phenyl$ring$ Cervical$Tissue$ Lyng$2007$1227^1247$ Amide$III$(vC^N,$δN^H$)$β^sheet$ β^sheet$protein$secondary$structure$ Mahadevan^Jansen$1996$1235^1270$ Amide$III$(vC^N,$δN^H$)$unordered$ $ Mahadevan^Jansen$1996$1236$ vCN,$δNH$amide$III$band$ Cervical$Tissue$ Lyng$2007$1238$ Amide$III$in$elastin$ Sigma$Aldrich$E1625$ Kendall$2002$1239$ Thymine$ DNA$(A),$RNA$(A)$ Mahadevan^Jansen$1996$1240$ Vibration$of$pyrimidine$bases$(cytosine$and$thymine)$
DNA$ Mahadevan^Jansen$1996$
1240$ Amide$III$^$v(C^N)$ Benign$breast$tumour$ Alfano$1991$1240$ Amide$III$collagen$ Sigma$Aldrich$C7774$ Kendall$2002$1240$ Amide$III$$^$v(C^N)$ Uterus$cancer$ Liu$1992$1240$ vCN,$δNH$amide$III$band$ Cervical$Tissue$ Lyng$2007$1240^1265$ Amide$III$(vC^H$of$proteins,$mainly$α^helix)$ Oesophagus$tissue$ Stone$2002$1245^1305$ Amide$III(vC^N$$δN^H)$ Histones$ Mahadevan^Jansen$1996$1246$ Amide$III$ Bovine$serum$albumin$ Fredericks$1995$1246$ Amide$III$–$v(C^N)$ Collagen$and$DNA$ Mahadevan$1995$1246$ Amide$III$–$v(C^N)$ Human$cervix$precancer$ Mahadevan$
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1995$1246$ Amide$III$(vC^N)$ Human$cervical$biopsies$ Mahadevan$1995$1246$ Amide$III$(vC^N)$ $ Liu$1992$1247$ Amide$III$ Type$I$collagen$(human$placenta)$and$infiltrating$ductal$carcinoma$(breast)$
Frank$1995$
1247$ Amide$III$–$v(C^N)$ Endometrium$cancer$ Liu$1992$1248$ Amide$III$ Breast$ Manoharan$1998$1248$ Amide$III$(vC^N,$δN^H)$ Collagen$ Mahadevan^Jansen$1996$1250$ Cytosine$ DNA$(B)$ Mahadevan^Jansen$1996$1250$ Amide$III$ Peripheral$blood$lymphocytes$ Pully$2010$1254$ Amide$III$(vC^N,$δN^H)$ Elastin$ Mahadevan^Jansen$1996$1254$ Amide$III$ Tear$fluid$ Filik$2008$1254$ Amide$III$ Tear$fluid$ Filik$2009$1256$ Glycogen$ Sigma$Aldrich$G0885$ Kendall$2002$1258^1304$ Amide$III$(vC^N,$δN^H)$ α^helix$protein$secondary$structure$ Mahadevan^Jansen$1996$1260$ Structural$protein$ Breast$ Manoharan$1998$1260^1280$ Amide$III$ Bovine$serum$albumin$ Fredericks$1995$1262$ Amide$III$–$v(C^N)$ Benign$or$normal$cervix$ Liu$1992$1262$ Amide$III$–$v(C^N)$ Benign$or$normal$uterus$ Liu$1992$1262$ Amide$III$–$v(C^N)$ Benign$or$normal$endometrium$ Liu$1992$1262$ Amide$III$–$v(C^N)$ Benign$or$normal$ovary$ Liu$1992$1264$ Amide$III$collagen$ Sigma$Aldrich$C7774$ Kendall$2002$1265$ Amide$III$ Normal$breast$tissue$ Frank$1995$1267$ Amide$III$ Infiltrating$ductal$carcinoma$(breast)$ Frank$1995$1267$ δ(=C^H)$ Phospholipid$membrane$ Mahadevan^Jansen$1996$1268$ Amide$III$ Oleic$acid$methyl$ester$ Frank$1995$1268$ Amide$III$–$v(C^N)$and$δ(NH)$in$bovine$albumin$ Sigma$Aldrich$A2153$ Kendall$2002$1269$ Amide$III$ Type$I$collagen$(human$placenta)$ Frank$1995$1270$ Amide$III$$(vC^N)$$ Endometrium$cancer$ Liu$1992$1271$ Amide$III$(vC^N,$δN^H)$ Collagen$ Mahadevan^Jansen$1996$
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1337$ CH2$deformation$ Cervical$Tissue$ Lyng$2007$1338$ Tryptophan$$ $ Mahadevan^Jansen$1996$1339$ Adenine$ DNA$(B)$ Mahadevan^Jansen$1996$1339$ C^H$deformation$ Blood$Plasma$ Poon$2012$1343$ CH3CH2$wagging$ Type$I$collagen$(human$placenta)$and$infiltrating$ductal$carcinoma$(breast)$
Frank$1995$
1350$ Glucose$ Sigma$ Mahadevan^jansen$1998$1361$ Tryptophan$ $ Mahadevan^Jansen$1996$1366$ δCH2$$ Cervical$Tissue$ Lyng$2007$1375$ Tyrosine/Adenine/$Guanine$(ring$breathing$modes$DNA)$
Peripheral$blood$lymphocytes$ Pully$2010$
1377$ Glycogen$ Sigma$Aldrich$G0885$ Kendall$2002$1401$ sδ$CH3$proteins$ $ Mahadevan$1995$1421$ Adenine/Guanine$DNA/RNA$ Peripheral$blood$lymphocytes$ Pully$2010$1434$ CH2$in$lipids$ Peripheral$blood$lymphocytes$ Pully$2010$1439$ CH3CH2$deformation$ Normal$breast$tissue$ Frank$1995$1440$ δCH2$ Cervical$Tissue$ Lyng$2007$1442$ CH3CH2$deformation$ Oleic$acid$methyl$ester$ Frank$1995$1442$ Lipids^$fatty$acids$ Normal$breast$tissue$ Manoharan$1998$1443$ Elastin$ Sigma$Aldrich$E1625$ Kendall$2002$1445$ δ(CH2)$or$δ(CH3)$ Cervix$cancer$ Liu$1992$1445$ δ(CH2)$or$δ(CH3)$ Uterus$cancer$ Liu$1992$1445$ δ(CH2)$or$δ(CH3)$ Benign$or$normal$cervix$ Liu$1992$1445$ δ(CH2)$or$δ(CH3)$ Benign$or$normal$endometrium$ Liu$1992$1445$ δ(CH2)$or$δ(CH3)$ Benign$or$normal$ovary$ Liu$1992$1445$ δ(CH2)$or$δ(CH3)$ Human$breast$tissue$Benign$and$malignant$tumours$ Alfano$1991$1445$ δCH2$$ Normal$breast$tissue$ Manoharan$1998$1445$ CH3CH2$deformation$in$collagen$ Sigma$Aldrich$C7774$ Kendall$2002$1445^1447$ δCH2$proteins/lipids$ Peripheral$blood$lymphocytes$ Pully$2010$1446$ δCH2$proteins/$lipids$ Oesophagus$tissue$ Stone$2002$
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1447$ δCH3CH2$bovine$albumin$ Sigma$Aldrich$A2153$ Kendall$2002$1447$ C^H$deformation$ Blood$Plasma$ Poon$2012$1448$ Deoxyribose$ DNA$(B)$ Mahadevan^Jansen$1996$1449$ δCH2$ Albumin,$chicken$egg$Sigma$A5253$ Kopecky$2006$1449$ δCH3CH2$$ Bovine$serum$albumin$ Fredericks$1995$1449$ CH2$CH3$deformation$ Tear$fluid$ Filik$2008$1449$ CH2$CH3$deformation$ Tear$fluid$ Filik$2009$1450$ Glucose$ Blood$ Chaiken$2000$1450$ δCH2$$ $Diseased$breast$tissue$ Manoharan$1998$1450$ δ(CH2)$or$δ(CH3)$ Endometrium$cancer$ Liu$1992$1450$ $ Elastin$and$collagen$ Liu$1992$1450$ CH3CH2$deformation$ Infiltrating$ductal$carcinoma$ Frank$1995$1451$ CH3CH2$deformation$ Type$I$collagen$(human$placenta)$ Frank$1995$1451^1454$ δCH2$$ Histones$ Mahadevan^jansen$1998$1452$ Structural$protein$ Breast$ Manoharan$1998$1453$ δ(CH2)$or$δ(CH3)$ Ovary$cancer$ Liu$1992$1453$ δ(CH2)$or$δ(CH3)$ Benign$or$normal$uterus$ Liu$1992$1454$ δ(CH2)$or$δ(CH3)$ Elastin,$collagen$and$phospholipids$ Mahadevan^jansen$1998$1454$ δ(CH2)$or$δ(CH3)$ Human$cervix$ Mahadevan^jansen$1998$1454$ δCH3$proteins$ $ Mahadevan$1995$1455$ Glycogen$ Sigma$Aldrich$G0885$ Kendall$2002$1456$ δCH3$elastin$ Sigma$Aldrich$E1625$ Kendall$2002$1460$ Pentose$sugar$vibration$due$to$
δCH2$ DNA$ Mahadevan^Jansen$1996$1462$ Deoxyribose$ DNA$(B)$ Mahadevan^Jansen$1996$1480$ Vibration$of$purine$bases$(adenine$and$guanine)$ DNA$ Mahadevan^Jansen$1996$1484$ CH2$deformation$ Cervical$Tissue$ Lyng$2007$1487^1490$ Guanine$(DNA)$ Peripheral$blood$lymphocytes$ Pully$2010$1505$ Tyrosine$ Albumin,$chicken$egg$Sigma$A5253$ Kopecky$2006$1509$ Phenylalanine$ Bovine$serum$albumin$ Fredericks$
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1995$1520$ Carotenoid$ Blood$plasma$ Larrson$1974$1524$ C=C$vibration$carotenoids$ Peripheral$blood$lymphocytes$ Pully$2010$1548$ NH$deformation;$vCN$amide$II$band$ Cervical$Tissue$ Lyng$2007$1548$ Tryptophan$ Oesophagus$tissue$ Stone$2002$1552$ Tryptophan$ Blood$Plasma$ Poon$2012$1553$ Tryptophan$ $ Mahadevan^Jansen$1996$1553$ Tryptophan$indole$ring$ Tear$fluid$ Filik$2009$1556$ Tryptophan$ Bovine$serum$albumin$ Fredericks$1995$1570$ Vibration$of$purine$bases$(adenine$and$guanine)$ DNA$ Mahadevan^Jansen$1996$1576$ Guanine$ Peripheral$blood$lymphocytes$ Pully$2010$1578$ vC=C$olefinic$$ Cervical$Tissue$ Lyng$2007$1579$ Pyrimidine$ring$(nucleic$acids)$&$haem$protein$ Oesophagus$tissue$ Stone$2002$1585$ vC=C$$ Cervical$Tissue$ Lyng$2007$1585$ vC=C$ Blood$Plasma$ Poon$2012$1602$ vCO$$ Cervical$Tissue$ Lyng$2007$1603$ δC=C$phenylalanine/$tyrosine$ Oesophagus$tissue$ Stone$2002$1605$ Phenylalanine$phenol$ring$ Tear$fluid$ Filik$2009$1606$ Phenylalanine$ Bovine$serum$albumin$ Fredericks$1995$1606$ vC=C$phenylalanine$&$tryptophan$ Blood$Plasma$ Poon$2012$1601$ Tyrosine$ Albumin,$chicken$egg$Sigma$A5253$ Kopecky$2006$1607$ Phenylalanine$in$bovine$albumin$ Sigma$Aldrich$A2153$ Kendall$2002$1616$ Tyrosine$ Bovine$serum$albumin$ Fredericks$1995$1616$ vC=C$of$tyrosine/$tryptophan$ Oesophagus$tissue$ Stone$2002$1616$ vC=C$tyrosine$&$tryptophan$ Blood$Plasma$ Poon$2012$1642$ Amide$I$v(C=O)$ Collagen$ Mahadevan^Jansen$1996$1648^1661$ Amide$I$v(C=O)$ Histones$ Mahadevan^Jansen$1996$
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1650^1666$ C=C$vibration$cis$–$isomer$in$fatty$acid$chain$ Phospholipid$membrane$ Mahadevan^Jansen$1996$1651$ Amide$I$v(C=O)$ Benign$breast$tissue$and$malignant$tumours$ Alfano$1991$1651$ Amide$I$v(C=O)$in$collagen$ Sigma$Aldrich$C7774$ Kendall$2002$1651$ Amide$I$(vC=O)$ Ovarian$cancer$ Liu$1992$1653$ Amide$I$(vC=O)$in$bovine$albumin$ Sigma$Aldrich$A2153$ Kendall$2002$1654$ Amide$I$ Normal$breast$tissue$ Frank$1995$1654^1662$ Amide$I$(vC=O)$α^helix$ α^helix$protein$secondary$$structure$ Mahadevan^Jansen$1996$1654^1685$ Amide$I$(vC=O)$$ Unordered$protein$secondary$structure$ Mahadevan^Jansen$1996$1655$ Amide$I$$ Oleic$acid$methyl$ester$ Frank$1995$1655$ Amide$I$(vC=O)$ Endometrial$cancer$ Liu$1992$1655$ Amide$I$(vC=O$proteins,$α^helix$conformation)/$vC=C$lipid$
Oesophagus$tissue$ Stone$2002$
1656$ Amide$I$(vC=O)$ Collagen$ Mahadevan^Jansen$1998$1656$ Amide$I$(vC=O)$ Human$cervix$ Mahadevan^Jansen$1996$1656$ Amide$I$(vC=O)$ $ Mahadevan$1995$1656$ Amide$I$(vC=O)$ Benign$or$normal$endometrium$ Liu$1992$1657$ Amide$I$(vC=O)$ Cervical$cancer$ Liu$1992$1657$ Lipids$–$fatty$acids$ Breast$ Manoharan$1998$1657$ Amide$I$ Infiltrating$ductal$carcinoma$(breast)$ Frank$1995$1657$ Fatty$Acids$ Peripheral$blood$lymphocytes$ Pully$2010$1659$ Amide$I$(vC=O)$ Benign$breast$tumours$ Alfano$1991$1659$ Amide$I$(vC=O)$ Benign$or$normal$ovary,$cervix,$uterus$ Liu$1992$1659$ Amide$I$(vC=O)$ Uterus$cancer$ Liu$1992$1659$ Amide$I$(vC=O)$ Bovine$serum$albumin$ Fredericks$1995$1659$ Amide$I$(vC=O)$α^helix$ Blood$Plasma$ Poon$2012$1659$ Amide$I$ Tear$fluid$ Filik$2008$1659$ Amide$I$ Tear$fluid$ Filik$2009$1660^1665$ Amide$I$(vC=O)$α^helix$ Cervical$Tissue$ Lyng$2007$
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Figure# 3.# Mean# Blood# Cytospin# Raman# Spectra# of# the# Three# Pathologies;$purple:$healthy,$dark$blue:$CLL$(PUP),$light$blue:$CLL$(PTP)$$$
$
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Raman# and# Fourier# Transform# Infrared# Spectroscopy# for# the# Diagnosis# of#
Leukaemia#and#Lymphoma$(oral$presentation)$$LINC$meeting$of$trustees$2011$







Raman# and# Fourier# Transform# Infrared# Spectroscopy# for# the# Rapid# and# Early#
Diagnosis#of#Leukaemia#and#Lymphoma$(oral$presentation)$$$Cranfield/$Gloucester$Translational$Medicine$Day$2012$




Drop#Coating#Deposition#Spectroscopy# (DCDRS)# for#Leukaemia#Diagnosis$ (poster$presentation)$$Cranfield$Post^Graduate$Conference$2012$
Vibrational#Spectroscopy# for# the#Rapid#and#Early#Diagnosis#of#Acute#and#Chronic#
Leukaemias#and#Lymphomas$$(oral$presentation)$$$SPEC$2012$
Drop# Coating# Deposition# Spectroscopy# (DCDS)# for# the# Rapid# Identification# of#
Chronic#Lymphoblastic#Leukaemia#(CLL)$(oral$presentation$by$Nick$Stone)$$$
Prizes#BMLA$Travel$Award$2012,$registration$fee$waiver$+$£300$bursary$$Laser$Europe$2012$Educational$Award$of$£1000$
